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I Abstract 
 
Introduction: Liver X receptors (LXRα and LXRβ) are members of the nuclear 
receptor superfamily of ligand-activated transcription factors that regulate many 
biological and physiological processes. LXRs are important regulators of 
cholesterol and lipid metabolism and this is mediated by regulating a wide range of 
genes such as ABCA1 and ABCG1 that are involved in lipogenesis, cholesterol 
efflux and absorption, and bile acid synthesis. Since there is a relationship 
between chronic inflammatory diseases and lipid metabolic dysfunction, the role of 
LXRs has been investigated in different inflammatory diseases and disease 
models. Generally, LXRs have an anti-inflammatory effector function, however 
occasionally pro-inflammatory effects have also been reported. 
MicroRNAs (MiRNAs) are small, evolutionary conserved, single-stranded, non-
coding RNA molecules with 20- 22 nucleotide base pairs. They regulate mRNA 
translation by fine tuning the production of proteins involved in the initiation or 
maintenance of inflammation. MiR-155 is one of the most studied members of 
miRNAs, and it has a regulatory role in certain inflammatory diseases such as 
collagen induced arthritis, lung fibrosis, and cardiovascular diseases.  
Idiopathic pulmonary fibrosis (IPF) is a devastating inflammatory disease of 
unknown aetiopathogenesis characterised by progressive breathlessness. IPF is 
characterised by approximately 50% survival of around 3 years after diagnosis, 
and there is no effective treatment. The main imperative for pulmonary fibrosis 
research is to identify potential causal inflammatory and remodelling pathways that 
contribute to IPF initiation and progression in order to determine possible 
candidate pathways for therapeutic intervention.                                                                                               
Hypothesis: LXRs play an important role in lipid metabolism and cholesterol 
homeostasis and because there is a strong relationship between metabolic 
disease and chronic inflammatory and fibrotic diseases, e.g. LXR agonists may be 
beneficial for the treatment of RA. We proposed the following hypothesis ‘’ Liver X 
Receptors can modulate bleomycin-induced pulmonary fibrosis and therapeutic 
intervention with LXR agonists may be beneficial for the treatment of pulmonary 
fibrosis’.                                                                                 
Methods & Results: Administration of the LXR agonist GW3965 to LXR-/--/- or 
LXRwild type mice given bleomycin to induce pulmonary fibrosis significantly 
exacerbated the severity of the disease only in LXRwild type mice. The 
worsening of disease was seen as enhanced loss of body weight, increased 
inflammatory and fibrotic pathomorphological changes in the lung, increased 
inflammatory cells in the bronchoalveolar lavage, increased concentrations of 
several pro-inflammatory and pro-fibrotic mediators, and increased expression of 
genes that regulate inflammation and fibrosis, such as collagen and TGF, 
increased lung collagen content, and finally up-regulation of the expression of the 
alternative activated macrophages (M2)markers arginase 2 and IL-13 receptor 
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The effect of the LXR agonist was mediated specifically by LXRs because the 
severity of disease did not change in LXR-/--/- mice given bleomycin and treated 
with GW3965, nor on similarly treated single LXRα or LXRβ gene-deleted mice. 
Furthermore, similar activation of LXRs in primary human or murine fibroblasts 
demonstrated up-regulation of the expression of collagen. The function of LXR 
agonist was directly on collagen gene expression and did not require de novo 
protein synthesis as demonstrated by the addition of cycloheximide as a 
translation inhibitor to murine primary fibroblasts activated with LXR agonist. This 
suggested that the LXR may have acted directly on the promoter region of the 
collagen gene. Also I investigated if the collagen genes have response elements 
for LXR in their promoter regions using a cell reporter system. I demonstrated that 
the collagen genes have response elements for LXR in their promoter regions. 
In a parallel set of experiments, administration of bleomycin or PBS to miR-155-/- 
and miR-155 wild type mice demonstrated a significantly stronger inflammatory 
and fibrotic process in the miR-155 gene-deleted mice. This worsening of disease 
was seen as an enhanced loss of  body weight, increased inflammatory and 
fibrotic pathomorphological changes in the lung, increased inflammatory cells in 
the bronchoalveolar lavage, increased concentration of several pro-inflammatory 
and pro-fibrotic mediators, and increased expression of genes that regulate 
inflammation and fibrosis; such as collagen and TGFincreased lung collagen 
content, and finally up-regulation of the expression of the alternative activated 
macrophages (M2)markers arginase 2 and IL-13 receptor. The effect was 
mediated specifically by miR-155 because the severity of disease was increased 
in miR-155-/- mice compared with miR-155 wild type mice given bleomycin. Also no 
differences were observed in miR-155-/- and miR-155 wild type mice given PBS. 
Conclusion: My results demonstrate that both the LXR and miR-155 have an 
important impact on the progression and extent of murine pulmonary fibrosis. 
Since completing the work for this thesis some of my additional pilot work has 
shown that LXR is a target for miR-155 and therefore both may have an important 
role in lung homeostasis. 
My results suggest the therapeutic approaches for IPF might include targeting the 
LXRs or LXR-regulated pathways, including potential fine tuning levels of 
LXR with miR-155 antagonists. The aim would be to prevent excessive 
remodelling. Furthermore, any such therapeutic intervention would need to be 
done in a very careful way because LXRs are involved in many other physiological 
processes. Therefore, more targeted therapy perhaps controlling miR-155 may be 
of clinical relevance for therapeutic strategies. 
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VII Abbreviations 
 
ABCA1                                 ATP Binding Cassette A1 
AF1/2                                   Activation Function Domains1/2 
APO                                     Apolipoprotein 
AR                                        Androgen Receptor 
Arg2                                      Arginase 2 
BAL                                       Bronchoalveolar lavage 
BIC                                        B-cell Integration Cluster 
COX                                      Cyclooxygenase 
CTE                                       Constitutive Transport Element 
CYP7A1                                 Cholesterol 7α-hydroxylase A1 
DBD                                       DNA-Binding Domain 
DEPC                                     Diethyl Pyrocarbonate 
ECM                                       Extracellular Matrix 
FCS                                        Foetal Calf Serum 
FGF basic                           Basic Fibroblast Growth Factor 
GM-CSF                                 Granulocyte Macrophage Colony-Stimulating Factor  
GR                                          Glucocorticoid Receptor 
HRCT                                     High-Resolution Computed Tomography 
HDL                                        High Density Lipoproteins 
IPF                                          Idiopathic Pulmonary Fibrosis 
IL                                             Interleukin  
iNOS                                       Inducible Nitric Oxide Synthase 
LBD                                         Ligand Binding Domain  
LPS                                         Lipopolysaccharide 
LXR                                         Liver X Receptor  
LDL                                         Low Density Lipoprotein  
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LXRE                                      LXR Response Element  
MCSF                                     Macrophage Colony Stimulating Factor 
MIP                                         Macrophage Inhibitory Protein 
MCP                                       Monocyte Chemotactic Protein 
MMP                                       Matrix Metalloproteinase 
miRNA                                    MicroRNA 
miRISC                                   MiRNA-Induced Silencing Complex 
MR                                          Mineralocorticoid Receptor   
NF-κB                                     Nuclear Factor kappa-light-chain-enhancer of                           
                                      activated B cells  
NR                                          Nuclear Receptor 
PLTP                                       Phospholipid Transfer Protein 
PDGF-A                                  Platelet-Derived Growth Factor-A  
PPAR                                      Peroxisome Proliferator-Activated Receptor 
PR                                           Progesterone Receptor  
RA                                           Rheumatoid Arthritis 
RLD-1                                      Rat Liver Digest extract 1 
RXR                                        Retinoid X Receptor 
SMA                                        Smooth Muscle Actin  
SHIP1                                     Src Homology-2 domain-containing Inositol 5-  
                                               Phosphatase 1 
SREBP-1c                              Sterol Regulatory Element-Binding Protein 1c 
TBP                                        TATA Binding Protein                                                                                                               
TLR4                                      Toll Like Receptor 4 
TMB                                       Tetramethylbenzidine 
TNFα                                      Tumour Necrosis Factor α 
UR                                          Ubiquitous Receptor 
UTR                                        Untranslated Rregion  
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VEGF                                      Vascular Endothelial Growth Factor 
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1.1 Nuclear Receptors  
 
1.1.1 Introduction to nuclear receptors 
 
Nuclear receptors (NRs) are a family of ligand-activated transcription factors that 
regulate many biological and physiological processes, including lipid and glucose 
metabolism and homeostasis, drug detoxification, cellular differentiation, 
inflammation, fibrosis, regeneration, embryonic development and organ physiology 
[1, 2]. There are currently about 48 nuclear receptors described in humans [2, 3], 
and 49 in mice [3].  
Nuclear receptors are characterised by their ability to act as initiators of gene 
transcription by binding to their response elements which are located in the 
promoters of appropriate genes. Nuclear receptors can act as monomers, or can 
assemble into different isoforms such as homodimers, and heterodimers  with 
other nuclear receptors before binding to their response elements; for example 
ligand activation of the Liver X Receptor (LXR) requires forming a heterodimer with 
the Retinoid X Receptor (RXR), is a nuclear receptor; it has three isoforms RXR, 
RXR, and RXR. It participate in many physiological processes for example cell 
differentiation and homeostasis, it can make either homodimers or heterodimer 
with other receptors such as LXRs [4]. LXR/RXR heterodimer followed by binding 
of the ligand LXR/RXR complex  to its response elements thereby increasing the 
range and regulation options of  target gene promoters [5]. This process is 
illustrated in (Figure 1.1).  
The activated nuclear receptor acts either as an up-regulator of target gene 
expression through positive hormone response elements, or as a repressor of 
target gene expression through negative hormone response elements. Some of 
the nuclear receptors can recognise and bind to the same response elements, for 
example steroid hormone receptors such as the progesterone receptor (PR),  
androgen receptor (AR), mineralocorticoid receptor (MR), and glucocorticoid 
receptor (GR)  bind to response elements that  contain the  AGAACA motif [6]. 
Since their first recognition, NRs had been identified separately by different 
research groups; therefore, several names were often used for the same receptor. 
To resolve this, a new scientific nomenclature of NRs was established in 1999. 
This classification was based on Nuclear Receptor (NR)xyz rules, for example, 
Liver X receptor alpha (LXR) is classified as Nuclear Receptor subfamily I, group 
H and third gene in the group therefore it named as NR1H3. The Liver X receptor 
beta  (LXR) is NR1H2 [7].   
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Figure 1.1 Activation of the nuclear receptor LXR by natural and synthetic agonists                  
Activation of the nuclear receptor LXR by it is natural oxysterol (oxidised cholesterol 
metabolites) and synthetic (T090137 and GW3965) agonists leads to formation of 
heterodimer with RXR followed by binding to the Liver x Receptor response elements (LXRE) 
resulting in expression of target genes involved in lipid metabolism. 
 
 
1.1.2 Categorisation of nuclear receptors 
                                                                                                                                      
The nuclear receptor superfamily is classified according to the physiological 
ligands and potential function. These form three sub-groups as illustrated in 
(Figure 1.2). The sub-groups are as following: 
I- Endocrine receptors: characterized by high affinity for fat-soluble hormones and 
vitamins. They are important for endocrine and homeostatic control. This subgroup 
contains steroid receptors and heterodimeric receptors.  
II- Adopted orphan receptor: characterised by low affinity for lipids and xenobiotics. 
This subgroup contains lipid sensor receptors which control synthesis, uptake, 
storage or clearance of lipids and glucose homeostasis. This subgroup also 
contains enigmatic orphan receptors which have identified ligands, but the nature 
of the ligand-dependent regulation in physiology is still not demonstrated.  
III- Orphan receptors: This sub-group contains nuclear receptors that have as yet  
unidentified ligands [8]. 
 
LXRE 
RXR LXR 
ABCA1 
ABCG1   
ApoE 
Agonists 
Oxysterol 
T090137 
GW3965 
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Figure 1.2 Human nuclear receptor superfamily classification, the classification depends on 
their physiological ligands and potential functions (copied from [8] with permission). 
 
1.1.3 Structure of nuclear receptors 
     
Nuclear receptors can be found in both the cell cytoplasm and nucleus. These 
receptors are activated by ligands that freely cross cell membranes such as lipids, 
vitamins, thyroid hormones and steroid molecules. Binding leads to aggregation of 
these receptors and their active transport into the cell nucleus where they act by 
binding to specific recognition sites on DNA called response elements, enabling 
regulation of gene transcription in response to ligand activation. Generally all 
nuclear receptor structures consist of one homology polypeptide of five to six 
domains; designated A to F, from the N-terminal to the C-terminal end on the basis 
of regions of conserved sequence and function (Figure 1.3).  
Nuclear receptors contain two important regions; 1. The DNA-binding domain 
(DBD, region C), and 2. The ligand-binding domain (LBD, region E). The DNA 
binding domain consists of approximately 70 amino acids and contains two highly 
conserved zinc finger proteins which differentiate the nuclear receptors from other 
DNA-binding proteins. The DBD (N-terminal) acts as a target receptor to specific 
DNA sequences known as nuclear receptor response elements, for example, 
hormone response elements. These response elements are located in the 
promoter regions of genes relevant to the biological response to the ligand, and 
binding of the nuclear receptor can therefore regulate gene transcription. The LBD 
(C-terminal) consists of approximately 250 amino acids and is configured for 
ligand recognition and binding. The ligand recognition site is characterised by it is 
high specificity and selectivity to recognise appropriate ligands [2, 8-11].  
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Nuclear receptors contain two transcription activation function domains AF-1 and 
AF-2 that, act as coactivators of the nuclear receptor. AF-1 is located at the N-
terminal region and consists of the A/B domains. Its function is ligand-independent 
activation. The AF-2 domain is located at the C-terminal region within the LBD and 
its function is ligand-dependent activation [11, 12]. Synergy between these two 
domains is required to achieve full transcriptional activity.  
The NR contains a hinge region located in region D, which connects the DBD and 
LBD. This is associated with a constitutive transport element (CTE) which is 
involved in the trafficking and distribution of the NR. 
 
 
Figure 1.3 General structure of a putative nuclear receptor                                                            
The nuclear receptor consists of 6 domains (A, B, C, D, E and F). The DNA binding domain 
is located in the C domain and the ligand binding domain is located in the E domain. 
Nuclear receptors also contain a constitutive transport element (CTE), and two transcription 
activation function domain AF-1 and AF-2 (copied from [2] with permission).  
 
1.1.4 Liver X Receptors (LXRs) 
 
1.1.4.1 Structure and Function 
Liver X receptors (LXRs) are member of the nuclear receptor superfamily. They 
were first identified in 1994 and were initially named RLD-1 (see section 1.4.1.1. 
below for details) [13]. RLD-1had the features of a nuclear receptor and was able 
to interact with RXR, therefore was classified as LXR. The LXRs consist of two 
isoforms; LXR (NR1H3) and LXR (NR1H2) which are both ligand-activated 
transcription factors [14].The two LXRs (  and ) are highly conserved; with 78% 
shared identity of amino acid sequence in both the DBD and LBD  domains[15].  
Despite the structural similarity and conservation between LXRα and LXRβ they 
are located in different chromosomes and encoded by different genes; human 
LXR by HR1H3 on chromosome 11p11.2 and LXR by NR1H2 on chromosome 
19q13.3. LXRs were first identified as orphan receptors before the recognition of 
their natural ligand. As with the other nuclear receptors, the LXR molecule consists 
of four domains; two conserved domains (DBD & LBD), and two transcription 
activation function domains (AF1 and AF2)  (Figure 1.2) [16]. 
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1.4.1.2 Liver X Receptor alpha (LXR)                                               
The Liver X receptor alpha (LXR) was first identified as RLD-1 (from Rat Liver 
Digest extract 1). It was described in 1994 using Western blot analysis of rat’s liver 
extract which showed that RLD-1 formed a heterodimer structure with the Retinoid 
X Receptor (RXR), and was therefore recognised as a novel member of the 
nuclear receptor family. This new receptor consisted of 445 amino acids. The 
name of the Liver X receptor came from its conspicuously high expression in the 
liver [13] and the absence of an identified ligand was replaced by the letter X [17]. 
The tissue distribution of LXR expression varies; it’s abundantly expressed in 
liver, spleen, kidney, lung, intestine, pituitary and adipose tissue [13-15, 17]. Many 
inflammatory cells also express LXR including T lymphocytes, dendritic cells and 
monocytes / macrophages [18-20].                     . 
                                                                                                                     
1.1.4.3 Liver X Receptor beta (LXR) 
Liver X receptor beta (LXR) is the second isoform of LXR and was discovered in 
1994. It was named initially as a ubiquitous receptor (UR) because both the 
protein and mRNA for UR were identified in many cell types and functionally the 
rat  UR was found to heterodimerise with human Retinoid X Receptor alpha [21]. 
High structural similarity between UR protein with LXRα was identified, therefore, a 
new name was given to this new receptor; LXRβ. There was 77% similarity in 
amino acid sequences in both DBD and LBD for LXRα and LXRβ [17]. Generally, 
LXR heterodimerise with the Retinoid X receptor (RXR). LXR is expressed more 
ubiquitously than LXRα and can be observed in most tissues and cells   [14, 15, 22]                                                        
 
1.1.4.4 LXR ligands 
The Liver x Receptor was initially identified as an orphan nuclear receptor because 
neither a physiological nor synthetic ligand was recognised. Subsequently,  
metabolites of cholesterol and derivative oxysterols were discovered as potential 
endogenous physiological ligands for these receptors with the ability to activate 
them [23]. Cholesterol and common oxysterol structures are illustrated in (Figure 
1.4).  Activated Liver X receptors form a heterodimer with the Retinoid X receptor 
(RXR). Then the LXR/RXR complex binds to its response elements thereby 
increasing the range and regulation options of target gene promoters [5]. 
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Figure 1.4 Structures of cholesterol and most common oxysterols (copied from [24] with 
permission). 
Liver X receptors are important regulators of cholesterol and lipid metabolism. 
They control the regulation of genes involved in lipogenesis, cholesterol efflux in 
macrophages, bile acid synthesis in liver and intestinal cholesterol absorption. For 
example, LXRs regulate the Cholesterol 7α-hydroxylase A1 (CYP7A1) gene 
encoding cholesterol 7α-hydroxylase which is the rate- limiting enzyme in the 
conversion of cholesterol to bile acids in the liver [25]. Also activation of 
macrophage LXRα and LXRβ results in increased expression of genes involved in 
lipid metabolism and transportation such as Apolipoprotein E (APOE), ATP binding 
cassette A1 (ABCA1), ATP binding cassette G1 (ABCG1), ATP binding cassette 
G5 (ABCG5), and ATP binding cassette G8 (ABCG8), as well as CCL24 and Toll 
Like receptor 4 (TLR4) in the case of macrophage activation [19, 20, 26-28]. 
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These proteins, for example ABCA1 has been determined in macrophages as an 
engulfment receptor which plays a potential role in the treating of cellular lipids by 
enhancing the effluxes of cellular cholesterol and phospholipids to lipid-poor 
apolipoproteins. ABCA1 controls the process of reverse cholesterol transport 
including synthesis of high-density lipoproteins (HDL). Mutations in ABCA1 lead to 
development of Tangier disease, a severe HDL deficiency disease manifested by 
accumulation of cholesterol in tissue macrophages and atherosclerosis [29, 30].  
Oxysterols are oxidized derivatives of cholesterol and several have been identified 
as potent natural ligands for LXRs. These include, 20(S)-hydroxycholesterol,  
22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, 27-hydroxycholesterol, and 
24(S),25-epoxycholesterol; with the last being the most potent ligand having the 
highest binding affinity towards both isoforms of LXR [31]. Bile acids are steroid 
acids  that facilitate fat emulsification and digestion in the intestine. They are also 
identified as natural physiological ligand for LXRs. Bile acids such as 6α-
hydroxylated bile acids were able to activate LXRα specifically and selectively but 
higher concentration of 6α-hydroxylated were required to activate LXRβ [32].  
The liver is the main tissue for LXR function because it has both LXRα and LXRβ 
isoforms and because the important role of LXRs in regulation of lipid metabolism 
and cholesterol homeostasis occurs mainly in the liver. In addition, the liver is the 
primary organ responsibility for producing glucose. Glucose is another metabolite 
of particular importance [33]. Both glucose and d-glucose-6-phosphate are direct 
agonists for LXRs with higher affinity binding with LXRα than with LXRβ. These 
two forms of glucose were able to bind and activate the receptors resulting in 
expression of LXR target genes [34]. Physiological concentration of glucose were 
able to activate LXR except in liver; this observe when a significant glucose influx 
accompanied by disturbances in insulin regulation function [34] . 
Some LXR ligands can selectivity activate either LXRα or LXRβ. One example is a 
phenethylphenyl phthalimide derivative which is a potent and selective agonist for 
LXRα [35]. Whereas another group of synthetic LXRs ligands; the N-
acylthiadiazolines have a high selectivity for LXRβ but with modest activation 
potency. A study of macrophages derived from LXR mutant mice confirmed the 
selectivity of the ligand for LXRβ and the activity was confirmed by the ability of the 
compound to activate macrophages to induce apolipoprotein A1 (APOA1) 
dependent cholesterol efflux [36].  
Investigating different sources of LXR agonists including plant biological products 
discovered that sterols and stanols were able to activate LXRs [37]. The study 
demonstrated that sitosterol and sitostanol activated LXRα and LXRβ resulting in 
an increase in ABCA1 expression accompanied by a decrease in the 
concentration of LDL cholesterol and decreased intestinal absorption of 
cholesterol [37] .  
The most commonly used synthetic LXRs ligands bind both LXRα and LXRβ with 
high efficiency and potency are T1317 and GW3965 [38, 39]. T1317 is short for 
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T0901317 which is (N-(2,2,2-trifluoro-ethyl)-N-[4-(2,2,2-trif- luoro-1-hydroxy-1-
trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide. It is characterised by its 
specificity demonstrated by using transient transfection assays in HEK293 cells. 
The ligand was able to activate LXRα and LXRβ, but with a 35 fold higher potency 
for activating LXRα (35 fold) than LXRβ (15 fold) [40]. GW3965 is a nonsteroidal 
LXR ligand that was synthesized and introduced by the pharmaceutical company 
GlaxoSmithKline in the USA. It is characterised by its high potency and selectivity 
to induce the expression of ABCA1 in vitro and in vivo in mice after oral 
administration [41]. The specificity of GW3965 to human and murine LXR and 
LXR was demonstrated. A study had shown this specificity by using of a 
luciferase-based functional assay. The LBDs of human LXR, human LXR, 
mouse LXR , and mouse LXR were cloned and inserted into the pM2-GAL4 
vector to create LBD/GAL4 ‘chimeric’ receptors. Cells were transfected with the 
vector and activated with LXR agonist GW3965 resulted in expression of the 
reporter genes [42]. I acknowledge that the specificity of any chemical ligand is 
incomplete and I was aware that other molecules could be affected by the 
compound. 
LXRs can also be activated as an indirect consequence of activation of other 
nuclear receptors activation by their own specific ligands, followed by an obligatory 
heterodimerisation with LXR. Example of these include activation of Retinoid X 
receptors (RXRs) by its specific ligand rexinoids (e.g. LG268) results in RXR/LXR 
heterodimerisation and ABCA1 transcription [40].   
Also activation of Peroxisome proliferator-activated receptors (PPARs), nuclear 
receptor contains three subtypes PPARα, PPARγ and PPARδ had been shown 
correlation with LXR expression. A study had been shown that activation of 
PPARα or PPARγ with unsaturated fatty acids and synthetic PPAR ligands can 
lead to the induction of expression of LXRα resulting in stimulation of ABCA1 
expression and enhance cholesterol efflux to APOA. This was confirmed using 
human primary monocyte-derived macrophages and in macrophage-derived foam 
cells [43]. This was supported by another study carried out rats demonstrated that 
rat fed a high-fat diet rich in unsaturated fatty acids, or PPARα  agonist  such as 
Wy 14.643 results in an induction in LXRα mRNA and protein level expression by  
3 folds. This was confirmed in vitro cultured hepatocytes. This indicated a direct 
induction of LXR gene transcription via PPAR interacting with several PPREs in 
the LXR promoter [44].  
 
1.1.4.5 LXR regulation and expression 
The LXRs are considered as members of a class of receptors called ligand-
activated nuclear receptors and transcription factors that move between the 
nucleus and cytoplasm. LXRs vary in their localisation inside the cell; LXRα tends 
to be localised in the nucleus and LXRβ is detected in nucleus and cytoplasm [45]. 
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Activation of LXRs results in their binding with DNA response elements which in 
turn can regulate transcription of appropriate genes.                                              
These two LXR isoforms are expressed constitutively across a broad distribution 
of tissues. Different signalling pathways can be involved in the induction of LXR 
expression; these include specific endogenous and exogenous ligands which 
modulate LXR synthesis. The topic of what regulates LXR expression is 
unresolved. Many factors may be involved in the regulation of LXR expression but 
more work still needs to be done to understand the relative participation of many 
different pathways. For example, analysis of the LXR promoters demonstrated 
binding sites for different transcription factors such as Specificity Protein 1 (SP1), 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and 7 
members of E-twenty six family transcription protein (Ets-protein). Different 
mechanisms therefore can be involved in the regulation of LXR expression. The 
promoter regions for both LXRα and LXRβ are characterised by their abundant of 
GC and their numerous binding sites (response elements) for the SP1 
transcription factor which is responsible for basal expression levels of LXRα and 
LXRβ [46].  
LXR expression can be up-regulated or down-regulated by hormones. A recent 
study has shown that the thyroid hormone (T3) up-regulates the expression of 
LXRα but not LXRβ in mice. This was due to the LXRand thyroid hormone 
receptors sharing or competing for the same DNA response elements which have 
similar geometry and polarity. Moreover, reporter assays demonstrated that the 
thyroid hormone receptor β1 could regulate the transcription of the mouse LXRα 
gene [47]. Different hormones may lead to down-regulation of LXR expression, for 
example, treating mice with oestrogen (17beta-estradiol) lead to down-regulation 
of expression of LXRα and its target genes, e.g. ATP-binding cassette A1 
(ABCA1), ATP-binding cassette G1 (ABCG1), apolipoprotein E (APOE), sterol 
regulatory element-binding protein 1c (SREBP-1c), and phospholipid transfer 
protein (PLTP) [48]. 
LXR regulation and expression can be induced indirectly through the activation of 
other receptors. One study demonstrated that in human macrophages LXRα can 
be regulated and expressed using specific ligands for peroxisome proliferator-
activated receptor γ (PPARγ) e.g. rosiglitazone or GW7845, because the response 
element for this receptor is found in the LXR 5′-flanking region [49]. 
A gene expression profile microarray analysis demonstrated a 40-fold up-
regulation of LXR expression during Granulocyte macrophage colony-stimulating 
factor (GM-CSF) induced differentiation of human monocytes to macrophages 
[50]. Activation of the LXR in human macrophage cell lines by endogenous or 
synthetic ligands resulted in an induction of LXR expression [49, 51]. This auto-
regulation ability of LXR was confirmed by its disappearance in the rare case of a 
deletion or mutation inside the LXRpromoter region. This lead to the conclusion 
that the auto-regulation process is specifically associated with LXR expression 
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and it was cell specific because it was seen in human macrophages but not in 
hepatocytes. This auto-regulation of LXRresulting in an increased 
LXRexpression may perhaps explain why macrophages generally have higher 
expression levels of ABCA1 in comparison to hepatocytes. 
Cholesterol and its derivative oxysterols have been described as potential 
endogenous physiological agonists of LXR (22). The classical pathway of LXR 
activation can be summarised as follows:                                                                                   
Firstly, binding between the LXR agonist and the LXR occurs in the cytoplasm or 
nucleus and this leads to the formation of a heterodimer of the LXR with another 
nuclear transcription factor called the retinoid X receptor (RXR), which is 
necessary for LXR function.  
Secondly, the LXR/RXR heterodimer transport to bind to the LXR response 
elements (LXREs) which are located in the promoters of certain genes. The 
transportation and trafficking is mediated via constitutive transport elements (CTE) 
within the NR. 
Third, when bound to the LXRE, a conformational changes occur in the LXR/RXR 
complex with the release of transcriptional corepressors allowing transcriptional 
coactivator function, this is followed by switching on the promoters of target genes 
followed by their expression e.g. ABCA1 (Figure 1.5) [52]. 
 
 
 
 
 
 
 
Figure 1.5 Regulation and transcription of LXR                                                           
Cholesterol metabolites; oxysterols bind to LXR followed by formation of LXR/RXR 
heterodimer which in turn binds to the LXREs located in the target gene promoters. Ligand 
binding induces the conformational change of the LXR/RXR complex inducing the release of 
transcriptional corepressors which exchange into transcriptional coactivator, switching on 
the promoters of target genes followed by their expression e.g. ABCA1. (copied from [52]  
with permission).  
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1.1.5 LXR in physiology, inflammation and disease   
1.1.5.1 The role of LXR in obesity 
 
Fat is the main energy reserve in mammals. Fat accumulation occurs in all parts of 
the body especially in the abdominal and pelvic cavity in the form of white adipose 
tissue. This consists mainly of mature adipocytes originating from undifferentiated 
pre-adipocytes through a differentiation process controlled by transcription factors 
and hormones [53, 54]. Obesity is characterised by excessive deposition of fat in 
the tissues resulting in alteration in adipose tissue metabolism accompanied by 
excessive release of fatty acids and pro-inflammatory mediators. There is a strong 
relationship between chronic inflammatory diseases and obesity related metabolic 
dysfunctions, for example there is a strong relationship between obesity and 
hypertension and dyslipidaemia [55].  
LXRα and LXRβ are expressed in human and murine adipocytes. Studies have 
shown increased LXRα expression in mature human and murine adipocytes during 
lipogenesis. This was accompanied by increased lipid accumulation and fatty acid 
synthesis, and increased expression of LXR target genes sterol regulatory binding 
protein-1 (SREBP-1) and peroxisome proliferator-activated receptor gamma 
(PPARγ) [53, 54]. Mice that were given the LXRs agonist T0901317 had up-
regulation of expression of adipogenic and lipogenic genes in the liver and fat 
tissue. Interestingly, small interfering (si)RNA that silenced LXRα lead to 
suppression of adipocyte differentiation [54]. Macrophages are involved in 
metabolism and inflammation. The involvement of the macrophages in LXR 
glucose tolerance or obesity stimulated by a high-fat diet was investigated. The 
study found that transfer of LXR-/- bone marrow into wild-type recipients mice 
had no effect on the glucose tolerance or obesity [56].   
Macrophages express both LXRα and LXRβ and are distributed in all tissues 
including adipose tissue. The number and size of adipose tissue macrophages 
increase in obesity, and these are the source of all the Tumour Necrosis Factor α 
(TNF-α) and  most of the  inducible nitric oxide synthase (iNOS) and IL-6 
expression in adipose tissue [57]. Because of the strong association between 
obesity and cardiovascular and inflammatory diseases, there may be an important 
role for LXRs in the regulation of lipid metabolism and transportation. This is due 
to the ability of LXRs to regulate a wide range lipid-controlling genes such as 
ABCA1 and ABCG1 that may act as a control method on the development of 
obesity that may have a beneficial effect for the treatment of cardiovascular 
diseases and inflammation.  
 
1.1.5.2 The role of LXR in atherosclerosis  
 
Atherosclerosis is a chronic inflammatory disease characterised by progressive 
thickening of the inner lining of the medium and large artery walls as a result of the 
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accumulation of lipid deposits. The hallmark feature of these lesions is the 
presence of lipid-filled cells in the intima [58]. This observation suggests that the 
pathogenesis of the disease includes abnormalities in cholesterol metabolism. 
Furthermore, cholesterol and its derivatives are the physiological endogenous 
ligands for LXRs, and activation of LXR regulates genes involved in lipid 
metabolism and transportation which normally control the efflux of lipids out of 
foam cells [19, 20, 23]. Therefore, this suggests a potential role for LXRs in 
atherosclerosis. 
In the early stage of the development of atherosclerosis, local inflammation results 
in the generation of reactive oxygen species and cholesterol esters which are then 
bound by low density lipoproteins (LDL) present in the artery wall. These oxidised-
(ox)LDLs are then bound and removed by macrophages via their scavenger 
receptors. These are a wide family of receptors including CD36 that remove a 
range of waste material due to their broad ligand specificity. In the context of 
arthrosclerosis, locally produced oxLDL are taken up by the macrophage and can 
accumulate in lysosomes to form lipid-laden ‘foamy’ macrophages.   
The physiological response to this intracellular accumulation of oxLDL is that 
cholesterol is regenerated and secreted from the cell. This process is called 
reverse cholesterol transportation or efflux; a process in which cholesterol and 
phospholipid excretion is regulated by LXRs [58]. The mechanism was described 
in one study demonstrating that stimulation of mouse macrophages and fibroblast 
cell lines with an LXR agonist up-regulated the expression of the ABCA1 gene by 
~ 30 fold [59]. The process is illustrated in (Figure 1.6). 
 
 
 
 
Figure 1.6 Regulation of ABCA1 gene expression and cholesterol efflux by LXR as result of 
lipid loading                                                                                                                                         
Binding of oxLDL to scavenger receptors is followed by internalization and degradation in 
lysosomes. Then cholesterol and oxysterols enter the nucleus and activate the LXR/RXR 
heterodimer activating target genes for example ABCA1. Synthesis of ABCA1 protein leads 
to an increased efflux of cholesterol and/or phospholipids to apoAI (copied from [59] with 
permission).                                                                                                                                                                         
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Apolipoprotein E is another target gene for LXRs that participates in lipid 
transportation [40]. Accumulation of lipids inside macrophages is sufficient to 
activate LXRs resulting in increased expression of the ABCA1 and apolipoprotein 
E (ApoE) genes which are involved in cholesterol efflux. Experimental models 
demonstrate that LXRα is the key regulator of cholesterol efflux.  LXRα-/- mice 
developed severe atherosclerosis when fed a diet rich in cholesterol in comparison 
with LXRβ-/- and wild type mice [49, 60, 61].  
To understand whether the cholesterol and phospholipid efflux process is 
controlled by ABCA1 or in cooperation with ApoE, a study was performed using 
apolipoprotein-E gene-deleted mice. This demonstrated that agonists of LXR and 
RXR were still able to activate LXRs and to initiate expression of ABCA1 in 
macrophages resulting in cholesterol efflux but not in LXR gene-deleted mice 
[60]. They concluded that cholesterol efflux is mediated through direct expression 
of ABCA1 in response to LXR activation. These studies therefore suggest that the 
development of agonists that specifically activate LXR is beneficial for activation of 
LXRs resulting in regulation of body cholesterol. 
The development of atherosclerotic plaques is correlated with chronic 
inflammation and recently targeting LXRs have been suggested as a potential anti-
inflammatory candidate for therapy. It has been suggested that LXR agonists may 
suppress atherosclerosis. ApoE-/- mice treated with the LXR agonist T1317 had a 
reduction in the expression levels shown by microarray gene analysis in hepatic 
cells of the pro-inflammatory cytokines IL-1 and IL-6 as well as serum 
concentrations [62].  
LXRs can participate in the modulation of atherosclerosis by affecting macrophage 
up-take of oxLDL resulting in decreased cholesterol accumulation. This was 
shown experimentally by stimulating human monocyte-derived macrophages with 
either of the LXR agonists T0901317 or 22(R)-hydroxycholesterol, followed by 
incubation with oxLDL. This resulted in decreased oxLDL uptake. This was due by 
the ability of LXRs to down-regulate macrophage pinocytosis of oxLDL [63]. This 
mechanism could be another preventative mechanism by which LXRs can control 
macrophage foam cell formation. 
Some anti-oxidant extracts e.g. curcumin, a potent antioxidant extracted 
from Curcuma longa may participate in the modulation of cholesterol accumulation 
in macrophages by modulating oxLDL uptake. Cells treated with curcumin show 
increased expression of ABCA1 protein. Curcumin increased up-regulation of 
ABCA1 expression  through calmodulin (calcium-modulated-protein) for LXRα 
dependent transcriptional regulation [64].  
LXR agonists participate in the regulation of gene expression that regulate lipid 
metabolism; therefore, they may have potential antiatherogenic effect. One study 
using New Zealand white rabbits showed that administration of the LXR agonist 
T0901317 resulted in an increase in plasma LDL level, accompanied by an 
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increase in the activity of plasma cholesterol ester transfer protein (CETP), ABCA1 
and ABCG1, resulting in down-regulation of inflammatory gene expression [65]. 
LXRs also participate in the metabolism of phospholipid and triglycerides (TG). 
Oral administration of synthetic LXR agonists T0901317 to mice resulted in an 
increased concentration in plasma phospholipid and TGs and this lipogenic effect 
is mediated through the increased induction of fatty acid synthase (FAS), sterol 
regulatory element binding protein 1c (SREBP-1c) expression, and induced hyper-
triglyceridaemia [66].  
Generally, LXRs have a potential role in regulation of cholesterol metabolism, thus 
preventing over-accumulation which might lead to atherosclerosis.  
 
1.1.5.3 The role for LXR in inflammation  
                                              
LXRs can modulate inflammation because of their involvement in cholesterol 
metabolism and homeostasis. Since the relationship between chronic 
inflammatory diseases and lipid metabolic dysfunction has been observed, 
therefore, the role of LXRs in different inflammatory diseases has been 
investigated. LXRs are distributed across all tissues and cells, including T 
lymphocytes, dendritic cells, neutrophils and monocytes / macrophages [14, 15, 
67]. Generally, an anti-inflammatory effector function for LXRs had been observed 
but pro-inflammatory effects have also been observed.  
The role of LXR in inflammation can be demonstrated by either stimulating or 
inhibiting the expression of genes for certain pro-inflammatory mediators such as 
TNF, IL-1, IL-6, cyclooxygenase (COX)-2 and inducible nitric oxide synthase 
(iNOS) [68, 69]. The effect of LXR agonist on inflammation may be mediated by 
the effect on Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-
κB), which is the central transcriptional regulator of the innate immune response. 
Many of the genes inhibited by LXR are established target inflammatory genes of 
NF-κB signalling. Both of iNOS and COX-2 gene promoters demonstrated that 
down-regulation of these genes by LXR was mediated through antagonism of   
NF-κB. This study demonstrated that there is a relationship between immune 
response and lipid metabolism involving LXR.   
LXRs are also involved in the regulation of genes which participate in innate 
immunity. For example experimental knockdown of the LXRgene in human 
keratinocytes in culture resulted in significant down-regulation of genes coding for 
peroxisome proliferator-activated receptor-gamma (PPAR-), catalase and vitamin 
D receptor (VDR), and significant up-regulation of genes coding for interferon-
gamma (IFN), c-myc, interleukin-6 (IL-6) and interleukin-8 (IL-8) [52, 70]. In 
addition, LXRs have been shown to have anti-proliferative properties. Activation of 
LXRs during T-cell activation leads to suppression of mitogen driven expansion in 
contrast T-cells which lack LXRβ were mitogen stimulation has a synergistic 
proliferative effect. Furthermore, these mice lacking LXRβ-/- had an increase in 
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their response to antigenic challenge accompanied by lymphoid hyperplasia [71]. 
These anti-inflammatory and anti-proliferative effects of LXR may be consider as 
characteristic functional effects for activation of LXR activation. 
LXR have an involvement in the regulation of innate immune response. LXRα -/- 
mice exhibited increased susceptibility to intracellular infection by Listeria 
monocytogenes, associated with an increase in macrophage apoptosis after 
bacterial infection [72]. The activation of LXRs also caused an increased 
expression of TLR4 in human, but not in mouse, macrophages resulting in an 
enhanced lipopolysaccharide response [27]. During inflammation several factors 
affect the expression of LXRs; for example, one study demonstrated down-
regulation of LXRα and LXRβ expression in response to administration of 
Lipopolysaccharide (LPS) or pro-inflammatory cytokines such as TNFα. The 
inhibitory effect of LPS was mediated by the ability of TNFα to suppress the LXR 
response elements [73].  
LXRs may have an important role in inflammatory disorders of the nervous system 
e.g. Alzheimer's disease (AD). Activation of the LXRs protect cholinergic neurons 
and decrease the inflammatory response in an experimental model of AD in 
amyloid precursor protein (APP)/PS1 transgenic mice [69]. In another 
inflammatory disease model, LXRs have a positive regulatory effect on diabetic 
states; anti-diabetic effects were demonstrated in type 2 diabetic rodent models 
due to the ability of LXRs to increase peripheral glucose uptake, enhance insulin 
sensitivity, and thereby normalise glycemia [14]. The antidiabetic effect of LXR 
agonists is suggested to result predominantly from inhibition of hepatic 
gluconeogenesis. The potential mechanism of the anti-diabetic effect of LXR 
agonists is illustrated in Figure (1. 7). 
 
 
 
 
 
 
 
 
                                                                                                                              
Figure 1.7 Mechanisms involved in antidiabetic effect of LXR agonists (copied from [59] with 
permission).  
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In a common murine collagen-induced arthritis model, one recent study 
demonstrated that activation of LXR with T1317 and GW3965 agonists resulted in 
exacerbation of the inflammatory response, with excessive cartilage destruction 
[74].  
LXRs may also participate in the regulation of pulmonary inflammation and host 
defence. They are expressed by murine alveolar macrophages, alveolar epithelial 
type II cells and neutrophils. A study confirmed that stimulation of LXRs with the 
synthetic agonist TO-901317 (T1317) reduced the influx of neutrophils into the 
lung after several different challenge models; either with inhaled LPS, or intra-
tracheal administered of KC chemokine (Keratinocyte-derived Cytokine, a 
counterpart of human GRO protein), or intra-tracheal Klebsiella pneumonia, and 
impairs pulmonary host defences. One putative underlying mechanism was the 
impairment of the neutrophil motility due to inhibition of chemokine-induced RhoA 
activation [67].   
Previous work has shown that activation of LXR in mouse primary hepatic stellate 
cells lead to cell activation and suppression of fibrosis markers such as collagen 
1(I). Mice selectively deleted of the two LXR genes LXRαβ-/- had increased 
susceptibility to liver fibrosis and this was reflected by increased production of 
inflammatory mediators and expression of fibrogenic genes in their stellate cells 
[75].  
Further work is required to determine the nature and diversity in the pro- or anti-
inflammatory and pro- or anti-fibrotic responses of the LXR in different disease 
models. Studies are needed to investigate the control of the inflammatory and 
fibrotic responses at the level of LXR activation because targeting the LXR in vivo 
is of potential risk because of the involvement of these receptors in many 
physiological processes. It is possible that there are different endogenous 
physiological LXR ligands because there is a strong association between the 
metabolic diseases and the inflammatory and fibrotic diseases. Improved 
understanding of LXR in this context may therefore be of considerable clinical 
importance. 
 
 
 
 
 
 
 
 
 
 
35 
 
1.2 MicroRNA 
 
1.2.1 Introduction to microRNA 
  
MicroRNAs (miRNAs) are small, evolutionary conserved, single-stranded, non-
coding RNAs consisting of 20- 22 nucleotide bases. MiRNAs are endogenous 
regulators of mRNA translation. They do this by formation of an miRNA-induced 
silencing complex (miRISC) which provides a molecular structure in which the 
miRNA bind by Watson and Crick binding to complementary recognition elements 
within the 3′ untranslated region (UTRs) of target mRNA resulting in translational 
repression or enhanced degradation of the mRNA [76-78]. 
The first indication of the importance of these small non-coding miRNAs was 
identified by Lee and colleagues in 1993, who were investigating the role of the lin-
4 gene in the timing control of larval development of the worm Caenorhabditis 
elegans. Lin-4 function was characterised by its ability to negatively control the 
level of LIN-14 gene product, an important protein in larval stage development.  
They found that the lin-4 gene produces two small lin-4 transcripts of 
approximately 22 and 61 nucleotides  RNAs that do not code for protein [79]. 
These nucleotides bind and repress the translation of the LIN-14. 
In human, there have been approximately 533 miRNA loci identified [80], and 
more than 1000 miRNAs are predicted to function in humans with the possibility to 
regulate approximately 60% of human genes [78], with an estimated total of more 
than 45000 miRNA target sites [81].  
 
1.2.2 MicroRNA expression and function   
Both animals and plants express miRNAs. They are associated with the regulation 
of a major part of the protein-coding transcriptome with important roles in 
development, stress adaptation and hormone signalling [82]. In addition, miRNA 
networks regulate a wide range of biological processes such as cell proliferation, 
differentiation, migration, and apoptosis [78, 80]. 
The expression levels of miRNAs are different in different tissues to reflect their 
function. For example, the expression of miRNAs in mouse embryonic stem (ES) 
cells during differentiation. Some of miRNAs were suppressed during the 
differentiation of ES cells into embryoid bodies, and these became undetectable in 
adult mouse organs. This was in contrast to other miRNAs for which the 
expression was constant or increased during and after differentiation [83]. 
MiRNAs can also be characterised by their involvement in the outcome of normal 
and pathogenic immune responses. MiRNAs play an important role in modulating 
immune cell function. For example, stimulation of innate immune cells with LPS 
up-regulated miR-146a expression. This in turn inhibited the expression of TRAF6 
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and IRAK1, which are positive regulators involved in the Toll-like receptor 4 (TLR4) 
signalling pathways. This in turn inhibited the LPS-controlled TLR4 signal [84]. 
Also, in cancers of cells of immunological origin there is reduced expression of 
miRNAs with tumour suppressive function [85].   
 
1.2.3 MicroRNA biogenesis 
 
MicroRNAs (MiRNAs) originated from genome-encoded precursors which fold into 
imperfect hairpin structures. MiRNA genes transcribed by RNA polymerase II 
(PolII) into primary miRNA (pri-miRNA), a long hairpin structure consisting of 60–
80 nucleotides and may include one or more miRNAs embedded in a stem loop 
[86].  
The pri-miRNA is then processed by RNase III Drosha and DiGeorge syndrome 
critical region gene (DGCR8) to form ~70-nucleotide-long precursor miRNA (pre-
miRNA) (Figure 1.1). The pre-miRNA is exported from the nucleus into the 
cytoplasm, and then it undergoes cleavage by the cytoplasmic endonuclease 
enzyme called Dicer into short-lived double-stranded duplexes. These duplexes 
then separate into one single strand mature functional miRNA, while the other 
strand undergoes degradation. The mature miRNAs are incorporated into effector 
complexes containing the argonaute protein. These are called miRISC (miRNA-
containing RNA-induced silencing complex). The miRNA then guides the RISC to 
its target 3ʹ UTRs, leading to inhibition of mRNA translation or cleavage of mRNA 
(Figure 1.8) [85, 87].  
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Figure 1.8 The biogenesis of miRNAs  
Transcription of miRNA genes occur by RNA polymerase II (PloII) enzyme into primary 
miRNA (pri-miRNA). Then pri-miRNA followed by further processing by Drosha and DGCR8 
resulting in production of precursor miRNA (pre-miRNA) which exported from nucleus into 
cytoplasm. The pre-miRNA is cleaved by a Dicer enzyme to form a mature miRNA. Then the 
mature miRNA is loaded into RNA-induced silencing complex (RISC) resulting in mRNA 
translation repression or cleavage (copied from [87] with permission). 
 
 
1.2.4 MicroRNA mechanisms of action 
                                                                                                                                  
MiRNAs perform their inhibitory function by enhanced mRNA degradation or by  
inhibition of mRNA translational [88]. The exact mechanism by which a miRNA can 
identify and inhibit or facilitate cleavage a specific mRNA transcript is still not fully 
determined [76]. Therefore, using prediction algorithms of bases sequences is a 
reasonable method to predict whether a specific gene can be targeted by a 
specific miRNA.  
Generally, the ability of miRNAs to inhibit or catabolise its specific target mRNA 
can start when at least 6-8 of the nucleotides in the miRNA 5’ end (seed region) 
bind (even imperfectly) with base sequences in the 3' untranslated region of target 
gene mRNA [89]. In more detail, the proposed mechanism for miRNA action is that 
miRNAs target transcripts through imperfect base-pairing to multiple sites in 3' 
untranslated regions. The 5' end of miRNAs consist of 2–7 nucleotides and are 
crucial for targeting. Although less important, 3'-end pairing might contribute to 
target recognition, particularly when sites have weaker miRNA seed matches. The 
imperfect miRNA–mRNA can hybridise with central bulges (9–12 nucleotide 
bases). This can lead to target translational inhibition or exonucleolytic mRNA 
decay. The presence of multiple binding sites in the target mRNA can lead to 
increased repression [82]. The translation of target mRNA can be blocked or the 
mRNA can be cleaved as illustrated in (Figure 1.9). 
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Generally, one imperfect site is required for miRNA-induced cleavage of mRNA. 
The presence of multiple imperfect sites distinguished by one or more miRNAs is 
associated with highly effective inhibition of translation [78]. 
 
 
 
 
 
Figure 1.9 MiRNA biogenesis pathway and mechanisms of action                                                           
A schematic shows biogenesis of miRNA and mRNA. The miRNA load into RISC complex 
then the recognition process for mRNA starts.  MiRNA lead to either inhibition of mRNA 
translation or cleavage of mRNA (copied from [90] with permission). 
 
 
 
1.2.5 MicroRNA-155 
 
The gene for microRNA-155 (miR-155) is located in the B-cell Integration Cluster 
(BIC) which is a 1421 bp long non-coding gene located on chromosome 21. miR-
155 is encoded by nucleotides 241–262 of BIC [91]. BIC was demonstrated in the 
chicken to be a non-coding RNA proto-oncogene [92]. 
 
Initially, bic was identified as a gene in the B-cell lymphomas resulted by the avian 
leucosis virus (ALV). It is transcription can be stimulated by promoter insertion at a 
reteroviral integration site in B-cell lymphomas [93]. MiR-155 is processed from the 
BIC gene but does not encode for any protein. There are more than 100 gene 
mRNAs directly targeted by miR-155 [94].  
The highest levels of BIC expression are found in the spleen and thymus. There is 
high homology between human, chicken, and mouse BIC with 78% identity over 
138 nucleotides [95]. The miR155 gene is present in only one copy, and miR155 
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does not share significant sequence homology with other reported miRNAs, 
therefore, there is little overlapping with other miRNAs [96]. miR155 can be safely 
targeted for disruption without interfering with the expression of a protein-coding 
gene or a second transcriptionally-linked miRNA because it is located in an exon 
of the noncoding gene BIC which does not contain any other miRNAs or 
conserved RNA [96].  
 
 
1.2.6 Regulation of immunity and inflammation by miR-
155 
 
In humans, bic/miR-155 expression is found in activated mature B and T 
lymphocytes and activated monocytes, macrophages, and dendritic cells. It can 
regulate inflammation positively or negatively in mammals [97]. MiR-155 null mice 
haved serious immune defects in both adaptive and innate immunity [97]. 
O'Connell and colleagues have shown that  increased expression of miR-155 can 
lead to an increase in the number of immature granulocyte in vivo, and the 
proposed mRNA target that participates in this process is called Src homology-2 
domain-containing inositol 5-phosphatase 1 (SHIP1). This is an inhibitor of 
inflammation and this was modulated by the ability of miR-155 to repress SHIP1 
[98]. The inflammatory disease model of rheumatoid arthritis (RA) demonstrated 
an increased expression of miR-155 in synovial membrane and in synovial fluid 
CD14+ cells. The expression levels of miR-155 correlated with the inhibition of the 
expression of the miR-155 target SHIP-1. Because SHIP-1 is an inhibitor of 
inflammation, its down-regulation found in synovial tissue CD68+ cells and in 
peripheral blood CD14+ cells resulted in an increased production of pro-
inflammatory cytokines [99]. 
Macrophages are involve in inflammation, and an up-regulation in miR-155 
expression in macrophages was found in response to infection [100]. Similarly, the 
expression of miR-155 was increased in murine bone marrow-derived 
macrophages stimulated with Toll-like receptor (TLR) ligands, e.g. polyribocytidylic 
acid, or in response to cytokine such as tumor necrosis factor-a (TNF-) and 
interferon-β. Different signalling pathways are involved in this process such as 
TNF-α autocrine/paracrine signalling [101]. This shows the importance of miR-155 
in the innate immune response which provides a critical first line of defence 
against pathogens.  
Dendritic cells participate in the initiation of immunity and inflammation. Human 
monocyte-derived dendritic cells stimulated with LPS demonstrated high 
expression levels of miR-155. The mechanism of this is suggested to be  that miR-
155 targets Toll-like receptor/interleukin-1 (TLR/IL-1), which is supported by the 
observation that gene-deletion or ‘knock-down’ of miR-155 expression resulted in 
an increased expression of interleukin-1 (IL-1) [102]. Further evidence of this 
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interaction is found by the addition of exogenous miR-155 which can suppress the 
expression of an NF-κB reporter plasmid in cell lines [102].  
T lymphocyte differentiation is associated with functional miR-155. For example, in 
mice with a gene-deletion of miR-155 (miR-155-/-), the T lymphocyte differentiation 
is shifted towards T-helper 2 (Th2) lymphocytes, suggesting  that miR-155 
enhances the T lymphocyte differentiation towards T helper 1 (Th1) cells [85]. 
MiR-155 is also required for antibody production by B lymphocytes. For example 
miR-155-/- mice vaccinated with attenuated Salmonella showed a switch in the 
antibody isotype class. Murine B cells lacking miR-155 generated reduced 
extrafollicular and germinal centre responses and failed to produce high-affinity 
IgG1 antibodies in comparison with wild type murine B cells [103].  
Studies on mice deficient for bic/microRNA-155 demonstrated that these mice 
were immune-deficient and when challenged with Salmonella typhimurium they 
showed a reduction in survival, cell proliferation, IgG1 production, and IL-2 
production, this indicated that miR-155 is required for proper function of T and B 
lymphocytes and dendritic cells [104]. Of relevance to this thesis, this report also 
described an age-related increase in lung airway remodelling for which no 
mechanism was described. Microarray analyses of activated human and murine 
CD4+ Th cells and CD4+CD25+ regulatory T cells determined an up-regulation of 
mature miR-155 which suggests that miR-155 is necessary for Treg cell mediated 
tolerance. The mechanism proposed was that miR-155 regulate the susceptibility 
of CD4+ Th cells to Treg cell-mediated suppression,  In more details, CD4+ Th cells 
treated with miR-155 inhibitor demonstrated a much higher susceptibility to Treg-
mediated suppression than control CD4+ Th cells, this was explained by the ability 
of miR-155 to mediate of IL-2 expression in CD4+ Th cells and induced cell 
proliferation resulting in that these CD4+ Th cells to become insensitive to Treg 
cell-mediated suppression [105].  
MiR-155 is involved in regulation of inflammation and cell survival. Mir-155 has 
powerful anti-apoptotic function, and high expression of miR-155 in the cells led to 
suppression in FOXO3a, a gene member of the forkhead family of transcription 
factors related to cancer. This resulted in cell survival and chemo-resistance to 
multiple apoptosis inducing agents such as doxorubicin, paclitaxel, and VP-16 
[106]. Furthermore, a raised expression level of miR-155 has been demonstrated 
in Hodgkins lymphoma and in diffuse large B cell lymphomas [107]. Transgenic 
mice overexpressing miR-155 in B cells develop a pre-leukemic pre-B-cell 
proliferative disorder resulted in the development of full B-cell lymphomas [108]. 
The function indicated by this over-expression of miR-155 indicates that it is 
potentially an oncogene when it is expressed disproportionately. 
The expression of miR-155 is increased in breast cancer tissues compared with 
non-cancer tissues. The expression was positively associated with some clinic-
pathological induces such as greater tumor grade, advanced tumor stage and 
metastases to lymph nodes, whereas it was negatively associated with overall and 
disease-free survival [109]. One study demonstrated that miR-155 might play a 
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potential role in TGF induced epithelial-mesenchymal transition, cell migration 
and invasion by targeting RhoA. The authors proposed that miR-155 might be a 
potential therapeutic target for breast cancer intervention [110]. These data 
support the important role of miR-155 in inflammation, thus targeting miR-155 can 
be a potential mechanism for treatment of inflammatory diseases. 
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1.3 Pulmonary fibrosis 
 
1.6.1 Introduction: idiopathic pulmonary fibrosis (IPF) 
Pulmonary fibrosis was described in 1868 in a patient with chronic pneumonitis 
and bulbous fingertips, and this was the first formal recording as idiopathic 
pulmonary fibrosis (IPF) [111]. IPF is a devastating inflammatory disease of 
unknown etiopathogenesis characterized by progressive breathlessness [112]. 
Histologically the disease is characterised by fibrotic changes in the lung with 
excessive accumulation of fibroblasts and collagen production resulting in decline 
of alveolar function, and destruction of normal lung architecture [112, 113]; the 
incidence is increasing and there is no effective therapy [114]. IPF occurs mainly 
in older adults, the mechanisms that associate IPF with ageing are unknown, but it 
is proposed that epigenetic changes and abnormal developmental pathways may 
be involved [115]. IPF is characterised by short survival times of 3-5 years after 
diagnosis [116]. In the UK, the estimated survival time rate is worse than several 
types of cancer and increasingly more people will die each year from IPF [117]. 
Over the last 20 years the mortality rate for pulmonary fibrosis was increasing 
significantly in the USA [118], with a mortality rate of up to 50.8 per 1,000,000 of 
the population. The disease is distributed worldwide and affects approximately five 
million people [119]. Deaths with IPF are due to the consequence of fibrosis, for 
example respiratory failure, heart failure, ischemic heart disease, infection, 
bronchogenic carcinoma, and pulmonary embolism; with respiratory failure 
responsible for more than 80% of all deaths [120, 121]. 
 
1.3.2 Aetiology of IPF 
The aetiology of idiopathic pulmonary fibrosis is unknown despite extensive 
investigation of this devastating disease. The development of pulmonary fibrosis 
appears to be related to several endogenous and exogenous factors, host factors 
such as age, genetic susceptibility, and family background. For example a genome 
wide scan study in Finnish families demonstrated a gene with unknown 
physiological function called engulfment and motility domain containing 2 
(ELMOD2) which was a candidate gene for susceptibility to IPF [122, 123]. In 
addition there is involvement of some external predisposing factors including 
smoking, autoimmune processes, infection, environmental toxins, antigens and 
allergen, trauma and drug-induced reactions, metal and wood dust exposure, 
chemicals such as alkylating agents, pesticides, and ionizing radiation.  
The lungs are constantly exposed to the environment and are therefore in contact 
with aero-environmental risk factors which may cause lung injury. Tobacco 
smoking is considered one of the high-risk predisposing factors for initiation and 
progression of IPF; the odds ratio for IPF in smokers compared with non-smokers 
was 2.3 [124]. 
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 Smoking is thought to participate in the development of IPF by increasing 
oxidative stress, this had been demonstrated in current and former smokers and 
reflected by lower survival reported for current and former smokers in comparison 
with non-smokers [125]. For example a study on IPF patients testing the effect of 
the antioxidant N-acetylcysteine suggested that the cellular redox state had an 
important involvement in the progression of disease. The suggested mechanism 
involved activation of growth factors and regulation of matrix metalloproteinases 
and protease inhibitors [126].  
The involvement of genetic factors in IPF has been investigated. There is a family 
genetic component and development of IPF; approximately 3% of IPF cases are 
familial [127]. The genetic factor participates in the initiation and progression of 
IPF and this may be in response to common stressors in the shared familial 
environmental. Furthermore, heterogeneity of the disease observed within the 
families was depended  on the nature of the stressors among this families [128]. It 
is highly possible that there is a synergy between genetic factors and 
environmental factor in disease susceptibility and progression. 
Using genome-wide association study analysis, single nucleotide polymorphisms 
(SNP) have identified relationships with IPF e.g. SNPs in the cyclooxygenase 2 
gene (COX2.3050 and COX2.8473) are associated with an increase in IPF by 
approximately 1.4 fold at age 30 [129]. Latent viral infections, such as the herpes 
virus family, have been demonstrated in IPF [130]. Examination of lung specimens 
from 33 IPF patients using PCR analysis demonstrated the presence of at least 
one of four herpesviruses:- cytomegalovirus (CMV), Epstein-Barr Virus (EBV), 
human herpesvirus 7 (HHV-7), and human herpesvirus 8 ( HHV-8) in almost all 
patients [131].  
Environmental exposures are associated with IPF initiation and progression. 
Occupational exposure to metal and wood dusts are associated with a significantly 
increased risk of IPF [132]. Also, exposure to inorganic particles such as silicon 
and aluminum were possible causes for IPF, shown in an autopsy study where the 
presence of high concentrations of silicon and aluminium were found in the hilar 
lymph nodes of IPF patients [133].  
 
1.3.3 Pathogenesis of IPF 
The pathogenesis of IPF is unresolved. There are numerous mechanisms 
suggested to be responsible for the initiation and development of IPF, and it is 
likely that more than one mechanism is involved. Furthermore, IPF itself may be a 
diagnosis of overlapping disease syndromes, increasing the difficulty of identifying 
a simple causal mechanism. Typically, the initiating factors are unknown, but could 
be considered for the moment as a combination of accumulated environmental 
and susceptibility factors. It is easier to examine the consequences of these.  
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Disturbances in the wound healing process leads to development of pulmonary 
fibrosis; generally the wound healing process include four steps [134]. 
(1) Clotting and coagulation; 
(2) Migration of an inflammatory cell; 
(3) Migration, proliferation and activation of fibroblasts; and 
(4) Tissue remodelling and resolution (Figure 1.10) 
 In addition, the basement membrane of the alveolar–capillary barrier loses its 
integrity, with the collapse of alveolar structures, fusion of their basement 
membranes, and hyperplasia of type II epithelial cells and dysregulation of 
extracellular matrix formation [135]. 
IPF may be considered as a response to injury that comprises fibrosis and 
excessive extracellular matrix (ECM) deposition mediated by activation and 
proliferation of fibroblasts [86]. The histology of IPF is characterised by abnormal 
lung tissue remodelling accompanied by up-regulation of matrix metalloproteinase-
1 (MMP-1), which is the prototype of some of the MMPs capable of degrading 
fibrillar collagens types I, and III [136]. This study demonstrated that 
polymorphisms of the MMP-1 promoter correlated with increased risk for IPF and 
exhibited a putative gene-environment interaction such as with smoking. A 
relationship between IPF and oxidative stress resulting from smoking  was 
demonstrated [89], therefore, the use of therapeutic antioxidants may restore 
cellular redox balance, thereby regulating MMPs, growth factors, and protease 
inhibitors [126] 
A proposed mechanism is through epithelial-mesenchymal transition occurring for 
alveolar type II epithelial cells. The process involves transition of epithelial cells 
into mesenchymal cells for example fibroblasts and myofibroblasts. For example, 
Addition of TGF-1 to rat alveolar epithelial cells induces cell mesenchymal 
transition in vitro. The process manifested by losing of epithelial cell type specific 
markers for example E-cadherin and gain mesenchymal cell markers such as an 
increased expression of α-smooth muscle actin (α-SMA) [137]. This process is 
accompanied by increasing fibroblast proliferation, extracellular matrix protein 
deposition, accumulation of inflammatory cells and excessive generation of pro-
fibrotic mediators [138]. The main components involved in the pathogenesis of IPF 
are illustrated in (Figure 1.11). 
One causal mechanism proposed for IPF is the disturbances in surfactant protein 
(SP)-C folding [139]. Mutations in SP-C resulted in protein misfolding and 
deposition of misfolded aggregated SP-C resulted in abnormal endoplasmic 
reticulum stress. The consequential increased production of reactive oxygen 
species then cause DNA damage and contributed to IPF. 
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Figure 1.10 Stages of the wound healing process                                                                         
Wound healing includes four steps; (1) clotting and coagulation; (2) migration of an 
inflammatory cell; (3) migration, proliferation, and activation of fibroblast; and (4) tissue 
remodelling and resolution (copied from [134] with permission).  
 
 
 
 
 
Figure 1.11 Main components involved in the IPF pathogenesis                                                     
Dysregulation repair process following epithelial cell injury leads to IPF. The process 
involves an increase in fibroblast proliferation, an increase in matrix protein deposition, 
accumulation of inflammatory cell with a Th2 immune response, and excessive production 
of pro-fibrotic mediators (copied from [138] with permission). 
 
 
1.3.4 Collagen and pulmonary fibrosis 
                                                                                                                              
Collagen is the fibrous protein constituent of bone, cartilage, tendon, and other 
connective tissue. It is the most abundant tissue protein of mammals. The total 
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amount of collagen in tissue depends on the balance between collagen synthesis 
and catabolism. There can be an imbalance between these two regulatory 
processes in some remodelling diseases in which fibroblasts produce more 
collagen than is degraded [140]. Collagen types I, III, IV, and V can be 
demonstrated in healthy and fibrotic human lungs. Generally their localisation in 
the lung varies, for example collagen type I is mainly found in the interstitium of 
alveolar septa, collagen type III is more abundant and is found in alveolar septa  
and a perivascular, collagen type IV is found in alveolar and capillary basement 
membranes, and collagen type V is found in the interstitium [141].   
Collagen is the most abundant protein produced in the lungs and it is produced 
during the normal growth and repair processes. Excessive deposition in the lung is 
the main characteristic feature of IPF. Type I collagen (COL1 gene) is considered 
the main fibrous collagen synthesized by wound fibroblasts during the repair 
process [142]. During lung fibrosis there is an increased amount of collagen type I 
in thickened alveolar septa, with a reduced amount of collagen type III. There are 
no changes in collagen type IV, but an increase in collagen type V was observed 
in the interstitium and in areas of smooth muscle cell proliferation [141].   
Measurement of collagen metabolism is important in evaluating of the fibrosis in 
IPF patients. Analysis of IPF patients serum demonstrated an increase in the 
concentration of the 7S domain (7S collagen) of type IV collagen compared with 
serum from healthy people or people with other non-fibrotic pulmonary diseases 
[143]. Inhibiting collagen synthesis has a beneficial effect on fibrosis. 
Administration of antisense oligonucleotides (AS60) to type I collagen on a  human 
skin organ culture had a protective effect as shown by a reduction in the mRNA 
expression and translation of collagen type I [144].   
 
 
1.3.5 Fibroblasts and pulmonary fibrosis 
Many cells participate in the progression of pulmonary fibrosis, for example 
fibrocytes which are bone marrow-derived mesenchymal progenitor cells that can 
differentiate into fibroblasts, myofibroblasts and adipocytes [145]. Increased 
numbers of circulating fibrocytes have been found in the peripheral blood of mice 
in response to the bleomycin injury [146]. Fibrocytes produce proteins and 
glycoproteins which participate in tissue remodelling including collagen types I and 
III, vimentin and matrix metalloproteinases. Fibrocytes isolated from wounds of 
animal models of wound repair expressed mRNA for  IL-1β, IL-10, TNF-α, 
monocyte chemotactic protein (MCP), macrophage inhibitory protein-1α (MIP-1α), 
macrophage inhibitory protein-1β (MIP-1β), MIP-2, platelet-derived growth factor-
A (PDGF-A), TGF-β1, and M-CSF [147].  
It is widely accepted that activation in fibroblast foci and epithelial injury are key 
regulatory components that  trigger a cascade of changes leading to 
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reorganization of pulmonary tissue compartments [148]. Phenotypic characteristics 
of pulmonary fibroblasts, for example, their migratory and contractile properties 
participate in relocation of the lung fibroblast to wound areas resulting in an 
increase in fibrogenesis [149]. Fibroblasts cooperate with inflammatory cells to 
regulate fibrosis. Inflammatory cytokines, mediators and growth factors act directly 
on fibroblasts to induce proliferation and differentiation, therefore, the interaction 
between fibroblasts, inflammatory cells, parenchymal, and pulmonary epithelial 
and endothelial cells is important during fibrosis as illustrated in (Figure 1. 12) 
[150].  
Activation of fibrocytes results in their differentiation into fibroblasts. Fibroblasts 
are key cells involved in wound healing and fibrosis. They are characterised by 
their ability to produce extra cellular matrix (ECM) and to differentiate into 
myofibroblasts which participate in the contraction of wound edges and closing the 
injured tissue [151]. In IPF, the fibroblasts differentiate into myofibroblasts which 
are characterised by having a greater contractile and stronger pro-fibrotic activity. 
These myofibroblasts can differentiate from resident lung fibroblasts or they may 
be derived from epithelial cells through a process of epithelial-mesenchymal 
transition [152].  
Excessive myofibroblast differentiation including production of extracellular matrix 
components such as collagen I, III and fibronectin results in dysregulation in lung 
repair and remodelling [153].  
 
 
 
Figure 1.12 Main cells involve in pulmonary fibrosis                                                                         
Fibroblasts are the central cell in pulmonary fibrosis and their interaction with inflammatory 
and parenchymal cells is essential in the course of the disease (copied from [150] with 
permission). 
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1.3.6 Pulmonary immune and inflammatory cells in the lung 
It is unresolved whether inflammation is a necessary and sufficient prerequisite for 
IPF.  However IPF is characterised by the involvement of inflammation and 
different kinds of immune and inflammatory cells may participate in the initiation 
and continuation of the disease. These  immune and inflammatory cells include 
macrophages, lymphocytes, dendritic cells, and mast cells [150]. Macrophages are 
characterized by their production of a wide range of inflammatory mediators in 
response to stimulation. For example, in experimental models of pulmonary 
fibrosis stimulated by administration of bleomycin, lung macrophages produce 
mediators including TGF1 and TNF-α [154]. Macrophages are involved in the 
development of IPF. BAL alveolar macrophages from IPF patients have a reduced 
apoptotic rate that did not correlate with a reduction in the expression of mediators 
involved in the apoptotic pathways [155].  
Generally, IPF is characterised by an inflammatory response dominated by a 
helper T-cell (Th2-type) response and a shift to alternatively activated (M2) 
macrophagesthat normally control extracellular matrix and wound healing [156]. 
M2 macrophages are thought to be important for resolving inflammation and in the 
wound repair process. They produce anti-inflammatory cytokines such as 
interleukin-1 receptor antagonist (IL-1Ra) and pro-fibrotic cytokines such as TGFβ 
[157]. Also M2 macrophages markedly express tissue inhibitors of 
metalloproteinase that inhibit MMPs and impair remodelling of excess deposited 
ECM [158].  
There is some controversy concerning the role of T lymphocytes in IPF. Conflicting 
data suggested they have either a pro-fibrotic, an anti-fibrotic, or a neutral role in 
pulmonary fibrosis [159]. A recent study has suggested that IPF is an immunologic 
disease, because they demonstrated that lymphocytes can directly damage the 
lung tissue [160]. In a screening study of IPF patients, blood CD4 lymphocytes had 
significant down-regulation of CD28 in response to repeated antigen-driven 
proliferation in vitro, and these cells were characterised by an increased 
production of pro-inflammatory cytokines and cytotoxic mediators, which were 
associated with a poor prognosis for the IPF patient. In another study, regulatory 
CD4+CD25+FOXP3+ T cells (Treg) in the BAL of IPF patients had an impairment 
of their suppressor effect on helper T-cell type 1 and 2 cytokine secretion [161]. 
Dendritic cells (DCs) participate in sustaining the chronic inflammation of IPF by 
producing pro-inflammatory mediators. In lung tissue of IPF patients with 
advanced disease, there is an accumulation of DCs in the pulmonary parenchyma 
and in areas of epithelial hyperplasia and established fibrosis [162]. There is an 
increased absolute count and relative proportion of neutrophils in BAL of IPF 
patients which is associated with early mortality [163]. Increased numbers of mast 
cells have been demonstrated in lung tissue sections of IPF patients, but their role 
in pathogenesis is still unresolved. Studies on human mast cells identified that 
they are a source of some pro-fibrotic factors for example TGFβ and tryptase [164]. 
However bleomycin can induce fibrotic responses equally in wild type and mast 
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cell deficient mice strains (our own unpublished data and [165]), suggesting a non-
essential role. However, how this observation applies to humans is unknown. 
 
1.3.7 Inflammatory mediators in IPF 
Fibrogenic cytokines and growth factors are important mediators involved during 
the course of IPF. Mediators such as platelet-derived growth factor (PDGF), TNF-
α , and  TGFβ1 can mediate recruitment and phenotypic modulation of fibrocytes, 
fibroblasts and myofibroblasts [148]. TGFβ1 is an importantmediator in IPF. It 
regulates the differentiation of pulmonary fibroblasts into myofibroblasts, as seen 
by their expression of smooth muscle actin (SMA), and by their increased tissue 
fibrogenesis and migratory activities [142].  
IL-1is an important pro-inflammatory cytokine. Animal experiment performed on 
rat models of IL-1β induced fibrosis demonstrated high expression levels of pro-
inflammatory and pro-fibrotic mediators e.g. TNF-, IL-6, PDGF, and TGF-1,  
associated with progressive fibrotic changes in the lung manifested by 
accumulation of fibroblasts, myofibroblasts, collagen and fibronectin [166].  
TNF-, a potent pro-inflammatory cytokine with an involvementrole in IPF. Animal 
model of bleomycin-induced pulmonary fibrosis using TNF--/- mice demonstrated 
intense and persistent inflammation due to reduced apoptosis of inflammatory 
cells. Administration of exogenous murine recombinant TNF to these mice lead to 
elimination of inflammatory cells from the bronchoalveolar space by apoptosis and 
improved tissue repair of damaged lungs [167].  
Chemokines and their receptors have been demonstrated in IPF. MCP-1/CCL2 
and MIP-1α/CCL3 are pro-inflammatory chemokines produced by macrophages, 
lymphocytes and fibroblasts which can regulate monocyte recruitment. CCL2 and 
CCL3 are up-regulated in BAL fluid of mice with bleomycin-induced lung fibrosis  
and of IPF patient [168].   
The major pro-inflammatory and pro-fibrotic mediators that participate in fibrosis 
are illustrated in (Figure 1.13). 
 
 
 
50 
 
 
 
 
Figure 1.13 Major pro-inflammatory and pro-fibrotic mediators that participate in fibrosis                              
Entry of irritants such as bleomycin lead to injury of lung epithelial cells and this may be 
detected by the Nalp3 inflammasome in macrophages. Irritants also stimulate the 
production of inflammatory mediators (cytokines, chemokines, and ROS). These mediators 
potentiate leukocyte recruitment and activation. For example, IL-1β can induce the 
activation of ROS-expressing neutrophils resulting in addition destruction of epithelial cells. 
IL-1β also promotes production of TGFβ1 which can 1- Stimulate fibroblast proliferation and 
differentiation. 2- Stimulate epithelial-mesenchymal transition resulting in the formation of 
ECM-producing myofibroblasts. 3- Stimulating the differentiation of Th17 resulting in 
promotion of inflammatory process (copied from [134] with permission). 
 
 
1.3.8 Symptoms and Diagnosis 
The lung has considerable functional reserve and elasticity which helps to 
compensate for any decrease in oxygen tension or tissue damage. This reserve 
means that there can be extensive lung damage before symptoms become 
apparent. During conditions for example in pulmonary fibrosis the lungs lose 
elasticity because of the deposition of excess collagen, and the consequent 
thickening or the alveolar walls restricts gas transfer resulting in shortness of 
breath. The symptoms of IPF include cough and progressive dyspnoea. 
As the symptoms and signs of IPF are common symptoms of many forms of 
respiratory disease, the diagnosis depends on the recognition of a pattern of 
symptoms and signs followed by more specific tests. Auscultation demonstrates 
fine end-inspiratory crackles on the basal areas. Lung physiological tests are used 
to demonstrate decreases in the partial pressure of oxygen in the blood (PaO2) 
and an impairment in gas exchange [135]. A tentative diagnosis can be performed 
using histo-pathological investigation and imaging, for example, high-resolution 
computed tomography (HRCT) scan [114].  
Histo-pathologically, the affected areas are subpleural and in the para-septal 
parenchyma. Fibrotic lung tissue sections show a heterogeneous appearance with 
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areas of fibrosis in comparison with the other areas of normal or less affected 
parenchyma. The fibrotic changes manifested by deposition of dense collagen, 
and fibrotic foci consist mainly of fibroblasts and myofibroblasts. The inflammatory 
changes are characterised by an infiltration of lymphocytes, plasma cells, 
hyperplasia of type 2 pneumocytes and bronchiolar epithelium. HRCT 
demonstrates these changes as honeycombing; basilar and sub-pleural reticular 
abnormalities and opacities [114]. 
Investigating serum biomarkers such as Krebs-van-den-Lungen KL-6, a high MW 
glycoprotein (MUC1 mucin), has been of diagnostic value. Serological examination 
performed on IPF patients demonstrated an increase in the level of circulating KL-
6. These levels can predict the increased risk of subsequent mortality [169]. 
Similarly, plasma concentrations of osteopontin (OPN), a fibrogenic cytokine 
produced by alveolar macrophages has been investigated in IPF patients. Plasma 
levels of OPN correlate inversely with arterial oxygen tension in IPF patients [170]. 
Measuring matrix metalloproteinase (MMP) concentration can help in the 
demonstration of asymptomatic IPF and correlated with prognosis. The analysis of 
IPF patients exhibited an increase in the level of MMP1 and MMP7 in BAL and 
plasma [171].  
 
1.3.9 Treatment 
There are few specific treatments available for IPF and none that are curative. 
Since there is no specific treatment, the main goal is to suppress the progression 
and control the symptoms of the disease. Treatment options depend on the stage 
and severity of the disease. 
Corticosteroids are characterised by their ability to limit acute inflammation. They 
inhibit lymphocyte and neutrophil migration into the lung and alter alveolar 
macrophage function. There is no clear long term beneficial effect on IPF patient 
survival in response to treatment with corticosteroids alone or in combination with 
other agent. Current evidence suggests that using corticosteroid alone is not 
indicated in the treatment of IPF [172]. The other main therapy is N-acetylcysteine, 
as a mucolytic agent which characterised by its anti-oxidant properties. 
Disturbances in oxidant/anti-oxidant balance may be one of the mechanisms for 
alveolar cell injury and controlling this by using a high dose of acetylcysteine, a 
precursor of the antioxidant glutathione, in addition to prednisone and azathioprine, 
preserves vital capacity and carbon monoxide diffusing capacity (DLCO) in 
patients with IPF better than single drug standard therapy [173].  
Targeting proteins involved in the development of IPF is another therapeutic 
approach. TGF-β1 is a powerful pro-fibrotic, pro-inflammatory, and 
immunomodulatory cytokine. TGFβ1 is involved in the dysregulation of tissue 
repair resulting in an increase in synthesis of extracellular matrix accompanied by 
inhibition of matrix degradation.  Targeting of inflammatory pathway steps 
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downstream of TGF-β1 activation induced c-Abelson (c-Abl), a proto-oncogene 
and Imatinib, a tyrosine kinase inhibitor and inhibitor of c-Abl, exhibited a beneficial 
effect preventing pulmonary fibrosis in a murine model of bleomycin induced 
fibrosis. However, Imatinib was unable to prevent IPF progression in a phase II/III 
study of patients [135]. Recently, pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) 
a new potential anti-inflammatory, anti-fibrotic and antioxidant drug that acts by 
inhibiting TGF-β has been tested. A study on IPF patient demonstrated that 
treatment with pirfenidone may decrease the rate of decline in vital capacity (VC) 
and may increase the progression-free survival (PFS) time over 52 weeks [174]. 
Another promising molecule is Galectin-3, a β-galactoside binding lectin highly 
expressed in fibrotic tissue of diverse diseases. A study of murine bleomycin 
models of lung fibrosis using galactin-3-/-  mice or mice treated with a novel 
inhibitor of galectin-3, TD139, demonstrated an inhibition of TGFβ1-induced EMT 
and myofibroblast activation and blocking of collagen production [175]. 
Recently, more studies have been looking to determine a number of potential 
molecular therapeutic targets for IPF such as endothelin-1 (ET-1), a 
vasoconstrictor and mitogenic peptide [176], studies in humans have determined 
that ET-1 is a mediator in IPF, therefore, targeting of this molecule is beneficial. 
Bosentan, a nonselective endothelin receptor antagonist approved in the USA and 
Europe for the treatment of patients with pulmonary arterial hypertension. Recent 
trial study demonstrated that there was no significant difference between IPF 
patient treated with treatment with Bosentan and placebo groups for time to death 
or to IPF worsening [177].  
Lung transplantation is the final resort in severe IPF. This procedure has 
considerable risk in patients over 60 years and since the average age of IPF is 
around 70 years, therefore, only a small proportion of IPF patient may benefit with 
the emphasis in treating younger patients [178]. Good supportive care should be 
provided for IPF patients and this includes oxygen therapy, pulmonary 
rehabilitation, and use of analgesia.  
 
1.3.10 Animal models of pulmonary fibrosis 
The use of experimental animal models of fibrosis provides an opportunity to test 
the key aspects to improve the understanding of the pathogenesis of human IPF. 
We recognise that there are differences between IPF in human and animal models 
of fibrosis, however, using these models is one of the few research opportunities 
available. Different models have been demonstrated in animals, e.g. 
administration of bleomycin, fluorescein isothiocyanate, or silica, or by irradiation, 
or by transgenic expression of pro-fibrotic molecules including by viral vectors, and 
by adoptive cell transfer [179].  
Bleomycin-induced pulmonary fibrosis is the most widely used experimental model 
in animals. Bleomycin is an antibiotic generated by Streptomyces verticillus and 
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was discovered in 1966. It had limited anti-bacterial activity but had useful anti-
tumour ability and was developed for treating different types of tumours [180]. The 
main side-effect of treatment with bleomycin was the development of interstitial 
pulmonary fibrosis [181]. Because of this, bleomycin has been used in different 
species such as mouse, rat, dog, hamsters, rabbits, guinea pigs, and primates 
using different doses administrated via different routes e.g. intraperitoneal, 
intravenous, subcutaneous, or intra-tracheal resulting in a pathological response 
that includes  alveolar epithelial damage, consolidation of alveoli, fluid and plasma 
proteins leakage into the alveolar space, formation of hyaline membranes, type I 
epithelial cells necrosis, and type II epithelial cells metaplasia. Inflammatory 
infiltrates, and fibrosis develops in sub-pleural regions [179]. The acute 
inflammation start within hours of administration followed by fibrosis which 
develops commonly over a 2 to 3 week period [182]. 
Fluorescein isothiocyanate (FITC)-induced pulmonary fibrosis is induced after 
intra-tracheal installation of FITC. This results in development of inflammatory 
changes for example, infiltration of granulocytes, T lymphocytes in areas of FITC 
deposition associated with subsequent development of pulmonary fibrosis [183]. 
One advantage of this model is the ability to visualise areas where deposition 
occurs by using fluorescence which shows that the fibrotic changes occurred only 
in areas of FITC deposition and also that the fibrotic response continued for more 
than 6 months [183].      
Silica induced pulmonary fibrosis is another experimental model of pulmonary 
fibrosis that is considered to replicate occupational fibrosis found in stone masons. 
The model is induced by instilling silica particles into the lung which causes tissue 
damage associated with the inability of phagocytes to remove these particles, 
resulting in sustained inflammatory and fibrotic processes [182]. The use of silica 
in animals caused the development of a slowly progressive form of pulmonary 
fibrosis accompanied by granulomatous inflammation. This model requires a 
longer time period than bleomycin to develop pulmonary fibrosis. Several months 
were required to develop the same degree of fibrosis as that achieved by 
bleomycin in weeks. The advantage of this model is from the dependence of this 
model on macrophages and other mononuclear phagocytes; the fibrosis is 
demonstrated as fibrotic nodules that develop in areas of silica deposition [184, 
185]. 
Irradiation-induced pulmonary fibrosis is performed by exposure to a single dose 
of 12.5 Gy irradiation to the thorax resulting in pulmonary fibrosis at 26 weeks 
[186]. The fibrotic response in animals depends on the irradiation dose and their 
genetic background [187]. Histological examination of nine strains of mice 
exposed to irradiation demonstrated differences between strains in the focal 
fibrosis, the development of hyaline membranes and the fibrin concentration in 
oedema fluid. The inflammatory and fibrotic processes are characterised by sub-
pleural foci of collapsed alveolar walls with collagen deposition, the fibrotic 
response was stronger in C57 strains than the rest of experimental strains. TGFβ 
and TNF-α have been implicated as important signals in the development of 
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irradiation-induced fibrosis [188, 189]. One advantage of this model is the different 
response depending on the genetic background.   
Models of pulmonary fibrosis can be induced by transfer of transgenic mediators 
into laboratory animals. These transgenic models show the importance of the 
continuous expression and production of the mediators coded by the transgene to 
the patho-physiological fibrotic changes. An alternative method of transgenic 
delivery using vectors such as adenoviral vectors provides a more transient 
production of the mediator potentially involved in the processes of fibrosis. For 
example adenovirus-mediated gene transfer techniques were used to transfer 
some of the highly expressed growth factors, cytokines, and chemokines such as 
TGFβ which had been determined to cause a strong fibrotic lung injury in 
rodents. These viruses are highly trophic for epithelial cells with low transfection 
efficiency for other cell types found in the lung. Rat lung transfected with 
replication-deficient adenovirus vectors transferring the cDNA of TGF1 resulted in 
high expression of TGF1 accompanied by severe fibrosis and excessive 
deposition of collagen, fibronectin, and elastin [190]. Using this model helps to 
determine the effect of a single potentially inducible gene product on fibrosis. 
However, this model is limited by the immunogenicity of these vectors, thus 
preventing repeated dosing.  
Adoptive transfer of human cells into immune-deficient mice provides another 
potential model of pulmonary fibrosis. Human fibrocytes passively transferred into 
the mouse can migrating into the lung after challenge with bleomycin and can be 
shown to participate in lung remodelling [191]. While none of the animal models 
mentioned above have the ability to show all of the main characters of usual 
interstitial pneumonia, the pathologic correlate to IPF, these models are important 
because it provides an experimental models for understanding the mechanisms 
involved in the pulmonary fibrosis and also provide an opportunity to test a new 
therapeutic drugs. 
     
1.3.11 IPF: The clinical unmet need  
The incidence of IPF is greater than that of ovarian cancer, similar to those of 
pancreatic cancer and of all leukemias combined, and nearly 30 times that of 
cystic fibrosis. An estimated 100,000 people are living with IPF in the United 
States, and more than 30,000 new cases are diagnosed annually. In UK 
approximately 5000 people are diagnosed annually and the incidence has been 
rising; from 1 per 100,000 of the population in 1991-5, to 1.5 from 1996-1999, to 
2.5 from 2000-2003. Currently the incidence in Scotland is 5.7 per 100,000, 
making it one of the highest in the world. 
There is no effective therapy for IPF and this represents an increasing clinical 
unmet need. The necessary development of new therapies is limited by our lack of 
understanding of the disease process. We recognise that there is limited empirical 
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evidence to support a role for LXR in a fibrotic process; however, we feel that 
there is sufficient to justify this project. Our approach is novel and will therefore 
generate new data. We will keep the focus of new findings on the potential 
benefits to patients. 
  
1.4 Hypothesis and Aims  
                                                                                                                                
Hypothesis: We hypothesised that LXRs can modulate bleomycin-induced 
pulmonary fibrosis.  
Aims:  To test this hypothesis, I tried to achieve the following aims:- 
1- My first aim was to validate the model by determining the optimum 
experimental condition for murine bleomycin-induced pulmonary fibrosis. I 
aimed to achieve the following:- 
 
A- Evaluate the time course require to get the optimum inflammatory and 
fibrotic changes. 
 
B- Select the dose of LXRs agonist GW3965 required to investigate the 
effects on the severity of the pulmonary fibrosis. 
 
 
C- Understand the effect of LXR agonist GW3965 and the vehicle excipient 
Cremophor on the wild type mice given PBS. 
 
D- Validate the accuracy of gene deletion for LXRαβ-/- mice. 
 
2- Determine the correlation of single or double Liver X Receptors activation 
and the development of lung fibrosis in murine model of pulmonary fibrosis. 
 
3- Demonstrate the role of MicroRNA-155 in the course of pulmonary fibrosis 
in a murine model of pulmonary fibrosis.   
To achieve these aims I used an experimental model of murine pulmonary fibrosis 
which occurs after administration of bleomycin sulphate. This was tested under 
different experimental conditions and using a variety of gene-deleted mice strains. 
These are outlined in the following Material section and in more detail is each 
Results chapter section. 
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2. Materials and Methods  
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2.1 General materials                                                                                                                                                                  
 
Chemicals: The chemicals used in these projects were purchased from Sigma 
(Dorset, UK) unless otherwise mentioned. 
 
Plastics: The plastic ware used in these projects were purchased from Corning 
and Gibco (Corning, NY, USA) unless otherwise mentioned.  
 
2.2 General buffers & reagents 
 
Complete medium RPMI 1640: Consists of RPMI1640 Invitrogen (Paisley, 
UK), 10% foetal calf serum, L-Glutamine (2mM), Penicillin (100 units/ml) and 
Streptomycin (100 g/ml). 
 
Wash medium: Consists of RPMI1640 (Invitrogen), L-Glutamine (2mM), Penicillin 
(100 units/ml) and Streptomycin (100 g /ml). 
 
Complete medium DMEM: Consists of Dulbecco’s Modified Eagle’s Medium 
(Sigma), 10% foetal calf serum, L-Glutamine (2mM), Penicillin (100 units/ml) and 
Streptomycin (100 g/ml). 
 
Complete medium RPMI:  Consists of RPMI 1640 (Invitrogen), 10% heat 
inactivated foetal bovine calf serum, Penicillin (100 units/ml), Streptomycin (100 
g/ml) and L-Glutamine (2 mM).  
 
Trypsin EDTA: Consist of trypsin EDTA 0.05% (Invitrogen). 
 
Bleomycin:  Bleomycin sulphate, from Streptomyces verticillus (Sigma) was 
dissolved in PBS at a stock 1mg/ml. A dose of 0.1mg in 30 l per 25 g mouse, was 
used in vivo administrated by intranasal installation under anaesthesia. 
 
LXR agonist: GW3965 was synthesised and donated by Schering-Plough 
Corporation (Hertfordshire, UK) and supplied in 2 g vials. This was dissolved in 5% 
Cremophor (Sigma)/ PBS as excipient and used in doses for daily administration 
in vivo by intraperitonial injection. For the in vitro work the agonist were dissolved 
in DMSO Riedel-de Haen (Hanover, Germany). 
 
PBS: Phosphate buffered saline (Invitrogen). 
 
ELISA wash buffer: 0.05% Tween 20 in PBS. 
 
Trypan blue solution:  Stock 0.4 g Trypan blue solution (0.4%) was purchased 
from (Sigma). This was diluted 1:10 with PBS before use. 
 
0.1 M Bicarbonate buffer (100 ml): 0.84 g sodium bicarbonate (NaHCO3) was 
dissolved in a final volume of 100 ml dH2O and stored at 4oC. 
 
1 N HCL (100 ml):  8.33 ml of 12 N HCL was added slowly to 91.67 ml deionised 
water and mixed well. 
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1.2 N NaOH/0.5 M HEPES (100 ml):  12 ml of 10 N NaOH was added to 75 ml 
deionised water to which was added 11.9 g HEPES and mixed well.   
 
2.5 N Acetic Acid/10 M Urea (250 ml):  150.2 g urea was added to 100 ml 
deionised water and mixed well until dissolved. To this was slowly added 35.9 ml 
glacial acetic acid then bring the final volume to 250 ml with deionised water. 
 
2.7 N NaOH/1 M HEPES (250 ml):  67.5 ml of 10 N NaOH was added to 140 ml 
deionised water and mixed well, then 59.5 g HEPES was added and the final 
volume was brought to 250 ml with deionised water.   
 
Tris-acetate-EDTA (TAE) buffer:  50 X TAE stock solution was made by 
dissolving of 242 g of Tris base in 750 ml dH2O. Mixed well then added to 57.1 ml 
glacial acetic acid and 100 ml 0.5 M EDTA (pH 8.0). The final volume was then 
made up to 1 litre with dH2O. The working concentration was made by diluting this 
buffer 1:50 with dH2O.  
 
Liquid broth (LB medium, Sigma): Prepared by dissolving 10 g tryptone, 5 g 
yeast extract, 10 g NaCL, and 15 g agar in one litre of distilled water. This was 
mixed well until all the components were dissolved completely, then sterilized by 
autoclave and stored at 4oC until use. 
 
Nutrient agar plates:  10 ml of liquid broth with 100 g/ml ampicillin was poured 
into Petri dishes and left to set at room temperature until it solid then stored at 4oC 
until use.    
 
2.3 In vivo work 
 
2.3.1 Animal husbandry 
 
Animals were housed in the Biological Services Joint Research Facility (JRF) at 
the University of Glasgow. All animals were kept in a pathogen free environment 
with free access to food and water. The procedures were carried out using an 
approved personal licence by the United Kingdom Home Office and in accordance 
with the Animals (Scientific Procedures) Act 1986. 
 
2.3.2 Mice 
                                                                                                                                
C57BL/6 mice: Male mice were purchased from Harlan (Blackthorn, UK) and 
allowed to adapt under quarantine for one week before the procedures were 
carried out. 
 
LXR null mice: LXRα-/-β-/- double knockout mice were bred in house from LXRα-/- 
and LXRβ-/- mice and wild-type (WT) littermates on a C57BL/6 background. The 
single knockout mice were generated by Lexicon (The Woodlands, TX, USA) and 
supplied by Schering Plough Corporation (UK).   
                                                                                                                                         
LXRα-/-β-/- double knockout mice were generated following a schematic breeding 
programme which included crossbreeding of LXRα-/- mice with LXRβ-/- mice 
resulting in the generation of LXR/ heterozygotes, which were confirmed by a 
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PCR demonstrating of genomic DNA for LXR genotype. These heterozygote mice 
were self-crossed resulting in the generation of LXRα-/-β-/- mice of both sexes, 
which was confirmed by PCR demonstrating the LXRα and LXRβ genotypes. 
Other genotypes were identified but they were not of interest for our study. LXRα-/-
β-/- mice were selected and crossbred to generate more breeding pairs, which 
were screened by PCR to confirm the absence of both LXRα and LXRβ before 
setting up breeding colonies. 
 
Mir-155 null mice: Male microRNA-155-/- knockout mice (miR-155-/-) mice on a 
C57BL/6 background were purchased from Jackson Laboratories (Bar Harbor, ME, 
USA). MiR-155-/- mice were backcrossed with C57BL/6 to get WT control 
littermates. Both strains then were bred in-house in a pathogen-free facility [44]. 
The absence of miR-155 confirmed by PCR and by experimentation.  
 
Justification of numbers of mice used power analysis: the purpose of a power 
analysis is to minimise type 1 and type 2 errors. This requires an estimate of 
variability in the primary end-point which is day 18 fibrosis. There are many 
publications describing the bleomycin-induced model of lung fibrosis but none to 
our knowledge which addresses this issue. This is similar to the use of the 
collagen-induced arthritis model. This suggests that group numbers are decided 
by pragmatism; based on our experience. We and others find that the bleomycin 
model is highly variable and our experience is that minimum group numbers of 8 
are required to show effects. 
 
 
2.3.3 Administration of PBS or bleomycin in C57BL/6 
mice  
 
Choice of species: I am fully committed to the concept of Replacement, 
Refinement and Reduction as an ethical and humane framework for conducting 
scientific experiments using animals. Mice are the least sentient species in which 
auto-immune and inflammatory models have been developed. Their use is a 
refinement of the use of higher animals. 
 
Choice of models: Mice don’t normally develop interstitial lung disease. This 
model therefore requires stimulation or disruption of cells or molecules involved in 
inflammation. Administration of bleomycin is the most commonly used model. We 
used the most up-to-date refined protocols that are widely accepted by the 
scientific community to represent human interstitial lung disease. 
 
Minimising animal suffering: We have several measures in place in order to reduce 
animal suffering, including daily monitoring.  
Male C57BL/6 mice were purchased at 7-8 weeks old. On day zero of the 
experiment the mice were anesthetised using isofluorane inhalation in an 
anaesthetic chamber. Mice were then given intranasally (i.n.) either 0.06 mg 
bleomycin in 30 l PBS or 30 l PBS as control [192]. The mice were observed 
daily and body weight were recorded until day 32 in the time course experiments, 
or more typically on day18 when the mice were culled. 
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2.3.4 Administration of different doses of LXR agonist 
GW3965 or vehicle Cremophor in C57BL/6 mice given 
bleomycin  
                                                                                                                                  
Different doses of LXR agonist (GW3965 in 5% Cremophor/PBS) or vehicle 
(excipient 5% Cremophor /PBS) were administered daily to male C57BL/6 mice for 
3 days before they were given bleomycin intranasally and then each day thereafter. 
The mice were divided into three groups (n=10 per group), 10-12 week old and 23-
25 g weight. Three days prior the experiment mice were given daily intraperitoneal 
injections of 3 mg/kg LXR agonist, 30 mg/kg LXR agonist or vehicle which 
continued until the end of the experiment. On day zero of the experiment all 
animals were anesthetised using isoflurane in an inhalation anaesthetic chamber. 
Then mice were then given intranasally 0.06 mg of bleomycin sulphate in 30 l 
PBS / 25g mouse. The mice were monitored daily for wellbeing and changes in 
body weight until day 18 when the mice were culled. The following table illustrate 
the typical samples collected at a cull (Table 2.1). 
 
 
Sample Usage 
Lung tissue Histology (H&E and Trichrome stain ) 
Soluble collagen content 
mRNA expression by PCR 
Bronchoalveolar lavage Cytology (total and differential cell 
count) 
Fluid cytokines 
Blood Serum cytokines 
                                                                                                                                                           
Table 2.1 Typical samples collected on a cull day 
 
 
2.3.5 Experimental detail of bleomycin-induced 
pulmonary fibrosis in LXR
-/-

-/-
 double knockout and 
LXR wild type mice  
                                                                                                                                
Bleomycin-induced pulmonary fibrosis is widely used as model for human 
pulmonary fibrosis. It was first described by Adamson and colleague [193]. 10-12 
weeks male LXRα-/-β-/- and LXRαβ wild-type mice were used for bleomycin-
induced pulmonary fibrosis.                                                                                                                                 
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Mice were allocated to 4 groups (n=19-23 mice per group):-                                                    
                                                                                                                                                  
A- WT treated with vehicle (control)                                                                                         
B- WT treated with LXR agonist                                                                     
C- LXRα-/-β-/- treated with vehicle 
D- LXRα-/-β-/- treated with LXR agonist  
On the day of induction (day zero) mice were anesthetised using isoflurane 
inhalation in an anaesthetic chamber. All animals were given bleomycin sulphate 
(Sigma) intranasally at concentration of 0.06mg in 30 l PBS / 25g mouse [192]. 
Mice were treated with either 30 mg/kg LXR agonist or vehicle. The daily 
intraperitoneal injection of this treatment started 3 days prior the inductions of the 
model and continued until the mice were culled. The mice were monitored daily for 
wellbeing and changes in body weight until day 18 when the mice were culled. 
 
2.3.6 Experimental detail of bleomycin-induced 
pulmonary fibrosis in LXR
-/-
 knockout and LXR
-/-
 
knockout mice 
                                                                                                                                                           
To determine the role of single LXR KO the following experiment was performed. 
10-12 weeks male of LXRα-/- and LXRβ-/- mice were used for induction of 
bleomycin pulmonary fibrosis.                                                                                                                                    
Mice were allocated to 4 groups (n=19-23 mice per group):-                                                       
A- LXRα-/- treated with vehicle                                                                                                                                          
B- LXRα-/- treated with LXR agonist                                                                                                      
C- LXR-/- treated with vehicle                                                                                               
D- LXR-/- treated with LXR agonist                                                                                      
Three days prior the experiment mice were treated with daily injections of LXR 
agonist or vehicle and this continued until day 18 when the mice were culled. On 
the day of induction of fibrosis (day zero) animals were anesthetised using 
isofluorane inhalation in an anaesthetic chamber. All animals were given 
bleomycin sulphate intranasally 0.06mg in 30 l PBS / animal. The mice were 
monitored daily for wellbeing and changes in body weight until day 18 when the 
mice were culled 
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2.3.7 Experimental detail of bleomycin-induced 
pulmonary fibrosis in MicroRNA-155
-/-
 and MicroRNA-155 
wild-type mice  
                                                                                                                       
Bleomycin-induced pulmonary fibrosis was established using miR-155-/- and miR-
155 wild-type mice. 10-12 week old male were used, and animals were allocated 
to four groups (n=7-14 mice per group):- 
A- WT given bleomycin 
B- WT given PBS 
C- MiR-155-/- given bleomycin  
D- MiR-155-/- given PBS  
On the day of induction of fibrosis (day zero) mice were anesthetised using 
isofluorane inhalation in an anaesthetic chamber. Mice were given intranasally 
either bleomycin sulphate 0.06mg in 30 l PBS / animal or 30 l PBS / animal. The 
mice were monitored daily for wellbeing and changes in body weight until day 18 
when the mice were culled. 
 
2.3.8 Clinical observation of mice  
                                                                                                                                  
The PhD candidate is qualified with a sufficient knowledge and with experience in 
clinical field. Mice were monitored daily for changes in body weight and general 
health. The maximum allowance for body weight loss was 20% of the weight on 
day zero. 
 
2.4 Cytological evaluation of bronchoalveolar lavage                                                          
Bronchoalveolar lavage (BAL) was performed to obtain leukocytes from the airway 
and alveolar spaces. The trachea was opened transversely sufficient to allow entry 
of a small polyethylene catheter 0.5 cm on the end of a syringe needle and this 
was located by a knot of surgical ligature. The lungs were washed by aspiration 
two times with separate 0.8 ml of PBS and the BAL fluid collected. This volume of 
fluid was chosen because it did not cause distortion affecting subsequent lung 
histological investigation. The BAL fluids were centrifuged at 1200 rpm for 5 
minutes. The supernatant was stored for measurement of airway cytokines 
measured by enzyme-linked immune-sorbent assay (ELISA). The cell pellet was 
re-suspended with PBS and the total and differential number of infiltrating 
leukocytes was quantified as described in [194]. Briefly, the total number of BAL 
leukocytes was demonstrated by counting leukocytes in a modiﬁed Neubauer 
chamber. Differential counts were obtained from cytospin (Shandon III) 
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preparations by determining the percentage of each leukocyte on a slide stained 
with Giemsa stain. 
2.5. Lung tissue preparation 
                                                                                                   
2.5.1 Preparation of lungs for histology 
                                                                                                          
2.5.1.1Tissue processing, embedding & sectioning 
 
Processing 
                                                                                                                                            
The whole lung units were excised from mice. The largest lobe (left lob) was 
separated from the others and preserved in 10 ml of 10% neutral buffered formalin 
(Sigma) for 24 hours at room temperature. The next day the tissue was incubated 
in 70% ethanol for two hours at room temperature before further processing by an 
automated tissue processor (Thermo, Citodel 1000) which transferred the tissues 
through increasing concentrations of ethanol until they were completely 
dehydrated and then embedded in wax. The conditions of this process are listed 
below: 
1. 10% neutral buffered formalin 24 hours 
2. 70% ethanol 2 hours 
3. 90% ethanol 1 hour 
4. 95% ethanol 1 hour 
5. 100% ethanol 2 hours – this step was repeated 3-fold 
6. Xylene 2 hours – this step was repeated 3-fold 
7. Paraffin wax 4 hours – this step was repeated 2-fold 
 
                                                                                                                            
Embedding 
                                                                                                                                          
Wax blocks were prepared immediately after the tissue processing was finished 
using Thermo scientific histocentre 3 embedding center (Loughborough, UK) 
followed by cooling of the blocks for 30 minutes. The blocks were stored at 4oC 
until they were used for sectioning. 
 
Sectioning  
                                                                                                                             
Tissue blocks were trimmed using a microtome set at 10 m to remove the excess 
wax. The blocks were placed on ice for 1 hour to harden the paraffin wax before 
further cutting. 4 m sections were cut and placed in a floating water bath set at 
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40oC. The sections were separated and placed on a charged frosted microscope 
slide (Superfrost plus, VWR, Lutterworth, Leicestershire, UK) and placed on a 
hotplate (Raymond A Lamb Hotplate, Thermo scientific) at 55oC for 1 hour to allow 
the tissue section to completely dry. The slides were stored at 4oC until required 
for staining. 
 
2.5.1.2 Haematoxylin and Eosin staining (H&E) 
                                                                                                                                  
For routine histological analysis the sections were stained using Haematoxylin and 
eosin (H&E). All the reagents used in the H&E staining were purchased from 
Sigma. The protocol is listed below and the different ethanol concentrations 
required were made by diluting 100% ethanol with dH2O to the required 
concentration (v/v). 
The staining procedure included several stages, softening of the wax by incubation 
the sections in an oven from GenLab (Cheshire, UK) at 60oC for 35 min followed 
by removing the wax from the section by immersing the sections in xylene. 
Rehydration of the sections was carried out by immersing the sections in gradually 
decreasing concentrations of ethanol to allow rehydration and subsequent staining 
with water soluble H&E. 
The two important components of the H&E are Harris Haematoxylin which stains 
nuclei and Eosin which stains the cytoplasmic structures. The staining was 
followed by dehydration of the sections by immersing them in gradually increasing 
concentrations of ethanol then the sections immersed in xylene before adding 
mounting fluid and coverslips.  
The steps are summarised in the following:  
1. Heating sections in oven at 60oC for 35 minutes 
2. Dewax in Xylene 3 minutes - repeated 2-times 
3. 100% Ethanol 3 minutes - repeated 2-times 
4. 90% Ethanol 3 minutes - repeated 2-times 
5. 70% Ethanol 3 minutes - repeated 2-times 
6. dH2O 3 minutes 
7. Harris Haematoxylin 2 minutes 
8. Running water 3 minutes 
9. 1% Acid/Alcohol few seconds 
10. Rinse under slow running tap water for a quick wash 
11. Scott’s tap water substitute 30 seconds 
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12. Rinse under slow running tap water for a quick wash  
13. 1% Eosin 2 minutes 
14. Running water 2 minutes 
12. 70% Ethanol 30 seconds 
13. 90% Ethanol 30 seconds 
14. 100% Ethanol 30 seconds - repeated 2-times 
15. Xylene 3 minutes - repeated 2-times 
16. The sections were mounted with one drop of DPX mount (VWR), the drop was 
placed on the section by Pasteur pipette then a cover slip (VWR) put over the 
section. The sections were allowed to dry in the hood before it examined under the 
microscope. 
                                                                                                                   
2.5.1.3 Gomori’s Trichrome stain  
                                                                                                                                          
The basic components of the Gomori’s Trichrome stain included chromotrope 2R 
(Sigma), fast green FCF (Thermo Scientific), phosphotungstic acid 
(Sigma).Different ethanol concentrations were prepared by diluting 100% ethanol 
with dH2O to the required concentration (v/v). 
Initially, the staining procedure started by softening of the wax by incubating the 
sections in an oven (GenLab) at 60oC for 35 min followed by removing the wax 
from the section by immersing them in Xylene. Rehydration of the sections was 
carried out by immersing the sections in gradually decreasing concentrations of 
ethanol. 
The sections were stained with Harris Haematoxylin which stains nuclei then by 
washing with dH2O. The sections were immersed with chromoptrope-green 
mixture to stain the collagen followed by quick rinse with acetic acid. This staining 
was followed by dehydration of the sections by immersing them in gradual 
increasing concentrations of ethanol then the sections were immersed in Xylene 
before mounting with coverslips.   
The steps are summarised as the following:   
1. Heating sections in oven at 60oC for 35 minutes 
2. Dewax in Xylene 3 minutes - repeated 2-times 
3. 100% Ethanol 3 minutes - repeated 2-times 
4. 90% Ethanol 3 minutes - repeated 2-times 
5. 70% Ethanol 3 minutes - repeated 2-times 
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6. dH2O 3 min 
7. Harris Haematoxylin 2 minutes 
8. Running water 3 minutes 
9. dH2O 5 minutes 
10. Chromoptrope-green mixture 20 minutes 
11. 0.2% acetic acid few seconds 
12. Running water 2 minutes 
13. 70% Ethanol 30 seconds 
14. 90% Ethanol 30 seconds 
15. 100% Ethanol 30 seconds repeated 2 times 
16. Xylene 3 minutes repeated 2 times 
The sections were mounted with one drop of DPX mount (VWR), and then a cover 
slip (VWR) was put over the section. The sections were allowed to dry in the fume 
hood before examination under the microscope. 
 
2.5.2 Histological evaluation of lung inflammation and 
fibrosis  
 
The severity of the inflammatory changes was assessed in the lungs by two 
observers blind to the experimental details. Typically 10 different low-power fields 
were used in the scoring of each tissue section. The parameters used in the 
scoring of the inflammation reflected the degree of inflammatory cells infiltration, 
perivascular haemorrhage, and parenchymal and alveolar changes.  
After an assessment of the literature and discussion with colleagues, there was an 
impression was that there is no gold-standard scoring system for murine lung 
inflammation therefore we designed our own. We used a pragmatic 5-point 
histological score as described in the following examples (Table 2.2): This was 
based on the extremes of normal compared with the worst possible (severe-with 
architectural changes), and then recognising a mild-point (Moderate). Even with 
brief experience, it became comfortable to score between these as mild and 
severe. 
The overall score for each tissue section was a mean of the measures. 
The examples are as follows: 
1 = Histologically normal  
2 = Mild inflammatory infiltrate  
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3 = Moderate inflammatory infiltrate 
4 = Severe inflammatory infiltrate  
5 = Severe inflammatory infiltrate, with loss of lung architecture 
 
Score Description Histological finding 
 
1 
 
Normal 
 
 
2 
 
Mild inflammation 
 
 
3 
 
Moderate inflammation 
 
 
4 
 
Severe inflammation 
 
 
5 
 
Severe inflammation and loss of 
lung architecture 
 
 
Table 2.2 Illustrative examples of the lung inflammation used to describe a scoring system 
for assessing inflammatory changes associated with murine bleomycin-induced pulmonary 
fibroses. 
The severity of fibrosis was assessed in the lung sections by staining with 
Gomori’s Trichrome stain. The sections were scored independently by two 
observers blinded to the nature of the samples. Each scored the fibrosis in 10 
different low-power fields per slide. The assessment of fibrosis was subjective and 
based on the size and distribution of the collagen deposition across the lung 
section. We used the arbitrary fibrosis score described below (Table 2.3). 
The overall score for each tissue section was a mean of the measures. 
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1 = Normal 
2 = Thin collagen deposition around bronchioles and blood vessels 
3 = Patches of collagen deposition across the parenchyma 
4 = Collagen deposition all over the tissue section 
 
Score Description Fibrosis finding 
 
1 
 
Normal 
 
 
2 
 
Thin collagen deposition around 
bronchioles and blood vessels  
 
 
3 
 
Patches of collagen deposition 
across the parenchyma 
 
 
4 
 
Collagen deposition all over the 
tissue section 
 
 
Table 2.3 Illustrative examples of the lung fibrosis used to describe a scoring system for 
assessing changes associated with murine bleomycin-induced pulmonary fibroses.  
 
2.6 Measurement of total lung collagen 
                                                                                                                                   
The total soluble collagen content of the lung tissues were measured using a 
commercial kit (Sircol) from Biocolor, (Carrickfergus, UK).  Sircol is a dye-binding 
method for the analysis of acid and pepsin-soluble collagens, the principal of this 
test is the binding of a dye to collagen. The collagen-bound dye is recovered by 
centrifugation, eluted with alkali, and measured using a spectrophotometer at 540 
nm. The intensity of colour measurement is proportional to the collagen 
concentration in a sample. All lungs were weighed and the lung tissue was diced 
and washed twice for one hour each by incubation in cold phosphate buffered 
saline. The tissue was transferred into 1.5 ml eppendorf tubes and incubated with 
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1 ml pepsin (Sigma) at a concentration of 0.1 mg/ml in 0.5 M acetic acid at 4oC 
overnight to remove the terminal non-helical telopeptides, in order to release the 
collagen into solution.   
Specific microcentrifuge tubes supplied with the kit were then used. 100 l of each 
test sample was added in duplicate to the tubes and a seven point standard curve 
was made using recombinant standard collagen dissolved in RPMI complete 
medium at a concentration of 400 g/ml followed by five doubling dilutions in 
duplicate, with two tubes containing only medium as a negative control. 1 ml of 
sircol dye reagent was added to each tube followed by washing with 750 l ice-
cold acetic-salt wash to remove unbounded dye from the surface of the stained 
collagen pellet and the inside surface of the tube. To release the collagen from the 
pellet 250 l of alkali reagent was added to each tube then 200 l of the samples 
and standards were added to 96 micro well plates and the mean intensity was 
read at 570nm on a microplate reader (Dynex Technology, Worthing, UK).  
The following steps summarise the procedure: 
1. 100 mg of diced lung tissue 
2. 1 ml pepsin/acetic acid 0.1 mg/ml 0.5 M acetic acid 4oC overnight 
3. Collagen standard 400, 250, 100, 50, 10, 5g/ml and Blank well with RPMI   
    complete medium. 
4. 100 l of samples and standard in microcentrifuge tubes - repeated 2-times 
5. 1 ml of sircol dye reagent 30 minutes with shake 
6. Centrifugation 12000 rpm for 10 minutes 
7. 750 l ice-cold acetic-salt wash  
8. Centrifugation 12000 rpm for 10 minutes  
9. 250 l of alkali reagent   
10. Mixing 5 minutes 
11. 200 l samples and standards in 96 micro well plates  
12. Read at 570nm on a microplate reader 
 
2.7 Serum and bronchoalveolar lavage fluid 
analysis 
                                                                                                      
2.7.1 Measurement of cytokines using a Luminex 
multiplex assay 
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The volume of serum retrieved was a limit to the number of soluble mediators that 
could be analysed. This was optimised by using a system that can simultaneously 
quantify multiple cytokines and chemokines in the small volumes of mouse serum 
and bronchoalveolar lavage fluid. Briefly, the principle of the assay was that 
differentially dual-fluorescent labelled microbeads were purchased pre-coated with 
antibody to different mediators. (Invitrogen) Depending on the mediator analytes of 
interest, listed below, a cocktail of beads was incubated with the serum or BAL. 
After washing off excess fluid the beads were incubated with fluorescent-labelled 
antibody to the analytes of interest. Analysis was based on the recognition of the 
characteristic dual-wavelength of the beads that captured a particular analyte, 
along with the fluorescent signal from the detection antibody which was 
proportional to the concentration of analyte (Luminex platform; Bio-Plex , Bio-Rad, 
Hertfordshire, UK). Standards were dissolved in 1 ml of assay diluent to 
reconstitute each cytokine standard to the required concentration.  
The twenty-plex assay was able to analyse the following cytokines, chemokines 
and growth factors in mouse serum and bronchoalveolar lavage fluids. 
 
Cytokines: 
Interleukin (IL)-1, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40/p70, IL-13, IL-17,  
Tumor necrosis factor (TNF) α, and interferon (IFN)γ, 
 
Chemokines : 
CXCL10 (IP-10), CXCL1 (KC), (CCL2) MCP-1, (CXCL9) MIG, and (CCL3 ) MIP-1α.  
 
Growth and colony stimulating factors: 
VEGF, FGFb, and GM-CSF.  
The serum samples were diluted 1:2 with assay diluent and 50 l added to each 
well in duplicate following the manufacturer’s protocol. The bronchoalveolar lavage 
samples were used without dilution and 50 l added to each well in duplicate 
following the manufacturer’s protocol. 
 
  
2.7.2 TGF-1 ELISA assay 
                                                                                                                                     
Mouse TGF1 was measured by commercial ELISA (R&D systems, Minneapolis, 
MN, USA). TGF1 is typically found in a latent nonimmunoreactive form, therefore, 
to be able to measure the actual concentration of TGF-1 we treated the samples 
as in (Table 2.4).      
Briefly this ELISA protocol specified using Immunol microtiter plates (Thermo 
Labsystems). These were coated with 100 l of capture antibody in phosphate 
buffer saline and incubated overnight at 4oC.  Before use, the plates were washed 
by immersion 3 times with 0.05% Tween 20/ PBS, then incubated with 300 l of 
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blocking buffer (5% Tween 20 in PBS with NaN3) to block non-specific protein 
binding, and incubated at room temperature for 2 hours. A seven-point standard 
curve with serial doubling dilutions from 2000 pg/ml was made using standard 
mouse TGF1 recombinant diluted in reagent diluents (1.4% delipidized bovine 
serum, Opticlear, Biocell (Compton, CA, USA ). 
The plates were washed with 0.05% Tween 20/ PBS and 100 l of sample or 
standards were added in duplicate to the plate along with two wells containing only 
reagent diluents then incubated at room temperature for 2 hours. The ELISA plate 
was then washed three times by immersion with 0.05% Tween 20/ PBS, and the 
next step was 100 l of detection antibody diluted in the reagent diluents were 
added to each well and incubated at room temperature for another 2 hours.   
The plates were then washed three times by immersion with 0.05% Tween 20/ 
PBS and 100 l of working dilution of streptavidin HRP(R&D) diluted 1:1000 with 
reagent diluent ) was added to each well and the plates were covered and 
incubated for 20 minutes at room temperature. After washing three times by 
immersion with 0.05% Tween 20/ PBS, 100 l of substrate solution (1:1 mixture of 
H2O2 and tetramethylbenzidine (TMB) peroxidise (R&D) was added. The plates 
were incubated for 20 minutes in darkness at room temperature, and then the 
reaction was stopped by addition of 50 l Stop Solution (Biosource, Nottingham, 
UK) which is 0.16 M sulphuric acid used to terminate the peroxidase/TMB reaction, 
and the mean intensity was read at 450nm on a microplate reader (Dynex 
Technology). 
Serum Bronchoalveolar lavage(BAL) 
To 0.1 ml sample add 0.1 ml of 2.5 N 
acetic acid/10 M urea  
To 0.5 ml sample add 0.1 ml of 1 N HCL  
Mix well Mix well 
Incubation 10 minutes at room 
temperature 
Incubation 10 minutes at room 
temperature 
Add 0.1 ml of 2.7 N NaOH/1 M HEPES 
for neutralization 
Add 0.1 ml of 1.2 N NaOH/0.5 M 
HEPES for neutralization 
Mix well Mix well 
Dilute samples 10 folds with reagent 
diluents before using in the assay 
Used in the assay  
Samples value results multiplied by 
dilution factor 30 
Samples value results multiplied by 
dilution factor 1.4 
                                                                                                                                                      
Table 2.4 Protocol for activation of latent form of mouse TGF1 in the serum and 
bronchoalveolar lavage to enable their measurement. 
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2.8 Investigation of gene expression   
                                                                                                       
2.8.1 Extraction of RNA from tissue 
                                                                                                                    
2.8.1.1 TRIZOL homogenization for tissue 
                                                                                                                                      
All lung tissues harvested from the mice were immediately put into RNALater and 
frozen in liquid nitrogen before being stored at -80oC until they were processed for 
RNA extraction. One lobe of the lung was homogenized with 1ml TRIZOL RNA 
stabilisation reagent (Invitrogen) in a homogeniser tube (Precellys Kit 
CK28,Stretton, UK)) followed by homogenisation in a Precellys homogeniser set at 
2 X 10 sec at 6500 rpm.  
To each sample tube 200 l of chloroform was added and vortexed until mixed 
well before being transferred into a new RNase-free eppendorf tube, then followed 
by centrifugation at 13,000 rpm for 20 min at 4oC. Three fluid phases were 
obtained and the upper aqueous phase which contained the RNA was transferred 
into a new RNase-free eppendorf tube. The RNA was precipitated by the addition 
of 500 μl of propan-2-ol followed by centrifugation at 13,000 rpm for 20 min at 4°C 
to precipitate the RNA.  
The propan-2-ol was removed from the tube and the precipitated RNA pellet was 
washed by the addition of 300 l of 70% ethanol followed by centrifugation at 
13,000 rpm for 5 minutes. The ethanol was removed from the tubes and the RNA 
pellet was allowed to dry in air for a few minutes until the ethanol had evaporated 
before it was dissolved in 100 l water treated with 0.1% v/v diethyl pyrocarbonate 
(DEPC) to maintain RNA-free conditions. 
RNA quantification was done by comparison of optical density at 260nm and at 
200nm using a spectrophotometer (Amersham Biosciences, Amersham, UK) to 
check for purity and protein contamination. One l of the RNA was used in this 
quantification and with this value a stock RNA solution of 200 ng/l was prepared 
with Diethyl Pyrocarbonate (DEPC) treated water and stored at -80oC until the 
cDNA synthesis was performed. 
 
                                                                                                                      
2.8.1.2 RNA extraction from cells 
                                                                                                                                        
Cells in suspension were prepared for RNA extraction using the RNeasy Mini Kit 
(Qiagen, Manchester, UK) as described by the manufactures. Adherent cells in 
culture flasks were removed by addition of 0.05% Trypsin-EDTA (Invitrogen), then 
washed with PBS and centrifuged to collect cells into a pellet. The cells pellet was 
resuspended in 350 l of RLT buffer (lysis buffer for lysing cells and tissues) from 
Qiagen, mixed gently until complete lysis of the cells occurred. These suspensions 
were stored at -80oC until they were required for RNA extraction. 
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RNA extraction was performed by following the manufacture’s guidelines: 
1. Addition of 350 l of 70% ethanol to the sample then transferred into MiniElute 
spin column. Then centrifugation at 10.000 RPM for 15 seconds. 
2. The flow through was discarded.  
3. Addition of 80 l DNase I followed by an incubation for 15 minutes at room 
temperature. 
4. Addition of 350 l of RW1 buffer followed by centrifugation at 10.000 RPM for 
15 seconds. 
5. The flow through was discarded. 
6. Addition of 500 l of RPE buffer followed by centrifugation at 10.000 RPM for 15 
seconds. 
7. The flow through was discarded. 
8. Addition of 500 l of 80% ethanol followed by centrifugation at 10.000 RPM for 2 
minutes. 
9. The flow through was discarded. 
10. Centrifugation 16.000 RPM for 5 minutes. 
11. Addition of 14 ml RNase free water to the pellet then centrifugation at 10.000 
RPM for 2 minutes. 
RNA quantification was done by using a spectrophotometer (Amersham 
Biosciences). One l of the RNA was used in quantification then the stock of 125 
ng/l was prepared with DEPC treated water and stored at -80oC until the cDNA 
synthesis was performed. 
  
 
2.8.2 Complementary DNA (cDNA) Synthesis 
                                                                                                                           
Complementary DNA (cDNA) was made from the RNA extracted from the mice or 
cells. The reaction was set in RNase free microcentrifuge tubes (Star lab, Milton 
Keynes, UK) as described by the manufacture (Qiaqen). The principles of the test 
are as the following:- 
                                                                                      Tissue          Cells 
RNA 1 mg....................................................................... 5 l ........... 8 l   
Random hexamers 50 ng/ml.......................................... 1 l ............ 1 l 
dNTP 10mM................................................................... 1 l ............ 1 l 
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DEPC water.................................................................... 3 l ............ 0 l   
Final reaction volume                                                     10 l             10 l      
The reaction components were mixed in the tubes by centrifugation before being 
placed in the PCR machine for RNA denaturation. The PCR machine was set as 
the following: 
1. 65oC 5 min  
2. 0oC 1 min 
3. 4oC 10 minutes 
Following the manufacture protocol, a second master mix was required to prepare 
as following: 
RT buffer 5X.................................................................... 4 l 
MgCl2 50 mM.................................................................. 2 l 
DTT 0.1 M........................................................................ 2 l 
RNase OUT...................................................................... 1 l 
Superscript II RT (200 u/ l).............................................25 l 
DEPC water.....................................................................75 l 
Final reaction volume                                                       10 l  
10 l from the second master mix were added to each microcentrifuge tube 
contained the denatured RNA, mixed well by centrifugation, the total volume was 
20 l in each tube. The tubes were placed in PCR machine again for cDNA 
synthesis using the following programme: 
1. 25oC 2 min 
2. 42oC 50 min 
3. 70oC 15 min 
4. 4oC 10 minutes 
After the incubation the cDNA was diluted with DEPC water 1:3 then stored at -
80oC until required for PCR target genes analysis. 
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2.8.3 SYBR Green reverse transcriptase-polymerase chain 
reaction (QRT-PCR) 
                                                                                                                                           
All QRT-PCR primers and probes were selected on the basis that they crossed 
intron / exon boundaries to achieve high efficiency of the qRT-PCR. 
SYBR Green quantitative reverse transcriptase-polymerase chain reaction (QRT-
PCR) was used for genes quantification. The reactions were made in Fast Optical 
96-Well Reaction Plate with Barcode (Applied Biosystems). The reactions were 
performed in triplicate using the final reaction volume of 20 l per each well as the 
following: 
cDNA................................................................................... 2l 
Power SYBR Green Master Mix.......................................... 10l 
Primer pairs (Forward & Reverse)....................................... 2l 
RNase water........................................................................ 6l 
Final reaction volume                                                          20l  
The primers were purchased from Integrated DNA Technology and designed to 
anneal to adjacent Exons to exclude possible amplification from genomic DNA, all 
other reagents were purchased from Applied Biosystem (Paisley, UK). To exclude 
any contamination of the reaction we used two controls with each plate (reaction 
with no RNA & reaction with water (no template). After adding all the reaction 
components in the plate, it was covered with an optical cover and centrifuged at 
1000 RPM for 1 minute to mix the contents.  
For developing the reaction, the plate was put in the QRT-PCR machine (Applied 
Biosystems 17900HT/7500) for 40 cycles. The expression of target genes was 
then quantified relative to the house keeping gene using SDS2.2 software Applied 
biosystem. 
 The following human and mouse primers were used for SYBR Green qPCR 
analysis (Table 2.5).  
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Mouse                       (F) (R) 
TBP                                                                                           
5'-TGC TGT TGG TGA TTG TTG GT-3' 
                                                                      
5'-AAC TGG CTT GTG TGG GAA AG-3' 
Col1A                                                                                       
5'-AGC TTT GTG GAC CTC CGG CT-3' 
                                                                         
5'-ACA CAG CCG TGC CAT TGT GG-3' 
Col3A                                                                                                       
5'-GTT CTA GAG GAT GGC TGT ACT A AA CAC A-3' 
                                                           
5'-TTG CCT TGC GTG TTT GAT ATT C-3' 
TGF1                                                                                       
5'-ACC CCC CAT TGCT GTC CCGT-3' 
                                                                              
5'-CCT TGG TTC AGC CAC TGC CG-3' 
ABCA1                                                                                        
5'-AGT ACC CCA GCC TGG AAC TT-3' 
                                                                          
5'-ACG TGT CCT TGG TCA GCT TC-3' 
Arg2                                                                                      
5'-ACC AGG AAC TGG CTG AAG TG-3' 
                                                                          
5'-TGA GCA TCA ACC CAG ATG AC-3' 
LXR                                                                                         
5'-GGA TAG GGT TGG AGT CAG CA-3' 
                                                                                      
5'-GGA GCG CCT GTT ACA CTG TT-3' 
LXR                                                                                               
5'-GCT CAG GAG CTG ATG ATC CA-3' 
                                                                         
5'-GCG CTT GAT CCT CGT GTA G-3' 
IL13R                                                                                              
5'-TCT GGT ATG AGG GCT TGG AT-3' 
                                                                    
5'-GCT GGA GGT AAT CAG CAC ACT-3' 
Ym1  
5'-CAT GAG CAA GAC TTG CGT GAC-3' 
 
5'-GGT CCA  AAC  TTC CAT CCT CCA-3' 
Nos2                                                                                       
5'-AGA CCT CAA CAG AGC CCT CA-3' 
                                                                          
5'-GCA GCC TCT TGT CTT TGA CC-3' 
Human    
GAPDH  
5'-TCG ACA GTC AGC CGC ATC TTC TTT-3' 
                                                                         
5'- ACC AAA TCC GTT GAC TCC GAC CTT -3' 
Col1A                                                                                       
5'-CAA TGC TGC CCT TTC TGC TCC TTT-3' 
                                                                          
5'- CAC TTG GGT GTT TGA GCA TTG CCT-3' 
Col3A                                                                                       
5'-TAT CGA ACA CGC AAG GCT GTG AGA -3' 
                                                                             
5'-GGC CAA CGT CCA CAC CAA ATT CTT-3' 
 
Table 2.5 Primers Used for Real-Time qPCR 
2.9 In vitro work 
2.9.1 Generation of murine fibroblast cell lines    
                                                                                                                                       
Mouse primary fibroblasts lines were generated from lung tissue. Fresh lung lobes 
were dissected and chopped into small fragments (~1-2 mm). These were 
suspended in 10 ml of complete DMEM medium and added to 25-ml tissue culture 
flasks.  
The cultures were incubated for 21 days in standard culture conditions which are 
at 37oC, 5% CO2 in a humidified atmosphere. The medium was replaced every 
week. After 3 weeks the attached fibroblasts were removed using 0.05 Trypsin 
EDTA, then the cells were washed with DMEM medium, then re-suspended at 
5x106 cells/ml in freezing mix (50% FCS and 50% DMSO) before being stored at   
-70oC for 24 hours then transferred to -80oC freezer until required.  
 
2.9.2 Generation of primary human fibroblast line 
                                                                                                                               
Human primary fibroblast lines generated from human tendons were used (Kindly 
donated by Dr Neil Miller, Immunology, Glasgow University. Tissue obtained with 
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ethics approval). The human fibroblasts were obtained from 3 different people 
(n=3). The cells were cultured in 10 ml of RPMI medium in 25 ml tissue culture 
flasks for 21 days at 37oC, 5% CO2.The medium was replaced every week. After 3 
weeks the attached fibroblasts were removed using 0.05 Trypsin EDTA, then the 
cells were washed with RPMI medium and stored in freezing mix at -70oC for 24 
hours before transferred to -80oC freezer until it required to use.    
     
2.9.3 Fibroblast stimulation with LXR agonist         
                                                                                                                              
Fibroblasts were retrieved from frozen stocks by rapid warming of the cryovials to 
37oC. The cells were washed three times in complete medium to remove the 
DMSO and then cultured at 1x105 cells/ml in either complete DMEM (murine 
fibroblast) or complete RPMI (human fibroblast). Cells were allowed to settle in 6 
well plates for 72 hours in standard culture conditions.  
The cells were activated with LXR agonist (GW3965) at a final concentration range 
between 0.125 M to 0.5 M or vehicle (DMSO) and incubated at 37oC, 5% CO2. 
The cells were cultured for 6, 12 and 24 hours. The supernatants were collected 
and used for measuring total soluble collagen and the cells were lysed with 350 l 
RLT lysing buffer and the RNA was purified and used for qPCR analysis.  
 
 
2.9.4 Fibroblast stimulation with LXR agonist and 
cycloheximide                                                                                                     
 
The cells were prepared and cultured in 6 well plates as described above (2.4.3). 
The cells were activated with LXR agonists (GW3965) at the final concentration of 
0.5 M, vehicle (DMSO), and medium only (DMEM or RPMI), Cycloheximide 
(Sigma) was added to each well at final concentration of 1 g/ml. The cells were 
incubated at 37oC, 5% CO2 for 24 hours. The cells were lysed with 350l RLT 
lysing buffer then RNA was purified and used for qPCR analysis.  
              
 
2.10 Promoter analysis of murine collagens 1 and 3 
 
The ability of LXR α/ß to directly regulate the expression of collagens 1 and 3 was 
investigated using a luciferase reporter system. In silico analysis identified putative 
LXR/RXR binding sites in the promoters of mouse collagens. 
 
2.10.1 In silico analysis of mouse collagens 1 and 3 
                                                                                                                                      
In silico analysis was performed using an on-line tool MatInspector, is a software 
tool that utilizes a large library of matrix descriptions for transcription factor binding 
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sites to locate matches in DNA sequences 
(http://www.genomatix.de/online_help/help_matinspector/.html). Putative 
conserved LXR/RXR binding sites were identified. 
 
2.10.2 Amplification of putative LXR/RXR binding sites  
                                                                                                                          
Genomic regions containing the candidate LXR/RXR binding sites were amplified 
by polymerase chain reaction (PCR) and cloned by TOPO cloning into pCR2.1 
TOPO vector (Invitrogen). Primers were designed using Integrated DNA 
Technologies (IDT) Primer Quest software such that they flanked each LXR/RXR 
sequence of interest (Table 2.6). Primers were purchased from IDT (Coralville, IA, 
USA) (Table 2.7). Each region was amplified using Go-Taq master-mix (Promega, 
Southampton, UK) according to the manufacturer’s instructions. A brief description 
of the reaction used is outlined below: 
25 l of 2x Go-Taq master mix 
1.25 l of 10M Forward primer 
1.25 l of 10M Reverse primer 
2 l mouse genomic DNA (isolated from NIH3T3 cells) 
20.5 l milli-Q water 
Reactions were placed into ABI thermocycler and amplified using the following 
settings): 
 
 Temperature (°C) Time  Cycles 
Initial Denaturation 95 2 minutes 1 
Denaturation 95 15 seconds  
35 Annealing 55 15 seconds 
Extension 72 1 minute 
Final Extension 72 7 minute 1 
 
Table 2.6 Amplification products were examined by agarose gel electrophoresis 
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Gene Name Species Primer Sequence Product 
Length 
Col (I) A1a Mouse 5'-AGG CAT GGC CAG GAG GAC CT-3' 
5'-CTC TTT GCG GCT GGG GTG GG-3' 
F 
R 
509 
Col (I) A1b Mouse 5'-GAG GGA GAC AGC CC GGG AGG-3' 
5'-AGT GGG GAT GGA GGC TGC CT-3' 
F 
R 
500 
Col (I) A1c Mouse 5'-CCA GCT GAC CTT CCT GCG CC-3' 
5'-AAG TGG GCT GGG TGG GAG GG-3' 
F 
R 
518 
Col (III) A1a Mouse 5'-TCA ACA GTT GCA GTG CTG TTC CT-3' 
5'-GGC TGA AGA AAT ACT GGA ACC AGG G-3' 
F 
R 
280 
 
Table 2.7 Primers used for producing PCR gene products  
 
 
2.10.3 Agarose gel electrophoresis 
                                                                                                                                      
DNA fragments generated by PCR were examined by agarose gel electrophoresis. 
DNA samples were prepared for agarose gel electrophoresis by adding 5l of DNA 
loading buffer (recipe on Table 2.8). 1.5 % (w/v) agarose gels were prepared by 
dissolving 1.5 grams agarose (Invitrogen) in 100 ml of 1xTAE. Agarose TAE 
solution was then heated in a microwave until the agarose was completely 
dissolved. At the same time 10 l of 10 mg/ml ethidium bromide (Sigma) (10mg/ml 
stock solution) was added and mixed by gentle swirling. Molten agarose was then 
poured into a gel-casting tray along with casting combs and allowed to set. Once 
set the combs were removed and the gel placed into an electrophoresis tank with 
enough 1xTAE to just cover the gel. DNA samples were loaded into each well 
along with 1 Kb plus (Invitrogen) DNA ladder, to allow the size of the DNA 
fragments to be estimated. Gels were run at 100 V until loading dye had migrated 
2/3 the length of the gel. Gels were visualised on a UV trans-illuminator and 
images recorded using Gel logic 200 imaging system.  
 
Reagent  
Tris base 242 g 
Glacial acetic acid 57.1 ml 
0.5M EDTA (pH8.0) 100 ml 
 
Table 2.8 Recipe for 50x TAE buffer 
 
 
2.10.4 Cloning of PCR amplified DNA fragments 
                                                                                                                   
2.10.4.1 TOPO cloning of PCR products 
                                                                                                                                  
Gel purified PCR products were cloned by TOPO cloning into the vector pCR2.1 
TOPO (Figure 2.1) (Invitrogen) according to the manufacturer’s instructions. This 
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technique takes advantage of the non-template encoded adenosine nucleotides 
added to the 3’ ends of Taq polymerase amplified fragments. The vector is 
supplied linearised with 3’ thymidine overhangs, topoisomerase I catalyses the 
ligation of PCR product in the following reaction: 
1 l of Salt solution 
4 l of PCR product 
1 l pCR2.1 TOPO vector 
Reactions were amplified at room temperature for 5 minutes, 3 l of this reaction 
was used to transform chemically competent One-shot XLI-Blue E. coli (Invitrogen). 
 
 
 
 
 
 
 
Figure 2.1 Map of pCR2.1 TOPO 
 
 
2.10.4.2 DNA transformation into competent E.coli 
                                                                                                                                      
Plasmid DNAs were transformed into chemically competent XL1-BLUE cells 
(Invitrogen) following manufacturer’s instructions (described below). 
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1- Competent cells were thawed and kept on ice. 3 l of ligation reaction was 
added to 50 l of competent cells, gently mixed together and incubated on ice for 
30 minutes.  
2- Cells were heat-shocked at 42°C for 30 seconds and placed on ice for 2-3 
minutes.  
3- 350 l of SOC medium was added to the cells and cells incubated at 37°C for 
45 minutes. 100 l of cell suspension was plated onto an LB agar plate containing 
50 g/ml ampicillin (Sigma).  
4- Plates were incubated overnight at 37°C. The following day individual colonies 
were picked into 30 ml universal containers containing 5 ml of LB plus 50 g/ml 
and grown overnight with shaking. 
 
2.10.4.3 Plasmid DNA purification 
                                                                                                                                     
Plasmid DNA was purified from over-night cultures using QIAprep Spin miniprep 
kit (Qiagen) following the manufacturer’s instructions. A brief description of this is 
described below. 
1- 1.5 ml of over-night culture was placed into 1.5 ml eppendorf tube and bacteria 
were pelleted by centrifugation at 16100 rpm in a microcentrifuge for 3 minutes.  
2- The supernatant was discarded and the pellet re-suspended in 250 l buffer P1. 
3- 250 l of buffer P2 lysis buffer was added to each sample and mixed thoroughly 
by inverting the tubes 4-6 times.  
4- 350 l of buffer N3 a neutralization buffer was added and mixed thoroughly by 
inverting the tubes 4-6 times.  
5- The tubes were centrifuged at 16100 rpm for 10 minutes at room temperature.  
6- Supernatants were transferred onto QIAprep spin columns and centrifuged at 
16100 rpm for 15 seconds. The flow through was discarded. 
7- 750 l of buffer PE were added to each column and centrifuged at 16100 rpm 
for 15 seconds. The flow through was discarded. 
8- Columns were then dried by further centrifugation at 16100 rpm for 1 minute. 
9- The QIAprep spin columns were transferred to fresh collection tubes and 50 l 
of elution buffer (EB) was added to the columns and allowed to stand for 1 minute 
before being centrifuged at 16100 rpm for one minute. DNA was eluted and 
quantified by Nanodrop.     
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2.10.4.4 Restriction endonuclease digestion of plasmid DNA  
                                                                                                                             
Plasmid DNA identities were confirmed by restriction endonuclease (RE) digestion. 
Diagnostic RE digests were chosen according to expected restriction maps 
generated using the sequence analysis software CloneManager. Restriction 
enzymes were purchased from a variety of suppliers depending on availability and 
incubated in the appropriate buffers according to the manufacturer’s 
recommendation. 
2.10.4.5 Gel purification of DNA fragments from agarose gel 
                                                                                                                                
DNA bands of interest were purified from agarose gel slices using QIAquick gel 
extraction kit (Qiagen) following manufactures instructions. A brief description of 
this procedure is outlined below. An excised gel slice is placed into a 1.5 ml 
Eppendorf tube along with 450 l solubilisation buffer QG and incubated at 56°C 
for 10 minutes. During this time the sample was vortexed every 2 minutes. Once 
the gel slice had dissolved, 150 l of 100% isopropanol was added and the sample 
was vortexed. The sample was added to a Spin column and centrifuged at 16,100 
g for 15 seconds. The flow through was discarded and 750 l of PE buffer was 
added to each column and centrifuged at 16,100 g for 15 seconds. The flow 
through was discarded. Columns were then dried by further centrifugation at 
16,100 g for 1 minute. The spin columns were transferred to fresh collection tubes 
50 l of elution buffer (EB) were added to the columns allowed to stand for 1 
minute before being centrifuged at 16,100 g for one minute. DNA was eluted and 
quantified by Nanodrop.  
 
 
2.10.4.6 DNA ligations 
                                                                                                                                          
DNA inserts were cloned into the appropriate plasmid vectors by ligation. DNA 
fragments containing compatible ends were ligated together using T4 DNA ligase. 
For this purpose T4 DNA ligase kit supplied by New England Biolabs was used 
according to manufacturer’s instructions. A typical example of a reaction is shown 
below (Table 2.9). 
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Component Volume (l) 
Vector 3 
Insert 10 
Buffer 2 
H2O 5 
T4 DNA Ligase 1 
 
Table 2.9 DNA ligation components  
Ligations mixes were incubated at room temp for 10 minutes, then 3 l were 
added to thawed competent cells and transformed as described in section 2.9.5.2. 
 
2.10.5 Construction of pGL3-promoter plasmids 
                                                                                                                                    
Genomic regions containing putative LXR response elements from Col1a1 and 
Col3a1 genes were amplified from mouse genomic DNA, cloned into 
pCR2.1TOPO. Their presence was confirmed by RE digest and then excised as 
an KpnI-XhoI fragment before being ligated into the same sites in the pGL3-
promoter (Promega) construct (see Figure 2.2). Plasmids containing the correct 
inserts were initially identified by restriction digest then subsequently confirmed by 
DNA sequencing. This was performed as a service by MWG Eurofins ( A  provider 
of genomic services. Ebersberg, Germany). 
 
 
 
 
 
Figure 2.2 pGL3-promoter plasmid 
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2.10.6 Cell transfection   
                                                                                                                                  
Endotoxin-free preparations of the various pGL3-promoter constructs plus a 
normalisation plasmid expressing Renilla, (an internal control reporters used in 
combination with any experimental reporter vector to cotransfect mammalian cells),  
were transfected into NIH3T3 cells using the transfection reagent Attractene 
(Qiagen) as follows: 
1- 4 x 104 cells/100 l of DMEM were seeded in a white 96-well plate (Greiner).  
2- 200 ng of sterile plasmid DNA plus 20 ng of the Renilla-expressing plasmid 
pRL-TK (Promega) was added to 50 l of OptiMEM (Invitrogen) and vortexed.  
3- 2 l of Attractene was added then vortexed for 2 minutes.  
4- The transfection complex was incubated at room temperature for 10-15 minutes.  
5- Complexes were added drop-wise to previously plated cells and incubated over-
night 37°C, 5% CO2. The process is illustrated below (Figure 2.3). 
 
 
 
 
 
Figure 2.3 Cell transfection pRL-TK 
 
 
2.10.7 Luciferase reporter assay 
                                                                                                                                    
Luciferase reporter assays were carried out using the Dual-Glo Luciferase assay 
system (Promega). The assay was carried out according to the manufacture’s 
guideline as follows: 
The medium of the cells transfected with luciferase reporter constructs was 
removed and replaced with 75 l of fresh medium. 75 l of Dual-Glo was added 
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to each well and incubated at room temperature for 10 minutes. The luminescence 
produced by each well was measured using a luminometer (Perkin Elmer precisely 
TLUX 2 DET) at 2-second measurement intervals followed by a 10-second 
measurement.  
Renilla activity was then measured after the addition of 75 l Dual-Glo® Stop & 
Glo® reagent followed by 10 minutes incubation at room temperature. 
Luminescence from renilla was measured as above. Luciferase activity was 
expressed as Relative Light Units (RLU) by normalising luciferase activity to 
Renilla activity: RLU= Luciferase activity/Renilla Activity 
 
2.11 Statistical analysis 
                                                                                                                                                             
All results are displayed as Mean ± Standard error of the mean (SEM) and all 
statistical analysis were performed by using of students T test,  ANOVA test, 
Mann-Whitney test, and Kruskal-Wallis test as indicated in figure legends, using 
the Graph Pad Prism 4 software. A p value of < 0.05 was considered statistically 
significant. 
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3. Results and Discussion  
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The Results chapter will include four main parts: 
3.1 Relationship between activation of Liver X Receptor and pulmonary     
      fibrosis in a murine pulmonary fibrosis model 
                                                                                                                                             
3.2 Exacerbation of pulmonary fibrosis is associated with the activation of  
      Liver X Receptor    
3.3 Requirement of LXR and LXR for fibrosis-enhancing effects of the  
LXR agonist 
                                                                                                                                   
3.4 Potential involvement of MicroRNA-155 in the development of pulmonary  
      fibrosis in a murine model 
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3.1 Relationship between activation of Liver X Receptor 
and pulmonary fibrosis in a murine pulmonary fibrosis 
model 
3.1.1 Introduction and Aims 
Many attempts have been made to determine the role of LXR in various biological 
and pathological circumstances beyond their recognised ability to control 
transcription of genes involved in regulation of high density lipoprotein cholesterol 
metabolism, hepatic cholesterol catabolism, and intestinal sterol absorption. 
Activation of the LXR exhibited diverse effects depending on the experimental 
model used. The activation of  LXR plays an important regulatory role in 
inflammation, for example in macrophages in response to bacterial infection or 
LPS stimulation, by inhibiting gene expression of  certain inflammatory cytokines 
including interleukin (IL-1), IL-6, inducible nitric oxide synthase (iNOS), 
cyclooxygenase (COX)-2,  granulocyte colony-stimulating factor (G-CSF), 
chemokines such as monocyte chemoattractant protein-1 (MCP-1, CCL2), (MCP-3, 
CCL7), macrophage inflammatory protein-1 (MIP-1, CCL4) and interferon-
inducible protein-10 (IP-10, CXCL10), and the metalloproteinase MMP-9 [68].  
The inhibition of expression of these inflammatory genes occurred by antagonising 
NF- B signalling by LXR ligands.  In murine models of atherosclerosis, elimination 
of LXR activity in bone marrow-derived cells resulted in splenomegaly, aberrant 
regulation of cholesterol transporter expression, lipid accumulation in 
macrophages, and increased atherosclerosis [195]. Binding of physiological 
ligands such as oxysterol to LXR lead to increased expression of genes which 
participate in lipid metabolism and cholesterol transportation. These include 
Apolipoprotein E (ApoE), ATP-binding cassette transporter A1 (ABCA1), and ATP-
binding cassette transporter G1 (ABCG1) in the case of macrophage activation 
resulting in cholesterol removal or efflux [196]. The involvement of macrophages in 
metabolic and inflammatory process lead to investigation of the specific role of 
LXR. Activation of LXR with synthetic agonists such as GW3965 and T0901317 
leads to up-regulation of arginase 2 (Arg 2) expression in macrophages 
demonstrating that the Arg 2 promoter contains functional LXR response elements 
[197].    
LXR-/--/- mice have marked susceptibility to liver fibrosis in a liver injury model 
and this was reflected by increased production of inflammatory mediators and 
expression of fibrogenic genes in their stellate cells [75]. One recent study in our 
lab demonstrated that activation of LXR with T1317 and GW3965 agonists in a 
murine collagen-induced arthritis model resulted in exacerbation of the 
inflammatory response with excessive cartilage destruction [74]. The different 
responses to LXR activation in these two examples of chronic inflammation are 
difficult to reconcile, however remodelling is clearly affected by LXR in both 
therefore investigating this apparent difference might be informative of the fibrotic 
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process in general. We decided to investigate this using an experimental murine 
model of lung fibrosis caused by administration of bleomycin. The experimental 
fibrotic response closely mimics the fibrotic response in lungs of patients given this 
anti-cancer drug therapeutically. It is therefore of potential value in understanding 
this treatment-limiting factor as well as understanding of the processes of 
pulmonary fibrosis. Idiopathic pulmonary fibrosis is a fatal disease but the role of 
LXR in the pathogenesis of this disease has not been investigated. 
Aim: Here we aimed to identify the optimal conditions for establishing the murine 
bleomycin-induced pulmonary fibrosis model and to adapt this model to explore 
the potential role of LXR in wound healing and tissue repair. 
                
3.1.2 Justification of the bleomycin-induced pulmonary fibrosis 
model in vivo 
3.1.2.1 The time course of bleomycin induced inflammation 
suggests maximum inflammatory and fibrotic changes at day 18 
after administration  
Introduction and Aim                                                                                                                                                                                                                                                                                                                                               
The murine bleomycin-induced pulmonary fibrosis is a widely use model 
resembling the fibrosis that can occur in patients taking this antineoplastic drug. 
Administration of bleomycin in humans and in experimental animals leads to the 
development of fibrotic lung abnormalities that are similar histologically and 
pathologically, therefore, the murine model is one of the best models resembling 
human lung fibrosis [198, 199].  
Previous data from our laboratory demonstrated that activation of LXR in a murine 
collagen induced arthritis (CIA) model leads to severe destructive inflammatory 
changes in the joints, and the data suggested that LXR-mediated pathways could 
exacerbate the chronic inflammatory response typical of RA [74]. Therefore, I 
extended this observation by investigating the role of LXR in another more 
accessible model of wound healing using bleomycin-induced pulmonary fibrosis. 
The aim of this section is to justify the experimental conditions of the model by 
exploring the most suitable time course of the fibrosis and the optimal dose of the 
LXR agonist GW3965. My primarily end point was checking the histo-
pathomorpholigical and histo-fibrotic changes in the lung of these mice and also 
BAL cytology for total and differential cell counts. 
 
Methods: - Two groups of C57BL/6 mice were used for optimising the time course 
of the development of the bleomycin-induced pulmonary fibrosis; (A) one group 
given bleomycin (n=30) and (B) one group given PBS (n=15). They were 
administered by the intranasal route as describe in the Materials and Methods 
(section 2.3.3). On day zero of the experiment all mice were lightly anesthetised 
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using isofluorane in an inhalation anaesthetic chamber then the mice were given 
either PBS or bleomycin sulphate solution 0.06 mg bleomycin in 30 l PBS or 30 
l PBS as control  intranasally. The mice were monitored daily for wellbeing and 
changes in body weight until day 32 when all mice were culled. The experiment 
time-frame is summarised in Figure (3.1), and the number of mice used in each 
group (Table 3.1). 
                                                                       
PBS (30 l / mouse) or Bleomycin (0.06mg in 30 l PBS / mouse)  
 
 
Day 0         3                                                     18                                              32 
                Cull                                                   Cull                                          Cull 
Figure 3.1 Experimental timeline for the optimisation of the time course of the bleomycin –
induced pulmonary fibrosis model in C57BL/6 mice                                                                                                                                                                                                              
3 groups of C57BL/6 mice were given bleomycin and 3 groups were given PBS at day 0.  A 
group were culled at 3, 18 and 32 days of experiment. Further details in (Materials and 
Methods section 2.3.3). n= 5-10 mice/group. 
 
 
Day/Treatment PBS Bleomycin 
Used Used 
Day 3 5 10 
Day 18 5 10 
Day 32 5 10 
                                                                                                                                
Table 3.1 Mice number for the optimisation of the course length of the bleomycin-induced 
pulmonary fibrosis model in C57BL/6 mice                                                                                        
6 groups of C57BL/6 mice male (8 weeks old), and all the mice were given either PBS (30 l / 
mouse) or bleomycin (0.06mg in 30 l PBS / mouse) intranasally. n= 5-10 mice/group.  
 
Bleomycin administration is associated with loss of body weight.                                                                                                                      
Intranasal installation of bleomycin or PBS to the C57BL/6 mice was characterised 
by a short-lived minor loss of body weight for those given PBS and a more 
prolonged loss of weight in mice given bleomycin. This difference was significant 
and maintained although there was a progressive increase in weight thereafter 
(Figure 3.2).  
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Figure 3.2 Daily body weight changes in mice given bleomycin or PBS                                   
Male C57BL/6 mice (8 weeks old) were randomised to receive either PBS (30 l / mouse) or 
bleomycin (0.06mg in 30 l PBS / mouse) intranasally. Systemic inflammation caused by 
bleomycin administration was associated with a significant loss of body weight p<0.001. 
Bleomycin treated mice lost weight during the first 5 days following bleomycin installation 
while in the PBS treated group the weight dropped for one day after PBS installation. 
Thereafter, the mice in both groups started gaining weight normally. Student t-Test; 
***p<0.001; Mean ± SEM; n= 5-10 mice/group.  
 
Bleomycin increased the histo-pathological inflammatory and fibrotic 
changes seen in the mouse lungs                                                                                                                 
Bleomycin installation caused morphological changes in the normal lung 
architecture (Figure 3. 3 A and B). Inflammatory and fibrotic changes were 
observed and were most severe at day 18 after bleomycin installation compared 
with days 3 and 32. PBS treated mice did not show any changes from normal lung 
architecture. Lung tissue sections stained with H&E showed a variable infiltration 
of inflammatory cells, perivascular haemorrhage, and collapse of the alveoli in 
groups given bleomycin but it was more excessive at day 18 in comparison to day 
3 and 32. No significant changes were observed in the lungs of mice given PBS at 
days 3, 18, and 32 (Figure 3.3 A and Figure 3.4).     
Using Gomori’s Trichrome stain for visualisation of collagen, there were no 
changes for collagen in lung tissue observed at day 3 after bleomycin installation 
or at all times in mice given PBS. Increased collagen deposition was observed in 
mice given bleomycin by days 18 and 32 (Figure 3.3 B). On day 18 after 
bleomycin installation, more collagen was deposition than on day 32; the 
increased collagen was seen as bundles and fibrotic foci distributed mainly around 
the lung bronchioles and blood vessels, and interstitium (Figure 3.3 B).  
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Figure 3.3 Histological inflammatory and fibrotic changes in the lung of mice given 
bleomycin or PBS                                                                                                                                                   
(A)  Representative images of lung tissue sections showing morphological changes in lung 
architecture after bleomycin installation, H&E staining shows inflammatory changes in 
bleomycin treated groups, significantly higher at day 18 than at day 3 and marginally higher 
that at day 32. No significant changes were observed in the group given PBS.  (B) Images of 
lung tissue sections showing morphological changes in lung architecture after bleomycin 
installation, increased collagen deposition in the lung of mice given bleomycin at day 18 
and day 32 compared with day 3, and marginally higher at day 18 compared with day 32 
(p=0.025). There were no significant changes observed at ay 18 and 32 compare with day 3 
after PBS installation.  Gomori’s Trichrome stain highlighted collagen patches around 
bronchioles, blood vessels and in the parenchyma. Sections were viewed under light 
microscopy (magnification x10). 
Lung inflammation score:                                                                                     
H&E stained lung sections were scored for inflammation based on our scoring 
grade (Materials and Methods section 2.5.2). The lung tissue sections from mice 
given bleomycin had higher inflammatory scores at day 18 and 32 compared with 
day 3 or at any time in the PBS treated mice (Figure 3.4). The main characteristic 
features of inflammation were infiltration of inflammatory cells, perivascular 
haemorrhage, and collapse of the alveoli. There was a modest but not significant 
(p=0.093) decrease in inflammation score between bleomycin treated mice at day 
32 compared with day18 (Figure 3.4). 
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Figure 3.4 Lung inflammation score of the mice given bleomycin or PBS                                  
The lung inflammation was quantified by a histological score described in Materials and 
Methods (section 2.5.2). A significantly higher score was recorded at day 18 and 32 in mice 
given bleomycin compared to PBS control groups. One-way ANOVA; n.s. p>0.05; ***p<0.001; 
bars=mean ± SEM; n= 5-10 mice/group. 
                                                                                                                            
Lung fibrosis score:                                                                                                
The histological assessment of lung fibrosis was quantified and the mice given 
bleomycin had a highly significant increased score at days 18 and 32 compared 
with day 3, and higher than mice given PBS. The main features of fibrosis were 
collagen bundles deposition around bronchioles, blood vessels, and parenchyma.  
PBS treated mice had no significant changes in the lung fibrosis score (Figure 3.5). 
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Figure 3.5 Lung fibrosis score of the mice given bleomycin or PBS                                             
Fibrosis was assessed by histological score described in Materials and Methods (section 
2.5.2). A highly significant lung fibrosis score was demonstrated for mice given bleomycin 
at day 18 and 32 compared with day 3. The score was significantly lower at day32 compared 
with day 18 for mice given bleomycin (p=0.025). One-way ANOVA; *p>0.05; ***p<0.001; 
bars=mean ± SEM; n= 5-10 mice/group.  
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Bleomycin administration increased the number of inflammatory cells in the 
lung airspace collected by bronchoalveolar lavage (BAL). 
Total cell count:                                                                                                                
The cells in the airspace were collected by bronchoalveolar lavage as described in 
Materials and Methods (section 2.3.9). The total cell counts in fluid obtained by 
BAL were quantified at 3, 18, and 32 days after PBS or after bleomycin installation. 
Mice The mean total BAL cell count in the bleomycin treated group at 18 and 32 
were significantly higher than bleomycin treated mice at day 3, and all PBS treated 
groups; day 3, 18, and 32 (p<0.001). The count was significantly lower at day32 
compared with day 18 for mice given bleomycin (p=0.0003). 
The mean of total BAL cell counts were as following:- 
Mice given bleomycin at days 3         0.23 x 106, 
Mice given bleomycin at days 18       0.82 x 106,   
Mice given bleomycin at days 32       0.53 x 106     
Mice given PBS at days 3                  0.15 x 106, 
Mice given PBS at days 18                0.16 x 106,   
Mice given PBS at days 32                0.15 x 106   (Figure 3.6). 
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Figure 3.6 Total BAL cell count in the BAL of mice given bleomycin or PBS                                                
The counts from mice given bleomycin at day 18 and 32 were significantly higher compared 
with the day 3 after bleomycin installation or all PBS treated groups. A significant reduction 
in cell counts was observed in the mice given bleomycin at day 18 compared with day 32 
(p=0.001). One-way ANOVA; ***p<0.001; bars=mean ± SEM; n= 5-10 mice/group.  
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Macrophage count:                                                                                                          
The higher total cell count of the BAL was reflected by changes in the differential 
cells count (Figure 3.7 and 3.8). The mean total BAL macrophage count in the 
bleomycin treated group at 18 and 32 were significantly higher than bleomycin 
treated mice at day 3, and all PBS treated groups; day 3, 18, and 32 (p<0.001). 
The total BAL macrophage count was significant reduced at day 32 compared with 
day 18 after bleomycin (p<0.001) (Figure 3.7). 
The mean of total BAL macrophage counts were as following:- 
Mice given bleomycin at days 3        0.21 x 106, 
Mice given bleomycin at days 18      0.64 x 106,   
Mice given bleomycin at days 32      0.38 x 106     
Mice given PBS at days 3                 0.13 x 106, 
Mice given PBS at days 18               0.15 x 106,   
Mice given PBS at days 32               0.12 x 106   (Figure 3.7). 
 
3  3 18 18  32  32
0.0
0.5
1.0
1.5
2.0
PBS
Bleomycin
***
***
***p<0.0001
Days post-bleomycin or PBS
B
A
L
 m
a
c
ro
p
h
a
g
e
s
 x
 1
0
6
/m
l
 
Figure 3.7 Macrophage cell count in the BAL of mice given bleomycin or PBS                                         
The macrophage cell count was significantly higher in the bronchoalveolar lavage fluid 
retrieved from the bleomycin treated mice at 18 and 32 days in comparison with bleomycin 
at day 3 or all PBS treated groups. A significant reduction in macrophage count was 
recorded between the bleomycin treated groups at day 32 compared with day 18. One-way 
ANOVA; ***p<0.001; bar=mean ± SEM; n= 5-10 mice/group.  
 
Lymphocyte count:                                                                                            
Lymphocyte cells count demonstrated high significant difference between 
bleomycin treated group at day 18 and 32 than the day 3 or all PBS treated groups. 
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The significant differences observed between bleomycin treated mice at day 18 
and day32 (P<0.001). There was a significant reduction in lymphocyte cell count at 
day 32 compared with day 18 after bleomycin (p<0.001) (Figure 3.8). 
The mean of total BAL lymphocyte counts were as following:- 
Mice given bleomycin at days 3        0.026 x 106, 
Mice given bleomycin at days 18      0.17 x 106,   
Mice given bleomycin at days 32      0.07 x 106     
Mice given PBS at days 3                 0.007 x 106, 
Mice given PBS at days 18               0.005 x 106,   
Mice given PBS at days 32               0.006 x 106   (Figure 3.8). 
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Figure 3.8 Lymphocyte cell count in the BAL of mice given bleomycin or PBS                                          
The lymphocyte cell count was significantly higher in the bronchoalveolar lavage fluid 
retrieved from the bleomycin treated mice at 18 and 32 days in comparison with day 3 or all 
PBS treated groups. A significant reduction was recorded between the bleomycin treated 
group at day 32 compared with day 18. One-way ANOVA; ***p<0.001; bar=mean ±SEM; n= 5-
10 mice/group. 
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3.1.2.2 Selection of the dose of LXR agonist (GW3965) required to 
investigate its role in the severity of the murine model of 
bleomycin-induced pulmonary fibrosis  
Introduction and Aim                                                                                                           
Many experimental attempts have been made to activate and understand LXR 
function in vivo by using different synthetic agonists, for example GW3965 and 
T1317. These synthetic compounds used for activating LXR in different models of 
disease use different doses, time courses, and routes of administration, therefore, 
it was necessary to determine the most effective dose required for activation of 
LXR in the murine bleomycin pulmonary fibrosis model. GW3965 was the agonist 
which was chosen, it has been used in the literature to explore the role or LXRs. 
GW3965 is a nonsteroidal LXR ligand that was synthesized and introduced by the 
pharmaceutical company GlaxoSmithKline in the USA. Its characterised by its high 
potency and selectivity confirmed by its ability to induce the expression of ABCA1 
in vitro and in the mice intestine after oral dose administration [58]. I selected the 
high dose 30 mg/kg GW3965 because this dose had previously shown to induce 
LXR activation, by intraperitoneal (IP) injection [74]. Also I tried to use dose of 3 
mg/kg GW3965 to see if there is any sufficient effectively to stimulate LXRs and to 
avoid using the higher optimised dose. 
Methods:- Three groups of male C57BL/6 mice were used (n=10 per group), 10-
12 week old and 23-25 grams weight. On day zero all mice were anesthetised 
using isofluorane in an inhalation anaesthetic chamber and all were given 0.06mg 
of bleomycin sulphate in 30 l PBS / by intra-nasal application. Three days prior to 
day zero, the mice were treated with daily intra-peritoneal (IP) injections of either 
vehicle (5% Cremophor /PBS), 3 mg/kg LXR agonist (GW3965 in 5% 
Cremophor/PBS) or 30 mg/kg LXR agonist (GW3965 in 5% Cremophor/PBS). The 
daily intra-peritoneal continued until day 18 were the mice were culled. The mice 
were monitored daily for wellbeing, changes in body weight. 
 
LXR agonist treatment exacerbated the loss of body weight in mice given 
bleomycin 
                                                                                                                                  
The characteristic loss of body weight suggesting systemic characteristics caused 
by bleomycin administration was evident in all groups of mice (Figure 3.9). The 
loss of body weight was significantly higher in the group treated with 30 mg/kg 
LXR agonist compared with the vehicle (p<0.001) or 3 mg/kg LXR agonist 
(p=0.004). 
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Figure 3.9 Daily body weight changes in mice given bleomycin and treated with different 
concentration doses of LXR agonist or vehicle                                                                                                                                  
Three groups of male C57BL/6 mice (8 weeks old) received bleomycin (0.06mg in 30 l PBS / 
mouse) intranasally. Mice groups were treated with daily intra-peritoneal injections of either 
vehicle (5% Cremophor /PBS), 3 mg/kg LXR agonist (GW3965 in 5% Cremophor/PBS) or 30 
mg/kg LXR agonist (GW3965 in 5% Cremophor/PBS). Progressive significant body weight 
loss was associated with the higher dose of LXR agonist compared with vehicle or 3 mg/kg 
LXR agonist. Student t-Test; **P<0.01; ***P<0.001; Error bars=mean ± SEM; n= 10 
mice/group. 
 
LXR agonist treatment exacerbated the histopathological inflammatory and 
fibrotic changes in the lungs of mice given bleomycin                        
Administration of LXR agonist lead to worsening of the pathomorphological 
changes in the lung architecture of these mice given bleomycin (Figure 3.10 A and 
B). The severity of these changes correlated with the concentration of the agonist; 
daily intraperitoneal administration of 30mg/kg LXR agonist lead to increased 
severity of the lung inflammatory (p<0.001, Figure 3.11) and fibrotic (p<0.001, 
Figure 3.12) changes in comparison with groups treated with 3mg/kg LXR agonist 
or vehicle (Figure3.10 A and B). 
Histological staining of mice lungs with H&E stain demonstrated severe 
inflammatory changes as shown by an infiltration of inflammatory cells, 
perivascular haemorrhage, oedema, and collapse of alveoli. This was more 
pronounced in mice that were treated with 30 mg/kg LXR agonist in comparison 
with mice treated with 3 mg/kg LXR agonist or vehicle (Figure3.10 A). 
Histo-fibrotic changes in lung tissue sections were determined by using Gomori’s 
Trichrome stain. Collagen deposition was seen as bundles and fibrotic foci 
distributed mainly around bronchioles, blood vessels, and parenchyma. These 
were observed predominantly in mice that were treated with 30 mg/kg LXR agonist 
in comparison with mice that were treated with 3 mg/kg LXR agonist or vehicle 
(Figure 3.10 B).  
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Figure 3.10 Histological inflammatory and fibrotic changes in the lung of mice given 
bleomycin and treated with different concentration doses of LXR agonist or vehicle                                                                                                                                         
(A) Representative images of stained lung tissue sections showing morphological changes 
in lung architecture after daily injection of either different doses of LXR agonist or vehicle. 
H&E staining shows more severe inflammatory changes in the group that was treated with 
30 mg/kg LXR agonist, compared with the group that was treated with 3 mg/kg LXR agonist 
or group that treated with vehicle. (B) Representative images of lung tissue sections stained 
with Gomori’s Trichrome stain showing collagen patches around bronchioles, blood 
vessels and in the parenchyma. The collagen deposition was more extensive in the lungs of 
mice given bleomycin and treated with 30 mg/kg LXR agonist, compared with lungs of mice 
given bleomycin and treated with either 3 mg/kg LXR agonist or vehicle. Sections were 
viewed under light microscopy (magnification x10). 
 
Lung sections stained with H&E and Gomori’s Trichrome stain were scored blind 
for a semi-quantitative score of inflammation and fibrosis. The scoring was blindly 
by me and an independent colleague both blind to the origin of the tissue section. 
There was a significantly higher score (p<0.001) for the lung inflammation in mice 
given bleomycin and treated with 30 mg/kg LXR agonist compared with those 
treated with either 3 mg/kg LXR agonist or vehicle (Figure 3.11). 
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Figure 3.11 Lung inflammation score of the mice given bleomycin and treated with different 
concentration doses of LXR agonist or vehicle                                                                                                                                           
Inflammation was assessed by histological score (details are described in the Materials and 
Methods section 2.5.2). There was a highly significant lung inflammation score in mice 
given bleomycin and treated with 30 mg/kg LXR agonist compared with groups treated with 
either 3 mg/kg LXR agonist or vehicle. One-way ANOVA; ***P<0.001; bar=mean ±SEM; n= 10 
mice/group.      
 
The lung tissue fibrosis score was quantified using the Gomori’s Trichrome stained 
lung tissue sections. This demonstrated a highly significant (p<0.001) increase in 
collagen deposition in the lung of mice given bleomycin and  treated with 30 mg/kg 
LXR agonist compared with those treated with either 3 mg/kg LXR agonist or 
vehicle (Figure 3.12).   
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Figure 3.12 Lung fibrosis score of the mice given bleomycin and treated with different 
concentration doses of LXR agonist or vehicle                                                                                                                       
The fibrosis score was assessed by fibrosis score (details are described in the Materials 
and Methods section 2.5.2). This demonstrated highly significant increase in fibrosis 
(p<0.001) in lungs of mice given bleomycin and treated with 30 mg/kg LXR agonist 
compared with  those  treated with 3 mg/kg LXR agonist or vehicle.  One-way ANOVA; 
***P<0.001; bar=mean ±SEM; n= 10 mice/group.  
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LXR agonist treatment increased the inflammatory cell numbers in the 
bronchoalveolar lavage (BAL) of mice given bleomycin                                                                       
Total cell count:                                                                                                                    
The mean BAL total cells for mice given bleomycin and treated with either 3, 30 
mg/kg LXR agonist or vehicle were as follow:                                                                            
Mice treated with vehicle                                     0.90 x 106,                                                                            
Mice treated with 3 mg/kg LXR agonist              0.87 x 106,                                                                     
Mice treated with 30 mg/kg LXR agonist            1.49 x 106,                                                                   
The total BAL cell count was significantly higher in the mice received 30 mg/kg 
LXR agonist than the other groups (p<0.001) (Figure 3.13). 
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Figure 3.13 Total BAL cell count in the BAL of mice given bleomycin and treated with 
different concentration doses of LXR agonist or vehicle                                                                                                                                       
The inflammatory cells were retrieved by bronchoalveolar lavage from all bleomycin treated 
mice. The cell counts were significantly increased in BAL from bleomycin treated mice that 
received 30 mg/kg LXR agonist compared with 3 mg/kg LXR agonist or vehicle. One-way 
ANOVA; ***P<0.001; bar=mean ±SEM; n= 10 mice/group. 
 
Macrophage count:                                                                                                   
Among of the inflammatory cells that were retrieved from the BAL, macrophages 
were the dominant cell type. The mean BAL macrophage counts for mice given 
bleomycin and treated with either 3, 30 mg/kg LXR agonist or vehicle were as 
follow:                                                                            
Mice treated with vehicle                                    0.74 x 106,                                                                            
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Mice treated with 3 mg/kg LXR agonist             0.69 x 106,                                                                     
Mice treated with 30 mg/kg LXR agonist           1.30 x 106,                                                                   
The mean macrophage count in the mice given bleomycin and with 30 mg/kg LXR 
agonist was significantly higher (p<0.001) than the mice given bleomycin and 
treated with either of 3 mg/kg LXR agonist or vehicle (Figure 3.14). 
 
0.0
0.5
1.0
1.5
2.0
Vehicle
3 mg/kg LXR agonist
30 mg/kg LXR agonist
***
Bleomycin
B
A
L
 m
a
c
ro
p
h
a
g
e
s
 x
 1
0
6
/m
l
 
Figure 3.14 Macrophage cell count in the BAL of mice given bleomycin and treated with 
different concentration doses of LXR agonist or vehicle. 
The BAL macrophage cell count was significantly higher in the bronchoalveolar lavage fluid 
from mice given bleomycin and treated with 30 mg/kg LXR agonist compared with those 
mice treated with either 3 mg/kg LXR agonist or vehicle.  One-way ANOVA; ***P<0.001; 
bar=mean ± SEM; n= 10 mice/group                                    
 
Lymphocyte count:                                                                                                              
The mean BAL lymphocyte count revealed that there were no significant 
differences in the lymphocyte count between all mice given bleomycin and treated 
with different doses of LXR agonist or vehicle. The mean BAL lymphocyte counts 
for mice given bleomycin and treated with either 3, 30 mg/kg LXR agonist or 
vehicle were as follow:                                                                            
Mice treated with vehicle                                    0.14 x 106                                                           
Mice treated with 3 mg/kg LXR agonist             0.17 x 106,                                                                     
Mice treated with 30 mg/kg LXR agonist           0.19 x 106,   (Figure 3.15). 
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Figure 3.15 Lymphocyte cell count in the BAL of mice given bleomycin and treated with 
different concentration doses of LXR agonist or vehicle                                                                                                                      
The lymphocyte cell count exhibited no significant differences between the groups treated 
with either 30 mg/kg LXR agonist, 3 mg/kg LXR agonist or vehicle.  One-way ANOVA; n.s. 
P>0.5; bar=mean ± SEM; n= 10 mice/group 
 
3.1.2.3 Treatment with LXR agonist (GW3965) had no effects on 
C57BL/6 mice given PBS 
Introduction and Aim                                                                                                               
We had shown above that daily treatment with LXR agonist (GW3965) to C57BL/6 
mice given bleomycin resulted in an exacerbation of the pulmonary inflammatory 
and fibrotic responses. This was shown by an increase in systemic and local 
inflammatory and fibrotic changes, therefore, it was an important to demonstrate 
the specificity of this effect by excluding that it was a nonspecific targeting of the 
LXR agonist.                                                                                                                                         
Methods: - Three groups of male C57BL/6 mice were used (n=10 per group), 10-
12 week old and 23-25 g weight.  Three days prior the experiment mice were 
treated with daily intra-peritoneal injection of either vehicle (5% Cremophor /PBS), 
3 mg/kg LXR agonist (GW3965 in 5% Cremophor/PBS) or 30 mg/kg LXR agonist 
(GW3965 in 5% Cremophor/PBS) that continued until day 18 when the mice were 
culled. On day zero, all mice were anesthetised using isofluorane in an inhalation 
anaesthetic chamber during which the mice were given intra-nasal 30 l PBS. The 
mice were monitored daily for wellbeing and changes in body weight until day 18 
when the mice were culled.                                                                                                     
 
LXR agonist treatment did not affect the body weight in mice given PBS                                                                                                                                           
Daily monitoring of body weight showed no differences in all mice groups tested. 
All the groups of mice lost weight in the first day due to the procedure of intranasal 
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administration of PBS but they recovered after that and started growing relatively 
equally between all groups that treated with different daily intraperitoneal injections 
of either 3 mg/kg LXR agonist, 30 mg/kg LXR agonist or vehicle,   (Figure 3.16). 
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Figure 3.16 Daily body weight changes in mice given PBS and treated with different 
concentration doses of LXR agonist or vehicle                                                                                                                                  
Daily body weight changes in male C57BL/6 mice (8 weeks old) that received PBS (30 l PBS 
/ mouse) intranasally. Mice groups were given daily intra-peritoneal injection of either 
vehicle (5% Cremophor /PBS), 3 mg/kg LXR agonist (GW3965 in 5% Cremophor/PBS) or 30 
mg/kg LXR agonist (GW3965 in 5% Cremophor/PBS). There were no differences in body 
weight were seen intra-peritoneal. Student t-Test; n.s. p>0.05; bar=mean ± SEM; n= 10 
mice/group. 
 
LXR agonist treatment did not affect histopathological inflammatory and 
fibrotic outcomes in lungs of mice given PBS                                      
Administration of PBS intra-nasally had no effect on the lung architecture, or 
caused any significant inflammatory or fibrotic changes from normal mice lungs 
were observed. Daily administration of the vehicle or 3 mg/kg or 30 mg/kg LXR 
agonist did not make any significant changes to the normal lung architecture. This 
was demonstrated by H&E stain and Gomori’s Trichrome stain of lung tissue 
sections of these mice (Figure 3.17 A and B). 
Lung section from mice given PBS and treated with vehicle or 3 mg/kg LXR 
agonist or 30 mg/kg LXR agonist were stained with H&E. This showed normal lung 
architecture without any inflammatory changes, normal blood vessels, normal 
alveolar structure and no inflammatory cell infiltration (Figure 3. 17 A). 
Gomori’s Trichrome stain was used to stain lung section from mice given PBS and 
treated with vehicle or 3 mg/kg LXR agonist or 30 mg/kg LXR agonist reviled 
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normal lung collagen content at lung bronchioles, blood vessels and interstitium 
without any significant fibrotic changes (Figure 3. 17 B). 
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Figure 3.17 Histological inflammatory and fibrotic changes in the lung of mice given PBS 
and treated with different concentration doses of LXR agonist or vehicle                                                                                                               
(A) Representative images of lung tissue sections stained with H&E. Sections demonstrated 
normal lung architecture without any significant morphological changes after daily injection 
of either of vehicle or different doses of LXR agonist (3 & 30 mg/kg).  (B) Representative 
images of lung tissue sections stained with Gomori’s Trichrome stain. Sections 
demonstrated normal lung architecture with basal collagen content around lung 
bronchioles and blood vessels without any significant fibrotic changes after daily injection 
of either different doses of vehicle or LXR agonist (3 & 30 mg/kg). Sections were viewed 
under light microscopy (magnification x10). 
 
Quantification of the PBS treated mice lung section stained with H&E and 
Gomori’s Trichrome stain were performed and scored blind for inflammation and 
fibrosis.  
Scoring of H&E stained lung sections from mice given PBS and treated with daily 
intra-peritoneal injection of either vehicle or 3 mg/kg LXR agonist or 30 mg/kg LXR 
agonist demonstrated a low score on our inflammation scoring grade described in 
(Materials and Methods section 2.5.2). There were no significant differences 
between the groups (Figure 3.18). 
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Figure 3.18 Lung inflammation score of mice given PBS and treated with different 
concentration doses of LXR agonist or vehicle                                                                                                                      
Inflammation was assessed by histological score (see Materials and Methods section 2.5.2). 
No differences were demonstrated between groups treated with either 3, 30 mg/kg LXR 
agonist or vehicle. One-way ANOVA; n.s. p>0.05; bar=mean ±SEM; n= 10 mice/group.         
 
Quantifying the tissue fibrosis was carried out on Gomori’s Trichrome stained lung 
tissue sections from groups mice given PBS and treated with vehicle or 3 mg/kg 
LXR agonist or 30 mg/kg LXR agonist. This demonstrated essentially normal 
collagen content reflected by a low fibrosis score using our fibrosis grade 
described in Materials and Methods section 2.5.2 (Figure 3.19). 
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Figure 3.19 Lung fibrosis score of mice given PBS and treated with different concentration 
doses of LXR agonist or vehicle                                                                                                                                         
Fibrosis was assessed by fibrosis score (see Materials and Methods section 2.5.2). No 
differences were shown between the groups. One-way ANOVA; n.s. P>0.05; bar=mean ±SEM; 
n= 10 mice/group. 
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LXR agonist treatment did not affect the inflammatory cell number or 
phenotype in the bronchoalveolar lavage (BAL) of mice given PBS                 
Total cell count:                                                                                                           
Total BAL cells were counted for mice given PBS and treated with daily intra-
peritoneal injections of either vehicle or 3, or 30 mg/kg LXR agonist. The total cell 
counts did not show any significant differences between these experimental 
groups. The mean total BAL cells counts were as follows:-                                                                                                                                      
Mice treated with vehicle                            0.161 x 106,                                                                           
Mice treated with 3 mg/kg LXR agonist      0.170 x 106,                                                                    
Mice treated with 30 mg/kg LXR agonist     0.150 x 106   (Figure 3.20). 
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Figure 3.20 Total BAL cell count in the BAL of mice given PBS and treated with different 
concentration doses of LXR agonist or vehicle                                                                                                                                               
The BAL total cell were retrieved by bronchoaleveolar lavage from all mice groups given 
PBS. The counts showed no significant differences between all experimental groups treated 
with different daily intra-peritoneal injections of vehicle, 3 mg/kg LXR agonist, or 30 mg/kg 
LXR agonist. One Way ANOVA; n.s. P>0.05; Mean ±SEM; n= 10 mice/group.  
 
Macrophage count:                                                                                                            
The BAL macrophage differential cell counts for all PBS given animals revealed no 
significant differences between the experimental groups although they received 
daily intra-peritoneal injections of either vehicle or 3 mg/kg LXR agonist or 30 
mg/kg LXR agonist. The mean macrophage cells counts were as follows:-                                                                                                                                         
Mice treated with vehicle                               0.143 x 106,                                                                    
Mice treated with 3 mg/kg LXR agonist         0.151 x 106,                                                             
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Mice treated with 30 mg/kg LXR agonist       0.129 x 106    (Figure 3.21). 
 
Lymphocyte count:                                                                                                   
The BAL lymphocyte differential cell counts for all PBS given animals showed no 
significant differences between the experimental groups and the mean values 
were as follows:                                                                                                                        
Mice treated with vehicle                               0.008 x 106,                                                                               
Mice treated with 3 mg/kg LXR agonist         0.007 x 106,                                                           
Mice treated with 30 mg/kg LXR agonist       0.010 x 106    (Figure 3.22). 
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Figure 3.21 Macrophage cell count in the BAL of mice given PBS and treated with different 
concentration doses of LXR agonist or vehicle                                                                                                                                                 
The BAL macrophage cell count showed no significant differences between the groups. 
One-way ANOVA; n.s. P>0.05; bar=mean ± SEM; n= 10 mice/group. 
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Figure 3.22 Lymphocyte cell count in the BAL of mice given PBS and treated with different 
concentration doses of LXR agonist or vehicle                                                                                                                                                  
The BAL lymphocyte cell count showed no significant differences between the groups. One-
way ANOVA; n.s. P>0.05; bar=mean ± SEM; n= 10 mice/group. 
 
3.1.2.4 Validation of LXR agonist function on LXR-/--/- mice 
Introduction and aim                                                                                               
The primary gene-target for LXR activation is ABCA1 and expression of this 
protein can act as a reporter of LXR activation. To validate our LXR-/--/- double 
gene-deleted mice we tried to look on the expression of  ABCA1, LXRα, and LXRβ 
in these mice in response to treatment with LXR agonist (GW3965) or vehicle. 
Methods: - Four groups of male mice (two LXR-/--/- and two LXR-/--/- wild-type) 
were used (n=5 per group), 10-12 week old and 23-25 g weight.  The mice were 
given either 30 mg/kg LXR agonist (GW3965 in 5% Cremophor/PBS) or vehicle 
(5% Cremophor /PBS). The mice were allocated in groups as the following:                             
A- WT mice treated with LXR agonist                                                                                      
B- WT mice treated with vehicle                                                                                               
C- LXR-/--/- mice treated with LXR agonist                                                                              
D- LXR-/--/- mice treated with vehicle                                                                                      
On day zero of the experiment mice were treated with daily intra-peritoneal 
injection of either vehicle (5% Cremophor /PBS) or 30 mg/kg LXR agonist 
(GW3965 in 5% Cremophor/PBS) until day 18 were all mice culled and lung 
sample collected. The mice were monitored daily for wellbeing.     
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LXR agonist had no effect on ABCA1 expression in lungs of LXR-/--/-                       
The expression of LXRα, LXRβ and ABCA1 in RNA extracted from lung tissue 
after 18 days is shown in (Figure 3.23). There were two important observations 
from this experiment:   
1- There was a significant up-regulation of mRNA expression for ABCA1, LXRα 
and LXRβ in the WT mice with LXR agonist compare to WT mice treated with 
vehicle, P<0.05 for LXR and p<0.001 for LXR and ABCA1 expression.                                               
2- The expression of ABCA1, LXRα and LXRβ were lower than normal in LXR-/--
/-   mice treated with either LXR agonist or vehicle (P<0.05). 
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Figure 3.23 ABCA1, LXRα, and LXRβ gene expression in lung of mice treated with vehicle or 
LXR agonist                                                                                                                                          
ABCA1, LXRα, and LXRβ expression levels in the lungs of four groups of mice treated with 
LXR agonist or vehicle.  ABCA1, LXRα, and LXRβ mRNA expression measured as fold-
increase compared with control vehicle-treated mice was significantly higher in the lungs of 
WT mice treated with LXR agonist than the WT mice treated with vehicle. There was reduced 
expression of ABCA1, LXRα and LXRβ observed in LXR
-/-

-/- 
  mice treated with vehicle or 
LXR agonist. One Way ANOVA; *p<0.05; ***p<0.001; Mean ± SEM; n=5 mice/group. 
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3.1.3 Discussion and Conclusion                                                                    
The overall purpose of this study was to explore the role of LXR in the 
inflammatory process; specifically in inflammatory lung disease. Previous studies 
identified the involvement of LXR in other inflammatory diseases such as 
atherosclerosis and rheumatoid arthritis, and their results varies depending on the 
model, for example, a study performed using apolipoprotein E gene-deleted mice 
had shown that agonists of LXR and RXR were able to activate LXRs and to 
initiate expression of ABCA1 from macrophages resulting in cholesterol efflux from 
ApoE gene deleted mice but not in LXR gene-deleted mice [60]. This lead to 
conclusion that cholesterol efflux is mediated through direct expression of ABCA1 
in response to LXR activation. Another study in our lab using a murine collagen 
induced arthritis model demonstrated that activation of LXR with T1317 and 
GW3965 agonists resulted in exacerbation of the inflammatory response, with 
excessive cartilage destruction [74]. Also a certain degree of liver fibrosis in the 
mice treated with LXR agonist (Data not shown), therefore, we tried to understand 
if LXR is involved in fibrosis and if LXR agonists can modulate the bleomycin-
induced pulmonary fibrosis. Our results suggested that administration of LXR 
agonist can lead to exacerbation in the pulmonary fibrosis which was 
demonstrated by an active inflammatory and fibrotic processes. I acknowledge the 
controversy related to LXR activation across different inflammatory model from an 
anti-inflammatory role in atherosclerosis to a pro-inflammatory role in collagen 
induced arthritis. This still unresolved for example in atherosclerosis model, 
activation of LXR reveals an anti-inflammatory effect manifested by removal of the 
cholesterol from the artery walls but these animals suffer from accumulation of 
excess amount of fat in their liver.  
In this Chapter the initial experiments were justified the conditions of the lung 
fibrosis model and the dose-response to the intervention drugs, and the 
characterisation of the gene-deleted mice used. This chapter demonstrated that 
day 18 after bleomycin administration was a useful time-point to determine the 
duration of the disease model. This was established by a loss of body weight 
which was a sign of cachexia and systemic inflammation. This was accompanied 
by histopathological inflammatory and fibrotic changes with local changes in 
airway cytology specifically the recruitment of inflammatory immune cells.  
These preliminary experiments were to demonstrate the effect of administration of 
LXR agonist (GW3965) to the bleomycin treated mice. GW3965 is a highly specific 
LXR agonist. It was used at different doses to determine firstly if the activation of 
LXR may contribute in the modulation of bleomycin-induced pulmonary fibrosis, 
and secondly the optimal dose of GW3965 required to sustain the LXR activation 
was established. Our results suggested that intra-peritoneal administration of 30 
mg/kg LXR agonist (GW3965) could augmented the pro-inflammatory and pro-
fibrotic process resulting in a more severe loss of body weight, more severe lung 
histo-pathological inflammatory and fibrotic processes and increased numbers of 
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local inflammatory cell infiltrate. Compared with this, administration of 3 mg/kg 
LXR agonist or vehicle (Cremophor) had no significant effect. 
Administration of different doses of LXR agonist into PBS treated mice showed no 
detectable effect on the lungs of PBS treated mice. This suggested that neither of 
LXR agonist nor vehicle alone affected the normal lung histology and cytology 
This suggests that LXR engagement had a dose dependent, profound effect upon 
bleomycin-induced inflammation and fibrosis. This is the first time to my 
knowledge that LXR pathway might be involved in lung fibrosis. This knowledge 
may be informative of the disease process as well as instructive for potential new 
therapeutic targets. 
Using bleomycin for the initiation of lung fibrosis is one of the common ways for 
establishing an experimental model. Bleomycin has fibrogenic side effects in 
cancer patients treated with bleomycin as an anticancer therapy. A similar 
pulmonary fibrosis can be introduced to mice by bleomycin administration 
suggesting that this is a relevant model. 
It was important to determine the time course for the model. We chose an 
intranasal route of administration of bleomycin to justify getting the drug to the 
airspace of the lung target.  
Determining the peak of the disease is one of the critical points of understanding 
of the model. A literature search for the optimal time course of the model used by 
different workers highlighted a lack of consistency.  A consensus was that the 
peak of disease inflammatory and fibrotic features occurred between 14-21 days 
after bleomycin administration [192, 200, 201]. Based on this, we tried to establish 
our own time points for the peak of the inflammatory and fibrotic changes in the 
mice; therefore, we investigated 3 time points after bleomycin administration; on 
days 3, 18 and 32. We chose day 3 to determine the early inflammatory changes 
that might determine the subsequent fibrotic response, day 18 an intermediate 
time point between the most common peak days of the disease remodelling 
reported in the literature, and day 32 to determining the start of disease resolution.   
Body weight changes indicated a systemic inflammatory response that started 
after bleomycin administration until days 8-11 then the mice started gaining weight 
(Figure 3.2). Our results are in agreement with other reports which show a similar 
20% reduction in body weight in mice given bleomycin [202].  
The local airway inflammatory parameters of airway leukocytosis and tissue 
inflammation and remodelling indicated that day 18 was a useful time point to 
demonstrate a peak of activity in our model. These results were consistent with a 
previous study that used Quantitative Image Analysis (QIA) which showed a mild 
increase in pathomorphological changes during 3-6 days after bleomycin 
installation while the maximum changes occurred between days 14-21[192]. 
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The pathomorphological changes were accompanied by a significantly higher BAL 
total cell count; predominantly macrophage and lymphocyte. My results identified 
that the inflammatory response to bleomycin administration is dominated by 
macrophage and to lesser extent by lymphocyte infiltration. Alveolar macrophages 
are characterised by their multi-functional capacity in the lung. After inflammation 
they have a resolution capacity by their ability to remove apoptotic and necrotic 
debris through a non-phlogistic pathway resulting in minimisation of inflammation. 
In tissue fibrosis, macrophages play an important role in enhancing tissue 
remodelling. Alternatively activated pro-fibrotic (M2) phenotype macrophages have 
been identified as predominant macrophages in the lung and monocytes from IPF 
patients in a  study that demonstrated an increased in the protein levels of several 
of (M2) macrophage-associated proteins [203].  
Lymphocytes are a minor proportion of cells in normal BAL. That they are 
increased in BAL from bleomycin treated mice suggest they have an important yet 
unspecified role in this model. They are one of the inflammatory cell types that can 
potentially play an important role in initiation, continuing and eventual suppression 
of the inflammation. Studies have shown an accumulation of lymphocytes and 
lymphoid follicles with germinal centres in histological analysis of biopsy tissues 
from  patients lung interstitium [204]. Both clinical and  laboratory studies have 
demonstrated a role for different lymphocyte subset in fibrosis; bleomycin-induced 
pulmonary fibrosis using mouse strains genetically lacking T lymphocytes, or some 
important T-cell receptors such as CD28 that is required for full T-cell activation, 
demonstrated an attenuation in the fibrosis, inhibition of fibroblast proliferation and 
reduction of extra-cellular matrix accumulation. This suggests that T-cells 
contribute to the pathogenesis. B lymphocyte are an important active inflammatory 
cell, because of their ability to produce of antibodies, they draw attention  because 
of presence of some auto antibodies such as anti-cytokeratins and anti-vimentin 
antibodies which act against alveolar epithelial cell antigens were determined in 
Idiopathic Pulmonary Fibrosis (IPF) patients [204]. Animal model of bleomycin 
pulmonary fibrosis performed on mouse strain genetically lacking CD19, an 
essential antigen co-receptor for B lymphocyte function, demonstrated a significant 
reduction in the susceptibility to bleomycin-induced fibrosis,  in contrast, mouse 
strains that genetically  over-express CD19 have enhanced susceptibility to 
bleomycin-induced fibrosis [205]. This suggests that B-cell activation contributes to 
pathology by an as yet unresolved mechanism. We did not quantify the 
lymphocyte subpopulation proportions and we suggest that future studies should 
include an extensive phenotyping of the airway (BAL) lymphocytes as well as 
lymphocytes isolated from dispersed interstitial lung tissue and draining thoracic 
lymph nodes. This could include an investigation of the presence and potential 
function of innate lymphocytes. These cells can produce type-2 cytokines e.g. IL-
13 that is known to promote collagen production and remodelling. 
My next preliminary experiment was to determine the most effective dose of the 
LXR agonist GW3965 required to maintain contentious activation of the receptors.  
GW3965 is a highly specific and highly potent agonist for LXR and has no off-
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target antagonism of other nuclear receptors. The most effective dose was 
interpreted by monitoring the general and local inflammatory responses in the 
murine bleomycin-induced pulmonary fibrosis model. The preliminary suggestion 
of dose was 30 mg/kg based on our experimental observations and observations 
on previous work which identified this as a sufficient dose to sustain the activation 
of LXR for 24 hours in murine collagen induced arthritic model CIA model [74].  
Using GW3965 at a concentration of 30 mg/kg resulted in worsening of bleomycin-
induced inflammation and remodelling (Figure 3.9). The fact that this agonist is 
selectively and highly specific for LXR strongly supports a role for this receptor in 
disease outcome. This is supported by additional experiments using LXR-/- mice 
reported later in this thesis. 
Constant with the general systemic inflammatory findings including the reduction 
of body weight among bleomycin treated mice that received 30 mg/kg GW3965, 
the pathomorphological findings in the lung demonstrated highly active 
inflammatory and fibrotic processes (Figure 3.11). Since the effect of the LXR 
agonist GW3965 is not limited to any specific cell type it is possible that its effect 
on macrophages and lymphocytes led to an amplification of their normal pro-
inflammatory and pro-fibrotic processes. LXR agonism has been shown to slow 
atherogenesis, but cause hepatic steatosis and dysfunction in C57BL/6 mice. The 
mechanism is probably that hepatic steatosis resulted from a high expression of 
sterol regulatory element binding protein 1-c (SREBP1-c), a transcription factor 
that up-regulates fatty acid synthesis [206].    
One of my preliminary experiments was to understand what effect of 
administration of 3 and 30 mg/kg GW3965 or vehicle to mice that only received 
PBS intra-nasally.  The aim was to demonstrate if there is any inflammatory or 
fibrotic outcome due to LXR agonism alone using these compounds. Clinical 
follow-up of these mice did not show any effect on the normal body weight (Figure 
3.16). Constant with this finding, an analysis of the pathomorphological changes in 
lung tissue sections and BAL total and differential cell counts did not reveal any 
differences among the study groups. These data suggested that there is no 
specific effect to the administration of this agonist alone in contrast to what was 
observed when GW3965 was administered at a concentration of 30 mg/kg to mice 
that received bleomycin. Thus LXR function to exacerbate an inflammatory 
response triggered by another stimulus. 
My last preliminary experiment was to validate our LXR-/--/- double gene-deleted 
mice. This was an important step to provide a strong base for my future work 
which will contain using of these mice. The validation performed by measuring of 
the expression level of mRNA for ABCA1, LXRα, and LXRβ in these mice in 
response to treatment with LXR agonist (GW3965) or vehicle. Activation of LXR 
characterised by up-regulation of ABCA1, LXRα, and LXRβ in wild type mice 
treated with LXR agonist.  
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3.2 Exacerbation of pulmonary fibrosis is associated with 
the activation of Liver X Receptors  
 
3.2.1 Introduction and Aims 
The justification for exploring the LXR in tissue remodelling using the bleomycin 
model of murine lung fibrosis has been detailed in the Results Chapter 3.1. In that 
chapter, the main objectives were to optimise the experimental conditions 
including the bleomycin dose used in the model, the length of the time-course of 
the model, and providing evidence for the LXRs deletion.   
Liver X receptors (LXRs) are cytosolic receptors and transcription factors that 
participate in lipid transport and anti-inflammatory signalling. A literature search for 
a novel role in the involvement of LXRs during inflammation suggested that it had 
mainly an anti-inflammatory effect [52, 68, 69]. However, other literature 
suggested a pro-inflammatory effect for LXRs [74]. In my previous experiments, 
LXR agonists caused a worsening of pulmonary fibrosis as demonstrated by 
potent pro-inflammatory and pro-fibrotic effects. The aim of this chapter is to 
provide evidence that these pro-inflammatory and pro-fibrotic effects were 
mediated specifically by the activation of LXRs. 
Idiopathic pulmonary fibrosis is a severe interstitial lung disease with no effective 
treatment. There is very little evidence in the literature for the involvement of LXR 
and fibrosis. One transcriptome profile study of genes associated with IPF 
identified that the LXR/RXR was one of the key pathways activated in lungs [207]. 
Fibrotic lesions in lung biopsies of patients with interstitial lung disease are 
sometimes associated with lipid-laden or ‘foamy’ macrophage, in particular in 
hypersensitivity pneumonitis [208]. Other literature that supports a role for LXR 
and fibrosis or remodelling includes one report describing hepatic stellate cell 
activation during chronic liver injury and LXR-mediated fibrotic response [75]. This 
study revealed that LXRs activation resulted in inhibition in stellate cell activation 
by suppressing collagen producing genes in primary mouse stellate cells. 
The link between LXR and fibrosis is unresolved therefore the aim of this chapter 
was to determine the association between activation of LXR and LXR with 
GW3965 and the development of lung fibrosis in murine pulmonary fibrosis model 
by comparing the responses to bleomycin in  LXRα-/-β-/-, and LXRαβ wild type mice.                                
                                                                                                             
3.2.2 LXRα-/-β-/- double knockout mice   
The LXRα-/-β-/- double knockout mice were generated in our lab by self-cross 
breeding of LXRα-/- and LXRβ-/- littermates on a C57BL/6 background. Firstly, the 
LXR heterozygotes LXRα±/β± were generated from cross breeding of LXRα-/- and 
LXRβ-/- littermates [209], these littermates were supplied by Lexicon 
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Pharmaceuticals (TX, USA). The details of this are provided in the Material and 
Methods (section 2.3.2). 
 
3.2.3 LXR-/--/-   mice develop less bleomycin-induced pulmonary 
fibrosis than LXR wild type mice; both given LXR agonist 
(GW3965)                                                                                                              
We aimed to demonstrate the specific role of LXRs in murine bleomycin-induced 
pulmonary fibroses.  The specificity of the role of LXR was confirmed by the use of 
LXR-/--/- mice as control. Our aim was to confirm that the inflammatory and 
fibrotic response is mediated specifically through direct activation of LXRs and is 
not because of any off targeting response of the agonist on other nuclear receptor 
transcription factors or because of the activity of endogenous LXR ligands; to 
achieve this aim we had to use LXR-/--/- mice.  
The experiment was performed with male LXRwild type and LXR-/--/- mice 
(10-12 weeks old and 22-25 grams weight).  Animals were divided into 4 groups 
(n=19-23 mice per group):-  
Group A- WT mice treated with vehicle (5% Cremophor in PBS as control)                                                      
Group B- WT mice treated with LXR agonist GW3965                                                                                
Group C- LXR-/--/- mice treated with vehicle                                                                                                
Group D- LXR-/--/- mice treated with LXR agonist  
All mice were given bleomycin intranasally at a dose of 0.06mg in 30 l PBS / 
animal. The mice were treated with daily intraperitoneal (IP) injection of vehicle 
(5% Cremophor v/v PBS) or LXR agonist GW3965 (30mg / kg dissolved in 5% 
Cremophor / PBS) according to the classified group.  
The daily injection regime was necessary because our pilot data demonstrated  
that daily IP injection of 30 mg/kg GW3965 is necessary to induced and maintain a 
20-fold up-regulation in expression of the ATP-binding cassette transporter 
(ABCA)1 gene which is the reporter gene of LXR activation [74]. The injections 
started 3 days prior to the bleomycin challenge to enable the agonist to function, 
and was continued daily until day 18 when all mice were culled. 
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3.2.3.1 Specific effect of LXR agonist in LXR WT but not    
LXR-/--/- mice in murine bleomycin-induced pulmonary fibrosis 
                                                                                                                                      
LXR agonists increase bleomycin induced loss of body weight.                       
The systemic inflammatory response to bleomycin administration was monitored 
by a progressive reduction in body weight (Figure 3.24). The weight loss was most 
evident up to approximately 6-9 days after bleomycin installation for all mice; 
probably reflecting acute inflammation. The wild-type mice had a typical weight-
loss response to bleomycin and the response in LXRα-/-β-/- mice was not 
significantly different. There was a significant reduction in the weight loss in the 
wild-type mice given bleomycin plus LXR agonist compared with wild type mice 
given bleomycin without the LXR agonist (***p<0.0001). This response was LXR-
dependent because it there was no exacerbation of weight loss by LXR agonist in 
the LXRαβ-/- mice (Figure 3.24). 
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Figure 3.24 Daily body weights changes in WT and LXR
-/-

-/-
 mice given bleomycin and 
treated with either LXR agonist or vehicle                                                                                                                               
Daily body weights for 10-12 week old, male WT and LXR
-/-

-/-
 mice that were given 
bleomycin. Some mice were treated with daily IP injections of vehicle (5% Cremophor v/v 
PBS) or LXR agonist GW3965 (30mg/kg dissolved in 5% Cremophor v/v in PBS). Student t-
Test; n.s. p>0.05; *** P < 0.0001; Mean ±SEM; n = 19-23 mice/group. 
                                                                                                                                                       
 
LXR agonist treatment increases the histopathological inflammatory and 
fibrotic changes in the lung of mice given bleomycin                                                             
 
Bleomycin installation caused severe morphological changes to the normal lung 
architecture demonstrated by inflammatory and fibrotic changes (Figure 3.25 A 
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and B respectively). Sections stained with H&E showed an infiltration of 
inflammatory cells, perivascular haemorrhage, and collapse of the alveoli as 
described in Materials and Methods (2.5.2). This was evident in all experimental 
groups, but this was more extensive in the WT mice treated with LXR agonist 
compared to the WT mice treated with vehicle, or in the other control groups; 
LXR-/--/- treated with vehicle and LXR-/--/- treated with LXR agonist (Figure 
3.25 A). 
Collagen was observed in all mice group by using Gomori’s Trichrome stain. The 
collagen bundles and fibrotic foci distribution were mainly around the lung 
bronchioles and blood vessels but it was more extensive in the WT mice treated 
with LXR agonist (Figure 3.25 B). The deposition of the collagen was extensive in 
the lung lobes resulting in severe loss of normal lung architecture.   
Quantification of the extent of the inflammation and fibrosis was performed on the 
lung sections of the WT and LXR-/--/- mice. The sections were labelled by an 
independent colleague who was unaware of the details of the experiment. The 
slides were then scored using an inflammation scoring scale described in 
Materials and Methods (section 2.5.2) by two independent observers thus the 
quantification for inflammation and fibrosis was performed blind to the origin of the 
samples. Scoring of H&E stained lung sections for WT mice given bleomycin and 
daily intraperitonial injection of LXR agonist revealed moderate to severe 
inflammation which was significantly greater (p<0.001) that  the score for the other 
groups;  WT mice given  vehicle, LXR-/--/- given LXR agonist, and LXR-/--/- 
given vehicle alone (Figure 3.26). There was no significant difference between 
these last groups. 
The quantitative score of fibrosis was performed blind on all mice groups given 
bleomycin. There was a significantly higher score for WT mice treated with LXR 
agonist (p<0.001) in comparison with all other experimental groups;  WT treated 
with vehicle, LXR-/--/- treated with LXR agonist, and LXR-/--/- treated with 
vehicle (Figure 3.27). 
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Figure 3.25 Histological inflammatory and fibrotic changes in the lung of WT and LXR
-/-

-/-
 
mice given bleomycin and treated with LXR agonist or vehicle                                                                                                                                                
(A) Representative images of lung lobe sections showing morphological changes in lung 
architecture after bleomycin installation, H&E staining shows severe inflammatory changes 
in all the mice groups which were greater in the WT mice treated with LXR agonist. (B) 
Collagen deposition in the lung of WT mice given bleomycin and treated with LXR agonist 
compared with the other groups. Gomori’s Trichrome stain demonstrated large collagen 
patches around bronchioles, blood vessels and in the parenchyma. Sections viewed under 
light microscope (magnification x10).   
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Figure 3.26 Lung inflammation score of WT and LXR
-/-

-/-
 mice given bleomycin and treated 
with LXR agonist or vehicle                                                                                                                 
Inflammation was assessed by a histological score (see Methods section 2.5.2). This  
demonstrated significantly higher inflammation in the WT mice group treated with LXR 
agonist compared with the other mice groups. One Way ANOVA; ***p<0.001; Mean ±SEM; 
n=19-23 mice/group. 
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Figure 3.27 Lung fibrosis score of WT and LXR
-/-

-/-
 mice given bleomycin and treated with 
LXR agonist or vehicle                                                                                                                      
Fibrosis was assessed by histological scoring (see Methods section 2.5.2). This 
demonstrated significantly higher fibrosis in the WT mice treated with LXR agonist 
compared with the other groups. One Way ANOVA; ***p<0.001; Mean ± SEM; n=19-23 
mice/group. 
  
LXR agonist increases the bleomycin-induced inflammatory cell numbers in 
the bronchoalveolar lavage fluid (BAL)                                                                 
 
The BAL total cell count and differential profiles were made after processing the 
bronchoalveolar lavage fluid.  
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Total cell count: 
 
Total BAL cell counts for bleomycin treated groups revealed significant differences 
between the groups. The total count was significantly higher in the WT mice 
treated with LXR agonist compared to the other experimental mice groups: WT 
mice treated with vehicle, LXR-/--/- mice treated with vehicle, and LXR-/--/- mice 
treated with LXR agonist  ( p<0.001) (Figure 3.28).  
The mean ± Standard error of the mean of  total BAL cell counts were as follows: 
WT mice treated with LXR agonist                 1.68 ± 0.21 x 106,  
WT mice treated with vehicle                          0.88 ± 0.19 x 106,                                                           
LXR-/--/- mice treated with vehicle                0.95 ± 0.20 x 106, 
LXR-/--/- mice treated with LXR agonist        1.01 ± 0.22 x 106     (Figure 3.28). 
There were no significant differences between these last three groups. 
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Figure 3.28 Total BAL cell count in the BAL of WT and LXR
-/-

-/- 
mice given bleomycin and 
treated with LXR agonist or vehicle                                                                                                          
The total cell count for the inflammatory cells retrieved from bronchoalveolar lavage from 
the experimental mice demonstrated that the counts from WT mice treated with LXR agonist 
group was significantly higher compared with the WT mice treated with vehicle, LXR
-/-

-/-
  
mice treated with vehicle, and LXR
-/-

-/- 
 mice treated with LXR agonist.  One Way ANOVA; 
***p<0.001; Mean ± SEM; n=19-23 mice/group. 
The differential cell count profiles were made from the bronchoalveolar lavage fluid 
processed by cyto-centrifuge and H&E staining. The higher total cell count of the 
BAL was reflected in differences in the differential cell counts. 
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Macrophage cell count:                                                                                           
 
The macrophage proportions in the WT mice treated with LXR agonist showed the 
greatest increase which was significantly greater (p<0.001) when compared with 
WT mice treated with vehicle, LXR-/--/- mice treated with vehicle, and LXR-/--/- 
mice treated with LXR agonist (Figure 3.29).  
The mean ± Standard deveation Standard error of the mean of macrophage cell 
counts were as follows: 
WT mice treated with LXR agonist                  1.30 ± 0.24 x 106,  
WT mice treated with vehicle                           0.62 ± 0.14 x 106,                                                           
LXR-/--/- mice treated with vehicle                 0.68 ± 0.20 x 106, 
LXR-/--/- mice treated with LXR agonist         0.74 ± 0.17 x 106     (Figure 3.29). 
There were no significant differences between these last three groups. 
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Figure 3.29 Macrophage cell count in the BAL of WT and LXR
-/-

-/- 
mice given bleomycin 
and treated with LXR agonist or vehicle                                                                                                 
The macrophage cell count was significantly higher in the bronchoalveolar lavage fluid 
retrieved from the WT mice treated with LXR agonist compared to the WT mice treated with 
vehicle, LXR
-/-

-/- 
mice treated with vehicle, and LXR
-/-

-/- 
mice treated with LXR agonist. 
One Way ANOVA; ***p<0.001; Mean ±SEM; n=19-23 mice/group. 
 
Lymphocyte cell count: 
                                                                                                                                      
There were no significant differences in the lymphocyte count between WT mice 
treated with LXR agonist and  both WT mice treated with vehicle and LXR-/--/- 
treated with LXR agonist. However, this was a significantly lower (p=0.0017) than 
the LXR-/--/- treated with vehicle (Figure 3.30).  
The mean ±  Standard error of the mean of lymphocyte cell counts were as follows: 
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WT mice treated with LXR agonist                  0.18 ± 0.06 x 106,  
WT mice treated with vehicle                           0.22 ± 0.04 x 106,                                                           
LXR-/--/- mice treated with vehicle                 0.23 ± 0.82 x 106, 
LXR-/--/- mice treated with LXR agonist         0.20 ± 0.06 x 106     (Figure 3.30). 
There were no significant differences between these last three groups. 
0.0
0.1
0.2
0.3
0.4
WT+V
WT+LXR agonist
LXR -/- -/-+V
LXR -/- -/-+LXR agonist
n.s.
**p=0.0017
B
A
L
 l
ym
p
h
o
c
yt
e
s
 x
 1
06
/m
l
 
Figure 3.30 Lymphocyte cell count in the BAL of WT and LXR
-/-

-/- 
mice given bleomycin 
and treated with LXR agonist or vehicle                                                                                                                                       
The lymphocyte cell count was not significantly different in the bronchoalveolar lavage fluid 
from the WT mice treated with LXR agonist compared to the WT mice treated with vehicle,  
and  LXR
-/-

-/- 
mice treated with LXR agonist groups but it was significantly differ from 
LXR
-/-

-/- 
mice treated with vehicle. One Way ANOVA; n.s. p>0.05; **p<0.01; Mean ±SEM; 
n=19-23 mice/group. 
 
Neutrophil cell count:                                                                                               
The neutrophil count for all the groups involved in the experiment showed no 
differences between groups. There were no significant differences between all 
experimental groups. The mean ±  Standard error of the mean of neutrophil cell 
counts were as follows: 
WT mice treated with LXR agonist                  3.37 ± 1.90 x 104,  
WT mice treated with vehicle                           3.16 ± 1.40 x 104,                                                           
LXR-/--/- mice treated with vehicle                 3.64 ± 1.36 x 104, 
LXR-/--/- mice treated with LXR agonist         2.81 ± 1.82 x 104     (Figure 3.31). 
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Figure 3.31 Neutrophil cell count in the BAL of WT and LXR
-/-

-/- 
mice given bleomycin and 
treated with LXR agonist or vehicle                                                                                                                             
The neutrophil cell count was not significantly different in the bronchoalveolar lavage fluid 
retrieved from the WT mice treated with LXR agonist compared to the other mice groups. 
One Way ANOVA; Mean ± SEM; n=19-23 mice/group. 
 
 
LXR agonist treatment increased the concentration of inflammatory and 
fibrotic mediators in the serum and BAL fluid of bleomycin treated mice.                                                                  
                                                                                                                                     
A pragmatic range of cytokines, chemokines and growth factors relevant to the 
inflammatory and fibrotic responses was quantified in serum (Table 3.2) and in 
BAL fluid (Table 3.3) from the experimental groups of mice. 
                                                                                                                                       
Serum mediators:                                                                                                       
The concentrations of TNF IL-1 IL-2, IL-13, FGF basic, MCP-1, MIP-1 and 
KC were increased in the WT mice treated with LXR agonist compared with the 
other groups (Table 3.2). The growth factors concentration in the serum of mice 
demonstrated a significant increase in TGF and bFGF in WT mice treated with 
LXR agonist group compared with the other groups. Chemokine results analysis 
demonstrated a significant increase in MCP-1, MIP-1, and KC. In the serum of 
WT mice treated with LXR agonist compared with the other groups. 
Bronchoalveolar lavage fluid:                                                                                                            
BAL analysis demonstrated a significant increased concentration of TGF1 and IL-
1in the BAL of WT mice treated with LXR agonist compare to the other 
experimental groups (Table 3.3). 
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serum 
Mediators  
(pg/ml ) 
WT  
+ V 
WT 
+ LXR 
agonist 
LXR-/--/-    
+ V 
LXR-/--/-          
+ LXR 
agonist 
p 
value 
Cytokines      
TNF 23 (8-59) 85
1,3 (52-127) 20 (17-44) 28 (16-69) 0.0495 
IFN 9 (0-27) 0 (0-15) 34 (0-72) 0 (0-34) 0.5296 
IL-1 0 (0-65) 24 (0-63) 80 (31-169) 0 (0-58) 0.1951 
IL-1 42 (18-79) 90
3.4 
(53-164) 
58 (27-109) 32 (24-52)  
0.0156 
IL-2 20 
(7-43) 
931.3.4 
(27-172) 
23 
(9-56) 
28 
(15-73) 
 
0.0319 
IL-4 13 (2-34) 0 (0-17) 39 (0-52) 0 (0-23) 0.1970 
IL-5 16 (0-35) 19 (5-49) 944 (21-172) 14 (6-27) 0.0703 
IL-6 0 (0-27) 19 (0-44) 61 (18-128) 16 (7-40) 0.5959 
IL-10 348 
(95-680) 
321 
(203-526) 
298 
(145-502) 
322 
(114-577) 
0.1290 
IL-12 993 
(0-326) 
671,3,4 
(15-168) 
1234 
(79-281) 
107 
(55-219) 
0.0040 
IL-13 73 (3-15) 1441,3,4 
(74-268) 
184 (0-43) 10 (0-31) 0.0047 
IL-17 0 (0-6) 0 (0-0) 17 (0-48) 0 (0-0) 0.4505 
Growth factors      
TGF 74
3 
(38-122) 
951,3,4 
(67-164) 
63 
(42-91) 
69 
(33-114) 
0.0041 
FGF basic 1903 
(88-419) 
29941,3,4 
(1373-6450) 
140 
(0-384) 
158 
(71-289) 
0.0011 
VEGF 16 (0-35) 21 (0-52) 19 (8-48) 13 (0-32) 0.0830 
GM-CSF 0 (0-0) 0 (0-0) 13 (0-37) 0 (0-0) 0.0719 
Chemokines      
MCP-1 28 (9-68) 841,3,4 
(57-136) 
34 (0-75) 30 (16-53)  
0.0138 
MIP-1 29 (0-64) 43
1,3,4 (11-99) 23 (9-45) 24 (0-56) 0.0311 
KC 1704 (73-
322) 
9561,3,4 (215-
1705) 
157 (63-
314) 
203 (117-
398) 
 
0.0005 
MIG 25 (0-57) 48 (22-93) 24 (17-38) 231 (35-515) 0.2815 
IP-10 0 (0-24) 0 (0-19) 8 (0-26) 0 (0-41) 0.6288 
                                                                                                                           
Table 3.2 Inflammatory and fibrotic mediators in the serum of WT and LXR-/--/- mice given 
bleomycin and treated with LXR agonist or vehicle                                                            
Inflammatory and fibrotic mediators exhibited a significantly higher concentration of TGF1, 
IL-13, IL-1 , TNFIL-2, MCP-1, MIP-1, KC, and bFGF in the serum of the WT mice treated 
with LXR agonist than the WT mice treated with vehicle, LXR
-/-

-/-  
mice treated with vehicle, 
and  LXR
-/-

-/- 
 mice treated with LXR agonist groups. Significant reduction of IL-12 
observed in the serum of the WT mice treated with LXR agonist than in the other groups. 
Median and interquartile range concentrations of each mediator were used to determine P-
value for between category and between group differences; Kruskal-Wallis test; Mann-
Whitney test respectively; *p<0.05; **p<0.01; ***p<0.001; groups n=19-23 mice/group. 
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BAL 
 Mediators  
(pg/ml ) 
WT + V WT 
+ LXR 
agonist 
LXR-/--/-  + 
V 
LXR-/--/-      
+ LXR 
agonist 
p value 
Cytokines      
TNF 46 (9-103) 49 (23-91) 42 (16-77) 40 (12-85) 0.0841 
IFN 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
IL-1 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
IL-1 85 (53-147) 140
1,3,4 (81-
235) 
97 (40-171) 91 (41-167) 0.0431  
IL-2 36 (18-71) 29 (13-56) 31 (8-74) 38 (14-89) 0.1402 
IL-4 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
IL-5 10 (0-31) 8 (0-22) 11 (0-25) 11 (0-39) 0.5682 
IL-6 0 (0-0) 0 (0-11) 33 (0-72) 0 (0-0) 0.4116 
IL-10 387 (144-
819) 
349 (207-
613) 
416 (168-
827) 
425 (235-
762) 
0.1073 
IL-12 80 (29-181) 102 (54-
176) 
91 (42-163) 63 (28-114) 0.0792 
IL-13 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
IL-17 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
Growth factors      
TGF 74
3 
(43-164) 
1431,3,4 
(62-349) 
644 
(27-122) 
72 
(31-158) 
0.0026 
FGF basic 56 (18-131) 61 (27-119) 65 (15-122) 53 (32-98) 0.5984 
VEGF 55 (27-136) 59 (18-110) 47 (12-94) 62 (20-124) 0.0922 
GM-CSF 0 (0-0) 8 (0-36) 8 (0-25) 0 (0-0) 0.5319 
Chemokines      
MCP-1 22 (7-46) 18 (11-34) 20 (6-42) 27 (15-49) 0.3631 
MIP-1 38 (21-69) 47 (16-105) 33 (18-74) 37 (7-81) 0.4227 
KC 73 (34-138) 95 (39-167) 57 (33-106) 65 (22-139) 0.1035 
MIG 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
IP-10 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
 
Table 3.3 Inflammatory and fibrotic mediators in the BAL of WT and LXR
-/-

-/- 
mice given 
bleomycin and treated with LXR agonist or vehicle                                                                            
Inflammatory and fibrotic mediators exhibited a significant high production of TGF1 and     
IL- 1in the BAL of the WT mice treated with LXR agonist than the WT mice treated with 
vehicle, LXR
-/-

-/-
   mice treated with vehicle, and  LXR
-/-

-/- 
 mice treated with LXR agonist 
groups. Median and interquartile range concentrations of each mediator were used to 
determine P-value for between category and between group differences; Kruskal-Wallis test; 
Mann-Whitney test respectively; *p<0.05; **p<0.01; ***p<0.001; groups n=19-23 mice/group. 
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LXR agonist increases bleomycin induced TGF and collagen gene 
expression and collagen production in the murine lung. 
 
TGF expression: 
                                                                                                                                   
Increased TGF beta and collagen gene expression is one of the characteristics of 
fibrosis. TGF-mRNA expression was determined in RNA extracted from the 
lung tissue of experimental groups of mice. This showed a significant (p<0.001) 
increase among the WT mice treated with LXR agonist compared with the WT 
mice treated with vehicle, LXR-/--/- mice treated with vehicle, and  LXR-/--/- mice 
treated with LXR agonist (Figure 3.32). 
 
Collagen expression:                                                                                                   
 
We demonstrated by using qPCR that treatment with LXR agonist increased the 
mRNA level of collagen type IA and collagen type IIIA expression (Figure 3.33). 
The Col IA mRNA expression in the WT mice treated with LXR agonist was 
upregulated significantly by approximately 2-fold compared to the other groups 
and Col IIIA mRNA expression increased by approximately 5-fold (Figure 3.33). 
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Figure 3.32 TGF1 gene expression in lung of WT and LXR
-/-

-/- 
mice given bleomycin and 
treated with LXR agonist or vehicle                                                                                            
TGF1 gene expression levels in the lungs of all groups of mice given bleomycin. TGF1 
mRNA expression measured as fold-increase compared with control vehicle-treated mice 
was significantly higher in the lungs of WT mice treated with LXR agonist than the other 
groups. One Way ANOVA; ***p<0.001; Mean ± SEM; n=19-23 mice/group. 
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Figure 3.33 Collagen gene expression in lung of WT and LXR
-/-

-/- 
mice given bleomycin and 
treated with LXR agonist or vehicle                                                                                                                                          
Collagen type IA and Col IIIA expression levels in the lungs of four groups of mice given 
bleomycin. Collagen IA and Col IIIA mRNA expression measured as fold-increase compared 
with control vehicle-treated mice was significantly higher in the lungs of WT mice treated 
with LXR agonist than the with the WT mice treated with vehicle, LXR
-/-

-/-
   mice treated 
with vehicle, and  LXR
-/-

-/-
 mice treated with LXR agonist groups. One Way ANOVA; 
***p<0.001; Mean ± SEM; n=19-23 mice/group. 
 
 
Collagen production: 
The soluble collagen content of the lung was evaluated by using a Sirius-red 
binding assay as described in Materials and Methods (section 2.6). The assay is 
based on the binding of Sirius red to acid and pepsin-soluble collagen. This 
demonstrated a significant increase (p<0.001) in lung collagen content in WT mice 
treated with LXR agonist compared with the WT mice treated with vehicle, LXR-/-
-/- mice treated with vehicle, and LXR-/--/- mice treated with LXR agonist (Figure 
3.34). The mean ± Standard error of the mean of lung soluble collagen content 
were as follows: 
                                                                                                                                         
WT mice treated with LXR agonist                   2.11± 0.14 mg/ml,  
WT mice treated with vehicle                           1.73 ± 0.11 mg/ml,                                                           
LXR-/--/- mice treated with vehicle                  1.83± 0.17 mg/ml, 
LXR-/--/- mice treated with LXR agonist         1.78 ± 0.13 mg/ml    (Figure 3.34). 
There were no significant differences between the last three groups.   
 
 
 
131 
 
1.0
1.5
2.0
2.5
3.0
WT+V
WT+ LXR agonist
LXR -/- -/-+V
LXR -/- -/-+ LXR agonist
***
L
u
n
g
 c
o
ll
a
g
e
n
 m
g
/m
l
 
Figure 3.34 Soluble collagen content in lungs of WT and LXR
-/-

-/- 
mice given bleomycin and 
treated with LXR agonist or vehicle                                                                                          
Soluble collagen content level in the lungs of the WT mice treated with LXR agonist was 
significantly greater than the other experimental groups. One Way ANOVA; ***p<0.001; Mean 
± SEM; n=19-23 mice/group.  
                                                                                                           
3.2.3.2 Mechanisms of LXR involvement in fibrosis                           
 
The likely main targets for LXR in the development of fibrosis are the fibroblast 
and the macrophage. In this section I will describe the expression pattern of 
phenotypic markers for classically activated macrophages (inducible nitric oxide 
synthase (iNOS2) and alternatively activated macrophages (chitinase-like lectin 
YM1, arginase type 2, IL-13 receptor), their changes associated with LXR 
activation and their relationship with fibrosis. 
 
3.2.3.2.1 LXR modulation of macrophage phenotype                             
The inflammatory and fibrotic processes in mice given bleomycin and treated with 
LXR agonist was associated with significant increased expression of YM1, Arg 2, 
and IL-13R compared with the WT mice treated with vehicle, LXR-/--/-  mice 
treated with vehicle, and LXR-/--/-  mice treated with LXR agonist (Figure 3.35). 
Nitric oxide synthase 2 (NOS2) expressions was down-regulated in the WT mice 
treated with LXR agonist compare to the other groups (Figure 3.35).  
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Figure 3.35 Expression levels of macrophage phenotype markers in the lungs of WT and  
LXR
-/-

-/- 
mice given bleomycin and treated with LXR agonist or vehicle                                                                                                       
Expression levels of macrophage phenotype markers YM1, IL-13R, Arg 2 and NOS 2 in lungs 
of bleomycin treated mice. YM1, Arg 2, and IL-13R were significantly up-regulated in WT 
mice that received LXR agonist compared to the other groups. NOS2 was down-regulated 
significantly in WT mice given LXR agonist compared to the other groups. One Way ANOVA; 
*p<0.05; ***p<0.001; Mean ±SEM; n=19-23 mice/group. 
 
 
3.2.3.2.2 LXR modulation of fibroblast function                                      
The role of LXR agonist on fibroblast function was tested by using collagen gene 
expression in primary mouse fibroblasts lines derived from the lungs of bleomycin 
treated mice, and in human fibroblasts. The culture conditions were explained in 
Materials and Methods (section 2.9.3). 
To explore the stimulation of fibroblasts, different concentrations of LXR agonist 
were used (0.125, 0.25 and 0.5uM) at different time points (6, 12 and 24 hours). 
The greatest increase in Col IA and Col IIIA mRNA expression in mouse lung 
fibroblast cultures was after 24 hours of stimulation using a dose of 0.5M LXR 
agonist (Figure 3.36). The increase for Col IA mRNA was approximately 3-fold and 
for Col IIIA mRNA was approximately 5-fold in WT mouse lung fibroblasts 
stimulated with LXR agonist compared with WT mouse lung fibroblast stimulated 
with the vehicle. The increase was significantly higher (p < 0.05 and p < 0.01) 
respectively. There were no significant changes observed in the Col IA and Col 
IIIA mRNA expression of LXR-/--/- mouse lung fibroblasts in culture (Figure3.36).  
Human fibroblasts exhibited the same pattern as the WT mouse lung fibroblast in 
their response to LXR agonist stimulation. Human primary fibroblast lines 
generated from human tendons were used (Kindly donated by Dr Neil Miller, 
Immunology, Glasgow University. Tissue obtained with ethics approval). Up-
regulation of Col IA and Col IIIA mRNA expression for human fibroblast was less 
than of the mice lung fibroblast and it was 2-fold for Col IA mRNA and 2.5-fold for 
Col IIIA mRNA (Figure 3.37). Both human and mouse fibroblast tends to produce 
more collagen in response to stimulation with LXR agonist, and both Col IA and 
Col IIIA mRNA expression were higher.  
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Figure 3.36 Collagen gene expression in primary mouse lung fibroblasts from WT and LXR
-
/-

-/- 
mice given bleomycin and treated with LXR agonist or vehicle                                                                                 
Mouse lung fibroblasts were cultured with medium alone or different doses of LXR agonist 
or their excipient DMSO, for different incubation times. Increased mRNA expression for Col 
IA and Col IIIA was detected in WT mouse lung fibroblasts in response to stimulation with 
0.5 M LXR agonist at 24 hours. Student t-Test; * P < 0.05; ** P < 0.01; Mean ± SEM; n=3 
independent experiment.            
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Figure 3.37 Collagen gene expression in primary human fibroblast treated with LXR agonist 
or vehicle                                                                                                                                                 
Human primary fibroblast cultured with medium alone or with alone or different doses of 
LXR agonist or their excipient DMSO for different incubation times. Collagen type IA and Col 
IIIA expression up-regulated in response to stimulation with LXR agonist. The up-regulation 
was higher at 24 hours with 0.5 M LXR agonist. Mean ± SEM; n=3 independent experiment.  
 
3.2.3.2.3 LXR directly targets collagen type I and III expression in 
murine fibroblast                                                                                  
Treatment with LXR agonist increased collagen gene expression and transcription 
in primary mouse fibroblasts as shown in Figure 4.36 above. To determine if the 
effect of LXR agonist on the expression of Col IA and Col IIIA mRNA required 
protein synthesis, the mouse primary fibroblasts were treated with cycloheximide; 
an inhibitor of translation. The cycloheximide was added at a concentration of 1 
g/ml. for 24 hours as described in Materials and Methods (section 2.9.4).  
The fibroblast stimulated with LXR agonist in presence of cycloheximide resulted 
in a significant up-regulation of Col IA and Col IIIA gene expression in comparison 
with the other experimental groups. There were no changes in the Col IA1 and Col 
IIIA gene expression in the fibroblast stimulated with DMSO and cycloheximide 
(Figure 3.38). This suggested that the function of LXR agonist on collagen gene 
expression did not require de novo protein synthesis and that this effect may have 
been directly on the promoter region of the collagen gene. 
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Figure 3.38 LXR agonist directly increased collagen gene expression in primary mouse lung 
fibroblasts                                                                                                                                   
Primary mouse lung fibroblasts were cultured with medium, vehicle (DMSO) and LXR 
agonist (GW3965) in addition to cycloheximide. WT mice fibroblast exhibited a significant 
up-regulation in Col IA and Col IIIA expression under LXR agonist stimulation in 
comparison with cells incubated with medium or DMSO vehicle. No changes had been 
observed among the primary fibroblasts derived from LXR
-/-

-/- 
mice. One Way ANOVA; 
***p<0.001; Mean ± SEM; n=3 independent experiment.            
 
3.2.3.2.4 Activation of LXR directly targets the promoters of 
collagen types I and III in the murine fibroblast cell line T1317 
To explore whether the increased Col IA and Col IIIA was a direct or indirect effect 
of LXR agonists, I tested the hypothesis that the collagen genes have response 
elements for LXR in their promoter regions. Since collagen is a major component 
in fibrosis, therefore, a luciferase reporter assay was used to determine the effect 
of LXR agonist on the promoters of collagen type IA1a, IA1b, IA1c, and IIIA1a. The 
details of this assay are described in the Material and methods section (2.10).   
The cells activated with LXR agonist GW3965 showed increased relative 
luciferase activity for collagen type IA1b and IIIA1a in comparison with the cells 
stimulated with the excipient DMSO control (Figure 3.39). The assay efficiency 
was performed by observing the luciferase activity changes in control positive 
promoter plasmid PGL3 (+) and control negative promoter plasmid PGL3 (basic) 
samples (Figure 3.39). 
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Figure 3.39 The effect of LXR agonist on luciferase activity indicating collagen gene 
expression in transfected mouse primary fibroblasts                                                                                                              
The T1317 murine fibroblast cell line was transfected with collagen type IA1a,  IA1b, I A1c, 
and IIIA1a then cultured with DMSO or LXR agonist. Collagen type IA1b and IIIA1a luciferase 
activity was increased in the cells activated with LXR agonist. One Way ANOVA; ***p<0.001; 
Mean ± SEM; n=3 independent experiments. 
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3.2.4 Discussion and Conclusion                                                                    
The aim of this results chapter was to provide evidence for a direct role for LXR 
activation in the inflammatory changes and tissue remodelling associated with 
bleomycin induced lung fibrosis. We demonstrated that activation of LXR by 
administration of the LXR agonist GW3965 lead to exacerbation in the 
inflammatory and fibrotic processes in mice given bleomycin. This was seen as 
increased loss of body weight, increased pathomorphological changes in the lung, 
increased number of inflammatory cells in the BAL, increased pro-inflammatory 
and pro-fibrotic mediators in the BAL and serum, and increased collagen 
expression and collagen content in the lung. 
Having demonstrated that LXR agonist can exacerbate bleomycin induced lung 
fibrosis, the first consideration was the specificity of the response. To achieve this 
purpose a control murine bleomycin-induced pulmonary fibrosis model was tested 
using LXR-/--/- mice. These mice responded to bleomycin with the same severity 
of pulmonary fibrosis as wild type mice, but was not exacerbated by agonist.   
Monitoring of the body weight among these mice indicated a severe reduction in 
body weight in LXR wild type mice treated with LXR agonist than vehicle treated 
control mice or LXR-/--/-   mice (Figure 3.24). These results indicated a 
development of systemic inflammation which was exacerbated by activating the 
LXRs. This was accompanied by pathomorphological changes in the lungs. In the 
LXR agonist treated WT mice given bleomycin, severe inflammatory responses 
were observed accompanied by a high fibrosis score as an index of collagen 
deposition compared with LXR-/--/- .  
Having shown that the exacerbation of inflammation and fibrosis was LXR-specific 
the next step was to interpret the mechanism as far as possible. Administration of 
LXR agonist stimulated a significant increase in the total number of inflammatory 
cells in the BAL; predominantly due to the proportion of macrophages and to a 
less extent to lymphocytes, that is BAL cell profile typical of bleomycin induced 
lung injury.  
One potential mechanism of this pro-fibrotic effect was that LXR agonists can shift 
macrophage phenotype from an innate phenotype towards an alternatively 
activated M2 macrophage phenotype by up-regulation of expression of some anti-
inflammatory genes such as Argenase 2 accompanied by suppression of  
expression of some pro-inflammatory genes such as inducible nitric oxide 
synthase ( iNOS) [197]. Marathe and colleagues reported that in vitro activation of 
LXR in macrophage cell lines and in primary murine macrophages lead to up-
regulation of  Arginase 2 accompanied  by down-regulation  of iNOS  and 
suggested that the mechanism of this reciprocal response was by antagonism of 
NF-kappa B activity [197]. The consequence of this alteration in the expression of 
Arginase 2 and iNOS led to shifting of inflammatory signalling within the 
macrophage. Expression of Arg 2 had been shown to have a selective effect on 
inflammatory pathways; this was determined by an absence of alteration on the 
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expression of other inflammatory mediators for example cyclooxygenase-2 (COX-
2) and prostaglandin-E2 (PGE2). M2 macrophages had been demonstrated as 
major component in the wound healing process, Arginase characterised by its 
ability to inhibit nitrogen oxide (NO) production resulting in production of ornithine, 
a precursor of hydroxyproline and polyamines [43]. Recently a study demonstrated 
that Argenase 2 promotes macrophage pro-inflammatory responses in 
atherosclerosis and type II diabetes mellitus and this effect were mediated through 
the mitochondrial reactive oxygen species [29]. 
To help understand the mechanisms of the systemic and local lung inflammation 
the next step was to identify the pattern of inflammatory cytokines in serum and 
BAL fluid. There was a wide range of concentrations of mediators in the different 
categories of pro-inflammatory cytokines, chemokines and growth factors. In 
serum from mice given bleomycin and treated with LXR agonist, the 
concentrations of TNF IL-1 IL-13, TGF1, FGF basic, MCP-1, MIP-1 and KC 
were higher than in serum of the other experimental groups. Similarly, in the BAL 
fluid of mice given bleomycin and treated with LXR agonist, the concentration of 
TGF1 and IL-1were higher than in WT mice given bleomycin and both LXR-/--
/- groups (Table 3.2 and Table 3.3). The interpretation of the increase in these 
particular mediators indicates the presence of an active pro-inflammatory and pro-
fibrotic process resulting from the activation of the LXRs, since the LXRs are 
ubiquitously distribution in the cells and tissues, therefore, activation of the 
receptor especially in the macrophages which is considered as a major source of 
pro-inflammatory and pro-fibrotic mediators lead to  high production of these 
mediators. Higher concentration of the pro-inflammatory and pro-fibrotic mediators 
in the serum and BAL of LXR treated mice and increased recruitment of the 
inflammatory cells suggest an active inflammatory and fibrotic process manifested 
by high involvement of macrophage. High macrophage numbers with low 
lymphocytes and neutrophil number in the BAL had been in other studies using 
bleomycin-induced pulmonary fibrosis [192, 210]. 
Generally, serum and BAL mediator data supported a pro-inflammatory and pro-
fibrotic role for LXRs. One of the mediator which is centrally important in the 
inflammatory and fibrotic processes, and was significantly increased in mice given 
bleomycin and treated with LXR agonist was TGF1. This is a powerful pro-fibrotic 
growth factor as shown by its ability to stimulate fibroblast collagen production and 
deposition [211]. There are three isoforms of TGFwith different gene expression 
levels during bleomycin-induced pulmonary fibrosis but they share the ability to 
stimulate fibroblast procollagen synthesis [212]. Interestingly, our data 
demonstrate a high concentration of Interleukin (IL)-13 in the serum and BAL of 
mice given bleomycin and treated with LXR agonist. IL-13 is associated with the 
induction of airway disease and considered as one of the most important 
mediators of tissue fibrosis [213]. It has fibrogenic effects mediated by TGF1 and 
is considered to be a strong activator and stimulator of TGF1 in vivo [214]. Lee 
and his colleagues showed that IL-13 was able selectively to stimulate TGF1 
production in transgenic mice. In the present study, IL-13 and TGF1 together play 
a cooperative role in the initiation and progression of the inflammatory and fibrotic 
process in the lung.  In addition, our analysis determined a high concentration of 
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interleukin 1and TNFwhich are potent pro-inflammatory cytokines, and severe 
lung fibrosis is associated with high concentration of IL-1 and TNF 
                                                                                                                                     
Consistent with the high concentration of TGF1 in the serum and BAL, our results 
show greater up-regulation of TGF1 gene expression in the lungs of WT mice 
given bleomycin and treated with LXR agonist in comparison with the other 
experimental groups (Figure 3.32). There was increased collagen gene expression 
and enhancement of collagen synthesis. This consisted of an increase in the 
collagen type IA and IIIA gene expression. The WT mice given bleomycin and 
treated with LXR agonist exhibited significantly higher collagen type IA and IIIA 
gene expression than the other study groups. Shahzeidi et al 1993 [215] reported 
that the early collagen deposition is partially due to activation of interstitial 
fibroblasts which lead to up-regulation in the collagen type III gene expression in 
bleomycin induced murine pulmonary fibrosis. Collagen type IA is the most 
abundant form of collagen, the mRNA expression of procollagen type IA is 
markedly higher than the mRNA expression of procollagen type IIIA in the lung of 
mice given bleomycin [216]. In the present study, the greater relative increase of 
collagen gene expression during bleomycin-induced pulmonary fibrosis was that of 
collagen type IIIA, which was expressed at a higher level than collagen type IA. A 
study of the ratio of collagen type I to collagen type III in normal and fibrotic lungs 
observed changes from a typical normal ratio of 2:1 to a ratio of 4:1 in fibrotic 
lungs [217]. The differences between our results and the ratio above is that in my 
work I demonstrated the gene expression level while in the other study observed 
the collagen by using antibodies to human collagen types I, III. It is possible that 
not all gene expression necessarily was translated into protein, also the dynamic 
of collagen synthesis and degradation during fibrosis may affect each type of 
collagen differently.   
Interrogating our data to interpret other possible mechanisms involved in the LXR-
mediated exacerbation of fibrosis was an important goal. For example, in our in 
vitro work we showed significantly raised expression levels of collagen type IA and 
IIIA mRNA in human and mouse fibroblasts in response to LXR agonist stimulation 
(Figure 3.36 and Figure 3.37).  
It was unknown whether the LXR agonist directly stimulated the expression of 
collagen or whether this was indirect through other mediators for example IL-13 
and TGF. To resolve this, investigations were carried out to determine if LXR 
agonist directly targeted collagen type 1 and 3 genes using mouse primary 
fibroblast lines generated from lung tissue of LXR-/--/- and LXR wild type mice 
Materials and Methods (section 2.9.4). Cyclohexamide was used as an inhibitor of 
translation to establish if the effects required de novo protein synthesis. Our 
results demonstrated that the increased expression of collagen was not affected 
by cyclohexamide, therefore, this is preliminary data to suggest that LXR agonist 
directly targeted collagen type 1 and 3 expression conducted through the 
activation of LXRs. To extend this observation we generated a cell reporter system 
to demonstrate that the collagen genes have response elements for LXR in their 
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promoter regions. This is important new unpublished and extends the potential 
role of LXR function from initially a regulator of lipid metabolism, to a regulator of 
inflammation and now extended by our data to a regulator of remodelling. 
  
Conclusion                                                                                                                      
The present work was established on the hypothesis that LXR agonist might be a 
mediator, and a suitable candidate for the treatment of pulmonary fibrosis. Several 
studies have shown that LXR agonists could play an anti-inflammatory role in the 
course of inflammation such as in atherosclerosis. We have determine that 
administration of LXR agonist to mice given bleomycin led to exacerbation of the 
inflammatory and in addition the fibrotic process which was seen as in pro-fibrotic 
mediators in the serum and BAL, increase in collagen expression and deposition 
in the lungs. These new findings will inform future therapy for chronic disease 
where collagen deposition is a life-limiting component. 
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3.3 Requirement of LXR and LXR for fibrosis-enhancing effects 
of the LXR agonist 
3.3.1 Introduction and Aims                                                                       
In Results Chapter 3.2 we demonstrated that wild-type mice given bleomycin had 
worsened inflammation and fibrosis when treated with the potent LXR agonist 
GW3965. This was not apparent in double LXRαβ gene-deleted mice. The 
potential role of any separate effect or redundancy of each single LXR receptor in 
this process was investigated. The involvement of the different LXRα or LXRβ 
receptor in the process of pulmonary fibrosis is an important consideration in this 
study. LXRα has been investigated widely in tissues and in immune cells, for 
example in the liver it enhances bile acid synthesis and excretion via ATP-binding 
cassette G5/G8 transporters resulting in inhibition of intracellular cholesterol 
deposition.  Also, it can enhance cholesterol reverse transport in macrophages 
[218].  
LXR has importance in controlling lipid metabolism, for example mice with 
inactivated LXR β had pathological accumulation of sterols and lipids develop 
adult-onset motor neuron disease [219]. Generally, either of the two receptors 
tends to compensate for a deletion of the other. In some animal experimental 
models the two LXRs act independently; LXR tends to be more important in the 
progression of atherosclerosis than LXR and its deletion could not compensate in 
a murine model of atherosclerosis [220]. But activation of the LXR by using of a 
highly specific synthetic agonist showed an ability to compensate the physiological 
effect of LXR deletion. Therefore, speciﬁc activation of LXR has a beneficial 
effect as an anti-atherosclerotic intervention. In a selective knockout study of wild 
type, LXRα-/- and LXRβ-/- mice, gene expression analysis demonstrated 
differences between these groups; LXRβ-/- tended to show stronger regulatory 
effects on genes coding for cytokines, whereas genes involved in carbohydrate 
metabolism tends to be more specific to LXRα regulation, and both LXRα and 
LXRβ showed equivalent effects on genes belonging to lipid/cholesterol 
metabolism [221]. 
The link between a single LXR and fibrosis is undetermined, therefore, the primary 
aim of this work is to identify  the relationship between activation of a single LXRα 
or LXRβ and the development of fibrosis in murine bleomycin-induced pulmonary 
fibrosis model using LXRα-/-, LXRβ-/-, and LXRαβ wild type mice. 
Methods: Bleomycin-induced pulmonary fibrosis was carried out on male LXRα-/-, 
and LXRβ-/- and LXRαβ wild type mice. The mice were 10-12 weeks old and 22-25 
grams weight and they were divided into groups as follows: 
Animals were randomly allocated into 5 groups (n=22-23 mice in each):-                                                                                                                              
A- WT treated with vehicle (5% Cremophor in PBS as control),                                                      
B- LXR-/- treated with vehicle                                                                                                
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C- LXR-/- treated with LXR agonist                                                                               
D- LXR-/- treated with vehicle                                                                                                
E- LXR-/- treated with LXR agonist 
All mice were given bleomycin intranasally 0.06mg in 30 l PBS / animal. 3 days 
prior to the bleomycin challenge all mice received daily IP injection of vehicle (5% 
Cremophor v/v PBS) or LXR agonist GW3965 (30mg / kg dissolved in 5% 
Cremophor / PBS) according to the group. The injections continued daily until day 
18 when all mice were culled 
3.3.2 LXRα-/- and LXRβ-/- mice   
The LXRα-/- and LXRβ-/- mice and wild type littermates on the C57BL/6 
background were supplied by Lexicon Pharmaceuticals (TX, USA). These mice 
were already in use in our lab for other inflammatory models for example collagen 
induced arthritis and atherosclerosis [209]. 
 
3.3.3 LXR activation had no effect on the augmentation of 
bleomycin-induced pulmonary fibrosis in single LXRα-/- or LXRβ-/- 
mice compared with wild-type mice  
                                                                                                                                        
LXR agonist exhibited some effects on loss of body weight in bleomycin-
induced pulmonary fibrosis initiated on single LXRα-/- or LXRβ-/- mice 
compared with wild-type mice 
 
The systemic inflammatory response to intra-nasal installation of bleomycin into 
murine lung was monitored by change in body weight (Figures 3.40). There were 
significant differences for change in body weight between the WT mice treated 
with vehicle and the rest of experimental group except LXR-/- given LXR agonist 
and LXR-/- given LXR agonist. The significant difference was with LXRα-/- mice 
given vehicle (p<0.001) and LXRβ-/- mice given vehicle (p<0.001). The weight loss 
was most evident during the phase of acute inflammation which was up to 9 days 
after bleomycin installation in all experimental groups (Figure 3.40). 
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Figure 3.40 Daily body weight changes in WT, LXR
-/- 
and LXR
-/-
 mice given bleomycin and 
treated with either LXR agonist or vehicle                                                                                                                                          
The daily body weight changes in male C57BL/6, LXR
-/-
 KO, and LXR
-/-
 KO mice (10-12 
weeks old). All mice received bleomycin and were treated daily with IP injection of vehicle 
(5% Cremophor w/v PBS) or LXR agonist GW3965 (30mg / kg dissolved in 5% Cremophor / 
PBS). All the groups exhibited a decline in body weight. One Way ANOVA; n.s. p>0.05; 
***p<0.001; Mean ± SEM; n=22-23 mice/group. 
                                                                                                                         
LXR agonist revealed no additional effect on lung histopathological 
inflammatory and fibrotic changes in bleomycin-induced pulmonary fibrosis 
in LXRα-/- or LXRβ-/- mice compared with wild type mice 
 
Bleomycin installation is characterised by severe inflammatory and fibrotic 
morphological changes to the normal lung architecture (Figure 41 A and B). 
Sections stained with H&E revealed a similar infiltration of inflammatory cells, 
perivascular haemorrhage, and collapse of the alveoli as described above in 
Materials and Methods section (2.5.2). This was similar in all experimental groups 
(Figure 3.41 A), and quantified on (Figure 3.42).  
Tissue collagen was demonstrated in all experimental groups by using Gomori’s 
Trichrome staining. The active fibrotic process manifested by a collagen bundles 
and fibrotic foci were distributed mainly around the lung bronchioles and blood 
vessels in all mice groups irrespective of whether they received LXR agonist or 
vehicle. Typical images are shown in (Figure 3.41 B), and quantified on (Figure 
3.43). 
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Figure 3.41 Histological inflammatory and fibrotic changes in the lung of the WT, LXR
-/-
 and 
LXR
-/-
 mice given bleomycin and treated with either LXR agonist or vehicle                                                                                                                                             
(A) H&E staining: representative images of lung tissue sections are presented, showing 
morphological inflammatory changes in lung architecture after bleomycin installation. 
Severe inflammatory changes were demonstrated in all experimental mice groups in spite of 
they received daily injections of LXR agonist or vehicle. (B) Gomori’s Trichrome staining: 
representative images of lung lobe sections are presented, showing extensive collagen 
deposition in the lung and large collagen patches around bronchioles, blood vessels and in 
the parenchyma. These fibrotic changes were similar in all mice groups. Sections were 
viewed under light microscopy (magnification x10).   
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Quantification of the extent of the inflammation and fibrosis was performed on the 
lung sections of the WT, LXR-/-, and LXR-/- mice. The lung tissue sections were 
labelled by an independent colleague who was unaware of the details of the 
experiment. The slides were then scored using an inflammation scoring scale 
described in Materials and Methods (section 2.5.2) by two independent observers 
thus the quantification for inflammation and fibrosis was performed blind to the 
origin of the samples. Scoring of H&E stained lung sections exhibited mild to 
moderate inflammation based on our inflammation scoring grade among all the 
experimental group; WT mice treated with vehicle, LXR-/- mice treated with 
vehicle,  LXR-/- mice treated with LXR agonist, LXR-/- mice treated with vehicle , 
and LXR-/- mice treated with LXR agonist (Figure 3.42). There was no significant 
difference between these groups. 
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Figure 3.42 Lung inflammation score of the WT, LXRα
-/-
 and LXRβ
-/-
 mice given bleomycin 
and treated with either LXR agonist or vehicle                                                                       
Inflammation was assessed by histological score (see Materials and Methods section 2.5.2). 
There were no significantly differences in the inflammation score between all the 
experimental groups. One Way ANOVA; Mean ± SEM; n=22-23 mice/group. 
 
Quantification of fibrosis was performed for all lung tissue sections stained with 
Gomori’s trichrome. Blind scoring of the fibrosis based on our scoring grades 
demonstrated mild fibrotic changes. The fibrosis  pattern was similar among all the 
experimental groups given bleomycin followed by daily IP injection of LXR agonist 
or vehicle, WT mice treated with vehicle, LXR-/- mice treated with vehicle, LXR-/- 
mice treated with LXR agonist, LXR-/- mice treated with vehicle , and LXR-/- mice 
treated with LXR agonist (Figure 3.43). There was no significant difference 
between these groups. 
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Figure 3.43 Lung fibrosis score of the WT, LXRα
-/-
 and LXRβ
-/-
 mice given bleomycin and 
treated with either LXR agonist or vehicle                                                                                      
Fibrosis was assessed by scoring (see materials and methods section 2.5.2). There was no 
significant differences between all mice experimental groups in spite of the received of 
either LXR agonist or vehicle. One Way ANOVA, Mean ± SEM; n=22-23 mice/group. 
 
LXR agonist revealed no additional effect on bronchoalveolar lavage fluid 
(BAL) cell counts in bleomycin-induced pulmonary fibrosis in LXRα-/- or 
LXRβ-/- mice compared with wild type mice 
Total BAL cell count:                                                                                               
The BAL total cell count was performed for all experimental groups of mice (Figure 
3.44). There were no significant differences between all bleomycin treated groups. 
The mean ± Standard error of the mean of  BAL total cell counts were as 
following:-                                                 
WT mice treated with vehicle                        0.88 ± 0.19 x 106,                
LXR-/- mice treated with vehicle                  0.82 ± 0.18 x 106,                                                 
LXR-/- mice treated with LXR agonist          0.89 ± 0.23 x 106,                                 
LXR-/- mice treated with vehicle                   0.77 ± 0.22 x 106,                                                       
LXR-/- mice treated with LXR agonist           0.87 ± 0.26 x 106     (Figure 3.44).  
There was no significant difference between these groups. 
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Figure 3.44 Total BAL cell count in the BAL of WT, LXRα
-/-
 and LXRβ
-/-
 mice given bleomycin 
and treated with either LXR agonist or vehicle                                                                                                                                      
Total BAL cell count for the inflammatory cell retrieved from bronchoalveolar lavage of all 
the experimental mice demonstrated no significant differences between groups. One Way 
ANOVA, Mean ± SEM; n=22-23 mice/group. 
 
Differential BAL cell count:                                                                                           
The differential cell count profiles for BAL were performed to demonstrate the 
proportion of the inflammatory cells in the bronchoalveolar lavage fluid.                                                                                           
Macrophage cell count:                                                                                                 
The macrophage cell count showed no significant differences between all the 
groups:                      
The mean ± Standard error of the mean of BAL macrophage counts were as 
following:-                                                 
WT mice treated with vehicle                        0.62 ± 0.14 x 106,                
LXR-/- mice treated with vehicle                  0.61 ± 0.21 x 106,                                                 
LXR-/- mice treated with LXR agonist          0.67 ± 0.20 x 106,                                 
LXR-/- mice treated with vehicle                   0.58 ± 0.13 x 106,                                                       
LXR-/- mice treated with LXR agonist           0.63 ± 0.17 x 106     (Figure 3.45).  
There was no significant difference between these groups. 
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Figure 3. 45 Macrophage cell count in the BAL of WT, LXRα
-/- 
and LXRβ
-/-
 mice given 
bleomycin and treated with either LXR agonist or vehicle                                                                                                                                       
The BAL macrophage cell count demonstrated no significant differences between the 
groups. One Way ANOVA, Mean ± SEM; n=22-23 mice/group. 
 
Lymphocyte cell count:                                                                                                   
The lymphocyte cell count showed no significant differences between all the 
groups:                                              
The mean ±  Standard error of the mean of BAL lymphocyte counts were as 
following:-                                                 
WT mice treated with vehicle                        0.22 ± 0.04 x 106,                
LXR-/- mice treated with vehicle                  0.19 ± 0.05 x 106,                                                 
LXR-/- mice treated with LXR agonist          0.20 ± 0.04 x 106,                                 
LXR-/- mice treated with vehicle                   0.18 ± 0.0.5 x 106,                                                       
LXR-/- mice treated with LXR agonist           0.21± 0.06 x 106     (Figure 3.46).  
There was no significant difference between these groups. 
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Figure 3.46 Lymphocyte cell count in the BAL of WT, LXRα
-/-
 and LXRβ
-/-
 mice given 
bleomycin and treated with either LXR agonist or vehicle                                                                                                                                       
The BAL lymphocyte cell count demonstrated no significant differences between the groups. 
One Way ANOVA; Mean ± SEM; n=22-23 mice/group. 
 
 
LXR agonist treatment demonstrated no changes in concentration of inflammatory 
and fibrotic mediators in bleomycin-induced pulmonary fibrosis in LXRα-/- and 
LXRβ-/- mice compared with wild-type mice                                                                                      
A pragmatic range of cytokines, chemokines and growth factors relevant to the 
inflammatory and fibrotic responses was quantified in serum (Table 3.4) and in 
BAL fluid (Table 3.5) from the experimental groups of mice. 
Serum and bronchoalveolar lavage (BAL) fluid mediators:                                                                     
                                                                                                                             
Serum and BAL analysis demonstrated no significant differences between the 
concentrations of any of the mediators in the serum or in the BAL of the WT mice 
treated with vehicle, LXR-/- mice treated with vehicle, LXR-/- mice treated with 
LXR agonist, LXR-/- mice treated with vehicle, and LXR-/- mice treated with LXR 
agonist (Tables 3.4 and 3.5). 
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serum 
Mediators  
(pg/ml ) 
LXR-/-   
+  
V 
LXR-/-
+LXR 
agonist 
LXR-/-  
+  
V 
LXR-/-
+LXR 
agonist 
p value 
Cytokines      
TNF 26 (3-47) 19 (0-53) 25 (11-65) 31 (8-71)  0.2683 
IFN 0 (0-19) 0 (0-35) 29 (4-48) 0 (0-0) 0.5294 
IL-1 67 (8-105) 48 (17-81) 18 (0-42) 37 (19-69) 0.1733 
IL-1 69 (22-118) 63 (35-108) 55 (16-136) 58 (0-123) 0.3818 
IL-2 17 (0-46) 24 (1-60) 27 (9-55) 23 (0-68) 0.3640 
IL-4 0 (0-0) 3 (0-8) 19 (0-41) 8 (0-23) 0.4187 
IL-5 22 (7-41) 0 (0-0) 13 (0-33) 12 (0-27) 0.1452 
IL-6 5 (0-11) 8 (0-22) 23 (9-48) 43 (15-83) 0.0826 
IL-10 349 
(135-788) 
364 
(219-540) 
338 
(95-641) 
371 
(178-622) 
0.2995 
IL-12 115 (47-191) 141 (88-
207) 
124 (65-
279) 
136 (32-
294) 
0.1814 
IL-13 18 (4-31) 25 (0-62) 23 (8-59) 17 (0-38) 0.3027 
IL-17 0 (0-0) 0 (0-0) 2 (0-5) 0 (0-0) 0.6114 
Growth factors      
TGF 67 
(34-105) 
62 
(25-123) 
59 
(19-117) 
66 
(28-131) 
0.0975 
FGF basic 213 (128-
459) 
175 (77-
282) 
162 (81-
317) 
181 (62-
325) 
0.1638 
VEGF 20 (3-45) 12 (0-27) 17 (9-29) 21 (11-36) 0.2573 
GM-CSF 2 (0-5) 0 (0-0) 0 (0-0) 5 (0-12) 0.4439 
Chemokines      
MCP-1 22 (0-49) 35 (16-57) 29 (18-63) 31 (0-78) 0.2071 
MIP-1 24 (9-55) 21 (0-39) 19 (7-44) 26 (15-62) 0.1525 
KC 183 
(68-391) 
211 
(128-448) 
177 
(53-327) 
195 
(88-403) 
0.8427 
MIG 82 
(36-145) 
73 
(0-121) 
0 
(0-0) 
18 
(10-32) 
0.3108 
IP-10 11 (0-29) 3 (0-7) 23 (6-44) 5 (0-12) 0.5969 
 
Table 3.4 Inflammatory and fibrotic mediators in the serum of WT, LXR
-/-
 and   LXR
-/-
 mice 
given bleomycin and treated with either LXR agonist or vehicle                                              
There were no significant differences in concentrations of cytokines, chemokines, and 
growth factors in the serum of the LXR
-/-
 mice treated with vehicle, LXR
-/-
 mice treated 
with LXR agonist, LXR
-/-
 mice treated with vehicle, and LXR
-/-
 mice treated with LXR 
agonist treated. Median and interquartile range concentrations of each mediator were used 
to determine P-value for between category and between group differences; Kruskal-Wallis 
test; Mann-Whitney test respectively; n.s. p>0.05; n=22-23 mice/group 
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BAL 
 Mediators  
(pg/ml ) 
LXR-/-   
+  
V 
LXR-/-
+LXR 
agonist 
LXR-/-  
+  
V 
LXR-/-
+LXR 
agonist 
p value 
Cytokines      
TNF 48 (17-93) 35 (9-61) 42 (26-79) 39 (12-74) 0.3274 
IFN 3 (0-5) 0 (0-0) 0 (0-0) 0 (0-0) 0.5859 
IL-1 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
IL-1 108 (69-196) 81 (52-170) 94 (36-
175) 
83 (45-143) 0.1662 
IL-2 24 (0-59) 32 (19-66) 29 (14-57) 25 (14-42) 0.3285 
IL-4 0 (0-0) 0 (0-0) 3 (0-8) 0 (0-0) 0.6819 
IL-5 5 (0-14) 2 (0-4) 16 (0-35) 0 (0-0) 0.2737 
IL-6 0 (0-0) 0 (0-0) 33 (0-71) 0 (0-0) 0.5116 
IL-10 427 (216-
768) 
291 (178-
435) 
352 (207-
542) 
376 (189-
662) 
0.0643 
IL-12 73 (30-128) 85 (57-144) 77 (26-
169) 
114 (73-
202) 
0.1928 
IL-13 0 (0-0) 0 (0-0) 2 (0-5) 0 (0-0) 0.5471 
IL-17 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
Growth factors      
TGF 108 (39-235) 81 (47-159) 94 (56-
182) 
83 (42-177) 0.1531 
FGF basic 62 (31-147) 46 (21-93) 54 (36-
124) 
52 (28-89) 0.2844 
VEGF 66 (34-115) 36 (19-71) 49 (26-
105) 
42 
(15-93) 
0.2537 
GM-CSF 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
Chemokines      
MCP-1 26 (8-58) 23 (11-40) 17 (7-41) 29 (15-67) 0.1489 
MIP-1 52 (31-99) 36 (14-78) 39 (20-71) 41 (18-82) 0.3185 
KC 63 (35-118) 59 (27-102) 74 (41-
132) 
83 (52-140) 0.4629 
MIG 0 (0-0) 1 (0-2) 0 (0-0) 0 (0-0) 0.6271 
IP-10 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
 
Table 3.5 Inflammatory and fibrotic mediators in the BAL of WT, LXR
-/-
 and   LXR
-/-
 mice 
given bleomycin and treated with either LXR agonist or vehicle                                              
There were no significant differences in concentrations of cytokines, chemokines, and 
growth factors in the BAL of the LXR
-/-
 mice treated with vehicle, LXR
-/-
  mice treated with 
LXR agonist, LXR
-/-
  mice treated with vehicle, and LXR
-/-
  mice treated with LXR agonist. 
Median  and interquartile range concentrations of each mediator  were used to determine P-
value for between category and between group differences; Kruskal-Wallis test; Mann-
Whitney test respectively; n.s. p>0.05; groups; n=22-23 mice/group 
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Administration of LXR agonist did not affect the expression of TGF1 and 
collagen 1 and 3 in bleomycin-induced lung fibrosis in single LXRα-/- or 
LXRβ-/- mice compared with wild-type mice   
 
Lung tissue RNA was collected from all experimental groups of mice and analysed 
by qPCR to demonstrate the mRNA level of collagen type TGF. No significant 
differences were measured between all groups (Figure 3.47). Similarly, collagen 
type IA and IIIA mRNA expression showed no significant differences between the 
groups (Figure 3.48). 
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Figure 3.47 TGF1 gene expression in lungs of WT, LXRα
-/-
 and LXRβ
-/- 
mice given bleomycin 
and treated with either LXR agonist or vehicle                                                                                        
There were no differences in TGF1 expression levels between the groups. One Way 
ANOVA; Mean ± SEM; n=22-23 mice/group. 
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Figure 3.48 Collagen gene expression in lungs of WT, LXRα
-/-
 and LXRβ
-/-
 mice given 
bleomycin and treated with either LXR agonist or vehicle                                                                                 
There were no differences in collagen type IA1 and Col IIIA1 expression levels between the 
groups. One Way ANOVA; Mean ± SEM; n=22-23 mice/group. 
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Administration of LXR agonist did not alter the lung collagen content in 
bleomycin induced lung fibrosis in single LXRα-/- or LXRβ-/- mice compared 
with wild type mice.  
 
Lung tissues were analysed for soluble collagen content. There was no significant 
difference between all experimental groups. The mean ± Standard error of the 
mean of  lung soluble collagen contents were as following:-                                                 
WT mice treated with vehicle                        1.73 ± 0.11 mg/ml,                
LXR-/- mice treated with vehicle                  1.86 ± 0.24mg/ml,                                                 
LXR-/- mice treated with LXR agonist          1.72± 0.20 mg/ml,                                 
LXR-/- mice treated with vehicle                   1.67 ± 0.22mg/ml,                                                       
LXR-/- mice treated with LXR agonist           1.79 ± 0.13mg/ml   (Figure 3.49).  
There was no significant difference between these groups. 
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Figure 3.49 Soluble collagen content in lungs of WT, LXRα
-/-
 and LXRβ
-/-
 mice given 
bleomycin and treated with either LXR agonist or vehicle                                                                                                                          
There were no significant differences of collagen content between the groups. One Way 
ANOVA; Mean ± SEM; n=22-23 mice/group. 
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3.3.4 Discussion and Conclusion                                                                    
The main aim of this experiment was to identify the potential individual roles of 
LXR and LXR in the inflammatory and fibrotic process associated with 
bleomycin-induced pulmonary fibrosis.  
LXR and LXR have 77% amino acid sequence identity in both the DNA- and 
ligand-binding domains, therefore, it is highly likely that they recognise similar 
ligands and target DNA [222], for example the potent LXR agonist (GW3965) used 
in these experiments was able to activate both receptors. Therefore, we 
hypothesised that there is no difference between the presence of each receptor 
type on the subsequent extent of fibrosis. 
We demonstrated that administration of LXR agonist 30 mg/kg into a single    
LXR-/- and LXR-/- mice given bleomycin had no significant effect on the severity 
of the lung inflammation or fibrosis compared with vehicle. There was a significant 
difference in body weight among some groups LXR-/- mice treated with vehicle, 
and LXR-/- mice treated with vehicle compared to wild type mice treated with 
vehicle (Figure 3.40). This suggested that there was an inflammation-related 
cachexia, however did not extend further to histological or inflammatory cellular 
involvement. It is possible that the loss of body weight in these circumstances 
related to metabolic changes which were beyond the scope of this thesis.  
The activation of either LXR receptor was sufficient to circumvent the additional 
pro-fibrotic tendency of the double receptor knock-out mouse to bleomycin-
induced fibrosis. The gene-deletion of either resulted in no significant differences 
in lung pathomorphology, lung collagen content and collagen gene type I, III and 
TGF1 expression.   
Joseph and colleagues reported that LXR-/- mice were highly susceptible to 
infection with Listeria monocytogenes, but they found no changes from normal  
between LXR-/- and LXR-/- mice and wild types in the serum inflammatory 
cytokines mediators [72]. This appeared to be in agreement with our results which 
showed no changes in the serum and BAL mediators between all experimental 
mice groups. It is possible that both LXRand LXRshare a synergistic effect on 
the promoters of genes of inflammation and fibrosis. It is also possible that LXRα 
or LXRβ may have different involvements, mainly in inflammation, but to have a 
detectable effect on bleomycin-induced pulmonary fibrosis both of the receptors 
were required. One of the suggestions is that LXRα or LXRβ act in a cooperative 
pathway, therefore, deletion of both of them is needed for additional pro-
inflammatory and pro-fibrotic changes, as detected by significant increases in the 
concentration of inflammatory and fibrotic mediators and associated processes. 
Laffitte and colleagues reported that both oxysterols and synthetic ligands  were 
able to regulate ApoE expression in peritoneal macrophages to different degrees 
[223]. They showed that ApoE expression was reduced in LXR-/- or LXR-/- mice, 
and was abolished in LXR-/- -/- mice. They also showed that any disruption of 
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both LXRα and LXRβ in mice was characterised by a highly severe metabolic 
defect suggesting  that both receptors have a degree of overlapping physiologic 
functions [223]. The results from my experiment were in contrast to those of 
Bradley et al [220]. They studied the contribution of both LXR isoforms to 
atherosclerosis [220]. Using the ApoE-/- model of atherosclerosis they determined 
that deletion of LXRα on these mice correlated with a progressive atherosclerotic 
process, demonstrated by accumulation of cholesterol in the peripheral tissues 
and aortic root. Therefore, they suggested that LXRβ is not sufficient to 
compensate for the absence of LXRα. However, using the high affinity LXRs 
agonist GW3965 that could bind with both receptor types, they were able to 
activate LXRβ resulting in attenuation of the atherosclerosis.  
It is possible that LXRα or LXRβ may have different individual involvements in lipid 
metabolism and in inflammation, but that this does not extend to fibrosis. We found 
that to have a detectable change in bleomycin-induced pulmonary fibrosis both of 
the receptors were required. One of the suggestion is that LXRα or LXRβ act in 
synergistic pathway, therefore, each one of them need the other for maximum 
activation which could be detected in form of significant differences certain levels 
of inflammatory and fibrotic process. 
 
Conclusion 
The purpose of this work was to understand the involvement of each of LXR and 
LXR receptor subtypes in the course bleomycin-induced pulmonary fibrosis. We 
have shown earlier that activation of both receptors in wild type mice led to 
exacerbation of inflammatory and fibrotic process. Interestingly, here we 
demonstrated that activation of either LXR receptor alone was not sufficient to 
have a significant effect on the inflammatory and fibrotic changes in the lung of 
mice given bleomycin, even in the presence of a highly potent LXR agonist 
(GW3965).   
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3.4 Potential involvement of MicroRNA-155 in the 
development of pulmonary fibrosis in a murine model   
 
3.4.1 Introduction and Aims 
Micro-RNA (miR) are small, evolutionary conserved, single-stranded, non-coding 
RNA molecule with 20- 22 nucleotide base pairs [76-78]. They have the ability to 
regulate mRNA translation resulting in fine tuning of the production of different 
molecules involved in the initiation or maintenance of inflammation in different 
diseases. For example, miR-155 is one of the most studied members of miR, and 
it has a regulatory role in certain inflammatory diseases such as collagen induced 
arthritis, lung fibrosis, and cardiovascular diseases [99, 104, 224]. Kurowska-
Stolarska and colleagues demonstrated that miR-155-/- mice were resistant to 
initiation of collagen induced arthritis model and this was characterised by 
inhibition of auto antibody response, antigen-speciﬁc Th17 cell, and suppression of 
articular inﬂammation [99]. In the first report describing the phenotype of a miR-
deleted mouse Rodriguez and colleague described that deletion of miR155 was 
associated with an age-related increase in airway sub-epithelial collagen 
deposition [104]. Transfection of human primary lung fibroblast with miR-155 
resulted in down-regulation of  angiotensin II receptor (AT1R) which participates in 
blood and cardiovascular diseases indicating that  miR-155 plays a protective role 
safeguarding against cardiovascular disease [224]. 
MiR-155 expression had been demonstrated in different cells including fibroblast 
and in different tissues such as epithelium, reproductive organs, central nervous 
system and haemopoietic tissue [225]. miR-155 has an important immune-
regulatory ability for example, a study using miR-155-/- mice has demonstrated that 
miR-155 was necessary for a normally functioning immune system [104]. Although 
this study also showed pathomorphological changes in the lung of miR-155-/- mice, 
the direct functional role of miR-155 in bleomycin-induced pulmonary fibrosis still 
not defined.  
We aimed to demonstrate the role of miR-155 in the course of pulmonary fibrosis 
in murine model of pulmonary fibrosis induced by bleomycin. 
 
3.4.2 MiR-155-/- mice develop worse bleomycin-induced 
pulmonary fibrosis in comparison with miR-155 wild type mice                                                                                                               
The aim of this experiment was to investigate if there was a role for miR-155 in the 
pathogenesis of bleomycin-induced pulmonary fibroses in a murine model. The 
experiment consisted of using miR-155-/- mice and miR-155 wild type littermates 
(10-12 weeks old and 22-25 grams weight). Mice were randomly allocated into 4 
groups (n=7-14 mice per group) as following: -                                                                                                                               
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A- WT mice given PBS (as control)                                                                                                                     
B- WT mice given bleomycin                                                                                               
C- MiR-155-/- mice given PBS                                                                                                
D- MiR-155-/- mice given bleomycin  
All mice given either bleomycin intranasally at 0.06mg in 30 l PBS / mouse or 30 
l PBS / mouse as a control according to the group classification. The animals 
were monitored for changes in body weight and survival until day 18 when all 
animal were culled. 
                                                                                                                                      
Bleomycin treated miR-155-/- mice exhibited a greater loss of body weight 
than miR-155 wild type mice.                                                                                                             
An evaluation of systemic inflammatory response based on the loss of body weight 
was observed in the groups given bleomycin (Figure 3.50). A progressive 
reduction in body weight was observed primarily in the miR155-/- group which was 
significantly greater than the control mice given PBS (p<0.001 for each) and the 
wild-type miR155 mice (p=0.008) given bleomycin (Figure 3.50). 
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Figure 3.50 Daily body weights changes for miR-155
-/-
 and miR-155 wild type mice given PBS 
or bleomycin                                                                                                                                            
10-12 week old male miR-155
-/-
 and WT mice were given either PBS or bleomycin. The 
groups of miR-155
-/-
 and WT mice given bleomycin lost significantly more body weight in 
comparison to mice given PBS (p<0.001) and (p=0.0209) respectively. The body weight loss 
revealed was significantly different between miR-155
-/-
 mice given bleomycin and WT mice 
given bleomycin (p=0.0079). One Way ANOVA; * P <0.05, ** P < 0.01, *** P < 0.001; Mean ± 
SEM; n = 7-14 mice/group.   
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MiR-155-/- mice given bleomycin had an increased in histopathological 
inflammatory and fibrotic changes in the lung compared with wild type 
littermates.  
                                                                                                                                          
Mice given bleomycin had severe histopathological changes to the normal lung 
architecture as indentified by evaluation of inflammatory and fibrotic changes 
(Figure 3.51 A and B).  
Lung sections stained with H&E from WT and miR-155-/- mice given bleomycin 
revealed an infiltration of inflammatory cells, perivascular haemorrhage, and 
collapse of the alveoli as described in Materials and Methods (section 2.5.2). The 
inflammatory changes were more severe in the lungs of miR-155-/- mice given 
bleomycin than in the WT mice given bleomycin (p<0.001). No significant 
inflammatory changes were observed in the lung of WT and miR-155-/- mice given 
PBS (Figure 3. 51 A). 
Collagen deposition was observed in the lung tissue sections using Gomori’s 
Trichrome stain. The collagen deposition was observed as bundles and fibrotic foci 
distributed mainly around the lung bronchioles and blood vessels. These collagen 
depositions were observed in WT and miR-155-/- mice given bleomycin and tended 
to be more abundant in the lungs of miR-155-/- mice group given bleomycin than 
WT mice group given bleomycin (p=0.0368). No significant fibrotic changes were 
observed in the lungs of WT and miR-155-/- mice given PBS (Figure 3.51 B). 
Quantification of the extent of the inflammation and fibrosis was performed on the 
lung tissue sections of the WT and miR-155-/- mice given either PBS or bleomycin. 
The sections were labelled by an independent colleague and the slides were then 
scored separately by two independent experienced observers unaware of the 
details of the experiment. Thus the quantification for inflammation and fibrosis was 
performed blind to the origin of the samples (Figure 3.52 and 3.53).  
Scoring of H&E stained lung sections from WT mice given bleomycin revealed 
mild to moderate inflammation based on our inflammation scoring grade described 
in the Materials and Methods (section 2.5.2), while moderate to severe 
inflammation was recorded in miR155-/- mice given bleomycin. WT and miR-155-/- 
mice given PBS revealed no significant inflammation (Figure 3.52). 
Quantifying the lung tissue fibrosis was carried out in a blinded manner by two 
independent observers. The mice groups given bleomycin were given a higher 
lung fibrosis score in comparison with the PBS treated groups (p<0.001 for both), 
furthermore, the lung of the miR-155-/- mice given bleomycin had a significantly 
higher fibrosis score than the WT mice given bleomycin (p=0.0368) (Figure 3.53). 
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Figure 3.51 Histological inflammatory and fibrotic changes in the lung of the lung of miR-
155
-/-
 and miR-155 wild type mice given PBS or bleomycin                                                                       
(A) Representative images of lung tissue sections showing morphological changes in lung 
architecture after PBS or bleomycin installation. H&E staining shows inflammatory changes 
in WT and miR-155
-/-
 mice given bleomycin, which were worse in the miR-155
-/-
 mice 
(p<0.037). No inflammatory changes observed in the lung of WT and miR-155
-/-
 mice given 
PBS. (B) Gomori’s Trichrome stain reveals large collagen patches around bronchioles, 
blood vessels and in the parenchyma. Extensive collagen deposition was seen in the lungs 
of WT and miR-155
-/- 
mice given bleomycin, with significantly higher deposition in the     
miR-155
-/-
 mice given bleomycin than WT mice given bleomycin. No significant fibrotic 
changes were observed in the lungs of WT and miR-155
-/-
 mice given PBS. Sections were 
viewed under light microscope (magnification x10).  
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Figure 3.52 Lung inflammation score of the miR-155
-/-
 and miR-155 wild type mice given PBS 
or bleomycin                                                                                                                           
Inflammation was assessed by a histological score (see Materials and Methods section 2.5.2) 
demonstrating significantly higher inflammation in the WT and miR-155
-/-
 mice group given 
bleomycin in comparison with WT and miR-155
-/-
 mice given PBS. Also a significant higher 
inflammation score observed between miR-155
-/-
 and WT mice group given bleomycin. One 
Way ANOVA; *** p<0.001; Mean ± SEM; n = 7-14 mice/group.   
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Figure 3.53 Lung fibrosis score of the miR-155
-/-
 and miR-155 wild type mice given PBS or 
bleomycin                                                                                                                                                                     
Fibrosis was assessed by histological scoring (see Materials and Methods section 2.5.2). 
MiR-155
-/-
 and WT mice given bleomycin exhibited highly significant fibrosis in comparison 
with the groups given PBS. Also a significant higher fibrosis score observed between          
miR-155
-/-
 mice and WT group given bleomycin. One Way ANOVA; ***p<0.001; Mean ± SEM; 
n = 7-14 mice/group. 
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MiR-155-/- mice given bleomycin have increased inflammatory cell numbers 
in the bronchoalveolar lavage fluid compared with wild type littermates                                           
 
The BAL total and differential cell profiles were made after processing the 
bronchoalveolar lavage fluid.  Administration of bleomycin to WT and miR-155-/- 
mice lead to significant increase in the BAL total cell count in comparison with the 
WT and miR-155-/- mice given PBS. The mean ± Standard error of the mean of 
counts were as following:-                                                                                                                            
WT mice given bleomycin                         1.31 ± 0.17 x 106;                                                     
MiR-155-/- mice given bleomycin               7.33 ± 1.06 x 106;                                                      
WT mice given PBS                                   0.15 ± 0.06 x 106;                                                                     
MiR-155-/- mice given PBS                         0.24 ± 0.12 x 106  (Figure 3.54). 
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Figure 3.54 Total BAL cell count in the BAL of miR-155
-/-
 and miR-155 wild type mice given 
PBS or bleomycin                                                                                                                                           
The counts from WT and miR-155
-/-
 mice given bleomycin were significantly higher than the 
WT and miR-155
-/-
 mice given PBS (p<0.001). Also the count was significantly higher in miR-
155
-/-
 mice compared with WT given bleomycin (p<0.001). One Way ANOVA; ***p<0.001; 
Mean ± SEM; n = 7-14 mice/group. 
 
The differential cell count profiles for the BAL were assessed after processing by 
cyto-centrifuge and H&E staining.  
Macrophages:                                                                                                             
The macrophages were found to be the greatest proportion of the BAL 
inflammatory cells. The macrophage count was significantly higher in the WT and 
miR-155-/- mice given bleomycin compared with the WT and miR-155-/- mice given 
PBS (p<0.001 for each). The macrophage count was significantly greater in the 
miR155-/- than the wild-type littermates given bleomycin (p<0.001). The mean ± 
Standard error of the mean of macrophage counts were as follows:                                                                                                          
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WT mice given bleomycin                        0.96 ± 0.12 x 106,                                                                   
MiR-155-/- mice given bleomycin              4.62 ± 1.07 x 106,                                                   
WT mice given PBS                                  0.13 ± 0.05 x 106,                                                                            
MiR-155-/- mice given PBS                        0.17 ± 0.12 x 106   (Figure 3.55). 
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Figure 3.55 Macrophage cell count in the BAL of miR-155
-/-
 and miR-155 wild type mice given 
PBS or bleomycin                                                                                                                                           
The macrophage cell count was significantly higher in the bronchoalveolar lavage fluid 
retrieved from the bleomycin treated groups compared to the PBS treated groups. Also the 
count was significantly higher in the miR-155
-/-
 mice than the WT; both given bleomycin. 
One Way ANOVA; ***p<0.001; Mean ± SEM; n = 7-14 mice/group.  
 
Lymphopcytes:                                                                                                           
The lymphocyte count significantly  increased in the BAL of the WT and miR-155-/- 
mice given bleomycin groups compared with the PBS treated groups (p<0.01 and  
p<0.001 respectively). The lymphocyte count was significantly greater in the    
miR-155-/- than the wild type littermates given bleomycin (p<0.001). The mean ± 
Standard error of the mean of lymphocyte counts were as follows:                                                                             
WT mice given bleomycin                         24.78 ± 19.6 x 104,                                                          
MiR-155-/- mice given bleomycin             237.56 ± 73.75 x 104,                                                           
WT mice given PBS                                     0.80 ± 0.4 x 104,                                                                               
MiR-155-/- mice given PBS                           2.92 ±1.3 x 104    (Figure 3.56). 
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Figure 3.56 Lymphocyte cell count in the BAL of miR-155
-/-
 and miR-155 wild type mice given 
PBS or bleomycin                                                                                                                                           
The BAL lymphocyte cell count was significantly greater in the bronchoalveolar lavage fluid 
from the WT and miR-155
-/-
 mice given bleomycin compared to the WT and miR-155
-/- 
mice 
given PBS (p<0.01 and  p<0.001 respectively). Also the count was significant greater in the 
miR155
-/-
 group than the WT group; both given bleomycin. One Way ANOVA; **p<0.01; 
***p<0.001; Mean ± SEM; n = 7-14 mice/group.   
 
MiR-155-/- mice given bleomycin had increased concentrations of 
inflammatory and fibrotic mediators in the serum and BAL fluid compared 
with wild-type littermates 
A pragmatic range of cytokines, chemokines and growth factors relevant to the 
inflammatory and fibrotic responses was quantified in serum (Table 3.6) and in 
BAL fluid (Table 3.7) from the experimental groups of mice. 
Serum mediators:                                                                                                      
Serum analysis demonstrated a significant increased concentration of TGF1 in 
the serum of the miR-155-/- and WT mice given bleomycin compared to miR-155-/- 
and WT mice given PBS (Table 3.6). No significant differences in cytokines and 
chemokine concentration were demonstrated between all experimental groups. 
Bronchoalveolar lavage fluid:                                                                                        
BAL analysis demonstrated a significant increased concentration of TGF1 in the 
BAL of the miR-155-/- and WT mice given bleomycin compared to miR-155-/- and 
WT mice given PBS. Also higher significant concentration of FGF basic in the BAL 
of miR-155-/- mice given bleomycin compare to the other experimental groups        
(Table 3.7). 
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serum 
Mediators  
(pg/ml ) 
WT  
+ 
 PBS 
WT 
+ 
Bleomycin 
miR-155-/-        
+ 
 PBS 
miR-155-/-    
 + 
Bleomycin  
p 
value 
Cytokines      
TNF 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-55) 0.1912 
IFN 0 (0-0) 0 (0-0) 0 (0-53) 0 (0-43) 0.1338 
IL-1 0 (0-60) 0 (0-0) 0 (0-76) 0 (0-0) 0.3780 
IL-1 0 (0-12) 0 (0-12) 126 (0-12) 11 (0-22) 0.6899 
IL-2 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
IL-4 0 (0-0) 0 (0-0) 0 (0-135) 0 (0-197) 0.1645 
IL-5 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-31) 0.0576 
IL-6 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
IL-10 0 (0-0) 03,4 (0-0) 60 (43-102) 74 (43-82) 0.0542 
IL-12 2 (1-2) 2 (1-2) 2 (1-3) 1 (0-1) 0.1509 
IL-13 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
IL-17 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
Growth 
factors 
     
TGF 
84 
(65-96) 
9651,3 
(83-107) 
80 
(70-88) 
981,3 
(91-108) 
0.0001 
FGF basic 152 (92-152) 94 (0-210) 129 (75-152) 114 (97-
268) 
0.5630 
VEGF 222 (14-51) 13 (4-14) 14 (10-27) 13 (6-41) 0.1099 
GM-CSF 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
Chemokines      
MCP-1 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-15) 0.0618 
MIP-1 110 (0-110) 44 (0-110) 110 (44-110) 110 (0-110) 0.3749 
KC 37 (0-51) 01,3 (0-0) 53 (0-111) 0 (0-21) 0.1479 
MIG 0 (0-63) 2 (0-12) 0 (0-0) 0 (0-4) 0.3479 
IP-10 12 (0-32) 0 (0-32)3 32 (15-32) 7 (0-32) 0.1326 
                                                                                                                                  
Table 3.6 Inflammatory and fibrotic mediators in the serum of miR-155
-/-
 and WT mice given 
PBS or bleomycin                                                                                                                         
Serum analysis exhibited a significantly higher concentration of TGF-1 in the serum of the 
miR-155
-/-
 and WT mice given bleomycin compared to miR-155
-/-
 and WT mice given PBS. 
Median and interquartile range concentrations of each mediator were used to determine P-
value for between category and between group differences; Kruskal-Wallis test; Mann-
Whitney test respectively; n.s. p>0.05; N.A.= no analysis was appropriate because all value 
were below assay detection limits; n=7-14 mice/group. 
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BAL 
 Mediators  
(pg/ml ) 
WT  
+ 
 PBS 
WT 
+ 
Bleomycin 
miR-155-/-    
 + 
 PBS 
miR-155-/-    
 + 
Bleomycin  
p 
value 
Cytokines      
TNF 0 (0-55)  27 (0-55) 0 (0-55) 0 (0-55) 0.6349  0(0-0) 
IFN 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
IL-1 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
IL-1 0 (0-0) 0 (0-12) 0 (0-12) 0 (0-12) 0.8198 
IL-2 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
IL-4 0 (0-0) 0 (0-40) 0 (0-0) 0 (0-0) 0.5254 
IL-5 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
IL-6 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
IL-10 102 (56-214) 91 (69-309) 75 (45-102) 64 (46-136) 0.3583 
IL-12 0 (0-1) 0 (0-2) 0 (0-0) 1 (0-1) 0.1944 
IL-13 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
IL-17 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) N.A. 
Growth 
factors 
     
TGF 9              (0-
6) 
1111,3 
(0-473) 
21 
(0-149) 
2081, 2, 3 
(0-823) 
0.0010 
FGF basic 27 (20-36) 22 (18-47) 21 (19-25) 391, 2, 3 (33-
87) 
0.0170 
VEGF 35 (16-102) 24 (13-51) 27(13-51) 161,3  (7-27) 0.0872 
GM-CSF 0 (0-0) 0 (0-0) 0(0-0) 0 (0-0) N.A. 
Chemokines      
MCP-1 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0.5125 
MIP-1 110 (44-110) 77  (44-110) 44 (11-110) 77 (0-110) 0.3724 
KC 863 (71-97) 65 (41-97) 45 (33-60) 78 (36-111) 0.2815 
MIG 0 (0-0) 0 (0-3) 0 (0-0) 0 (0-6) 0.6110 
IP-10 0 (0-0) 0 (0-32) 0 (0-32) 0 (0-32) 0.5306 
 
Table 3.7 Inflammatory and fibrotic mediators in the BAL of miR-155
-/-
 and WT mice given 
PBS or bleomycin                                                                                                                                     
BAL analysis exhibited a significantly higher concentration of TGF-1 in the BAL of the miR-
155
-/-
 and WT mice given bleomycin compared to miR-155
-/-
 and WT mice given PBS. Also 
higher significant concentration of FGF basic in the BAL of miR-155
-/-
 given bleomycin 
compare to all experimental groups. Median and interquartile range concentrations of each 
mediator were used to determine P-value for between category and between group 
differences; Kruskal-Wallis test; Mann-Whitney test respectively; n.s. p>0.05; N.A.= no 
analysis was appropriate because all value were below assay detection limits; n=7-14 
mice/group 
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MiR-155-/- mice given bleomycin had increased TGF beta and collagen gene 
expression and transcription in the lung compared with wild-type littermates 
 
Transcriptional analysis for TGF1 and collagen gene expression is performed on 
RNA extracted from lungs of mice in all groups. We used qPCR to demonstrate 
that miR-155-/- and WT mice given bleomycin expressed a significantly higher 
mRNA level of TGF1than their control group given PBS (p<0.001 for each). An 
approximate 4-fold increase was demonstrated in WT mice given bleomycin and a   
7-fold increase in miR-155-/- mice (Figure 3.57). The increase in the miR-155-/- 
compared with WT mice given bleomycin was significant (p<0.05) (Figure 3.57).  
The miR-155-/- mice given bleomycin expressed a significantly higher mRNA level 
of collagen type IA and collagen type IIIA expression than WT mice given 
bleomycin, (p<0.05 and p<0.05) respectively (Figure 3.58).  
The Col IA mRNA expression in the WT and miR155-/- mice given bleomycin was 
significantly higher than in their PBS control groups (p<0.05 and p<0.01) 
respectively. Col IIIA mRNA expression followed the same pattern of Col IA, The 
expression was significantly higher in WT and miR155-/- mice given bleomycin 
than PBS given groups, (p<0.001) (Figure 3.58). 
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Figure 3.57 TGF1 gene expression in lungs of miR-155
-/-
 and WT mice given PBS or 
bleomycin                                                                                                                                      
The measurement of TGF1 mRNA expression was calculated as fold-increase and showed 
a highly significant increase in miR155
-/-
 and WT mice given bleomycin in comparison with 
control PBS treated mice (p<0.001 for each). There was a significant increase in the   
miR155
-/-
 compared with the WT littermates given bleomycin (p<0.05). One Way ANOVA; 
*p<0.05; ***p<0.001; Mean ± SEM; n = 7-14 mice/group.   
 
169 
 
Col 1A Col 3A
0
5
10
15
20
WT+PBS
WT+Bleomycin
miR155-/-+PBS
miR155-/-+Bleomycin
***
***
**
*
*p<0.05
*p<0.05
L
u
n
g
 g
e
n
e
 f
o
ld
 e
x
p
re
s
s
io
n
 
 
Figure 3.58 Collagen gene expression in lungs of miR-155
-/-
 and WT mice given PBS or 
bleomycin 
Both collagen type IA and Col IIIA mRNA expression was measured as fold-increase 
compared with control PBS-treated mice. Both the miR-155
-/-
 and WT mice groups given 
bleomycin revealed a significant increase when compared with the groups given PBS. 
Expression levels were significantly higher in the lungs of miR-155
-/-
 mice given bleomycin 
than WT mice given bleomycin. No differences were observed in the PBS treated mice. One 
Way ANOVA; *p<0.05; **p<0.01; ***p<0.001; Mean ± SEM; n = 7-14 mice/group.   
 
 
MiR-155-/- mice given bleomycin had increased lung collagen compared with 
wild-type littermates 
                                                                                                                                       
Lung tissue samples from the four experimental groups were used for measuring 
the content of soluble collagen by using a Sirius-red binding assay as described in 
Materials and Methods (section 2.5). The assay protocol is based on the binding of 
Sirius red to acid and pepsin-soluble collagen. This assay demonstrated a 
significant increase in lung collagen content in the bleomycin treated groups 
compared with the PBS groups (<0.001 for each) (Figure 3.59). There was a 
significantly higher collagen content in the miR-155-/- mice than the WT given 
bleomycin, (p<0.01) (Figure 3.59). 
The mean ± Standard error of the mean of values were:                                                                        
WT mice given bleomycin                   2.64 ± 0.25 mg/ml,                                                                 
MiR-155-/- mice given bleomycin        3.01 ± 0.33 mg/ml,                                                            
WT mice given PBS                            2.04 ± 0.23 mg/ml,                                                                                
MiR-155-/- mice given PBS                  2.18 ± 0.27 mg/ml    (Figure 3.59).                                                                
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Figure 3.59 Soluble collagen content in lungs of miR-155
-/-
 and WT mice given PBS or 
bleomycin 
Soluble collagen content level in the lungs of the WT and miR-155
-/-
 mice given bleomycin 
were significantly higher than PBS treated groups of mice. The miR-155
-/-
 mice had 
significantly higher collagen than the WT mice (p<0.01); both given bleomycin. One Way 
ANOVA; **p<0.01; ***p<0.001; Mean ± SEM; n = 7-14 mice/group.   
  
3.4.3 The macrophages in the miR-155-/- mice had a different 
phenotype compared with the wild type littermates; both given 
bleomycin  
Introduction and Aim:                                                                                                   
The pathogenesis of the increased inflammation and remodelling in the miR155-/- 
mice is unknown. Previous studies in lung fibrosis suggest an important role for 
lung macrophages. Therefore we investigated whether there was an effect of the 
deletion of miR-155 on the macrophage phenotype.  
Method:                                                                                                                            
This was done by investigating the expression of the common phenotypic markers 
for the classically activated macrophages (inducible nitric oxide synthase (iNOS2) 
and comparing this with the alternatively-activated macrophages (chitinase-like 
lectin YM1, arginase type 2, IL-13 receptor). These changes were explored 
associated with the development of fibrosis in miR-155 WT and miR-155-/- mice 
given bleomycin.  
Studying the inflammatory and fibrotic processes comparing bleomycin or PBS 
treated mice; we studied the expression of macrophage phenotypic markers in 
RNA from lung tissue. We found a significantly upregulated expression of YM1, 
Arg 2, and IL-13R in miR-155-/- mice given bleomycin compared with the PBS 
control, (p<0.01, p<0.001 and p<0.001 respectively) (Figure 3.60). The WT mice 
given bleomycin demonstrated a significant up-regulated expression of YM1 and 
IL-13R compared with the PBS control, (p<0.05 for each). Nitric oxide synthase 2 
171 
 
(NOS2) expression did not show any significant differences among all 
experimental groups (Figure 3.60).  
 
YM1 IL-13R Arg.2 NOS2
0
1
2
3
4
5
6
7
8
9
WT+PBS
WT+Bleomycin
miR155-/-+PBS
miR155-/-+Bleomycin
*
**
***
***
*
G
e
n
e
 f
o
ld
 e
x
p
re
s
s
io
n
 
Figure 3.60 Expression levels of macrophage phenotype markers in the lungs of miR-155
-/-
 
and WT mice given PBS or bleomycin 
Expression levels of macrophage phenotype markers YM1, IL-13R, Arg 2 and NOS 2 in lungs 
of mice given bleomycin or PBS. YM1, Arg 2, and IL-13R were significantly upregulated in 
miR-155
-/-
 mice that given bleomycin compared with PBS treated groups. WT mice given 
bleomycin showed up-regulation in YM1 and IL-13R compared with PBS treated groups. No 
significant changes were found in NOS2 expression between all experimental groups. One 
Way ANOVA; *p<0.05; **p<0.01; ***p<0.001; Mean ± SEM; n = 7-14 mice/group.   
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3.4.4 Discussion and Conclusion 
This second part of my thesis was to investigate and determine the possible 
mediators involved in the development of bleomycin-induced pulmonary fibrosis. 
The inspiration to study microRNA-155 came from several observations: The first 
report describing a miR gene deleted mouse was investigated using miR155 and 
part of this mouse phenotype was an age-related increase in airway sub-epithelial 
collagen deposition [104]. This observation was not further explained by the 
authors and to our knowledge this aspect has not been reported by others. The 
second observation was from our own pilot data from the Glasgow COPD and 
asthma dataset (Glasgow CAB study) that catalogued serum airway fluid and lung 
transcript biomarkers of disease. We found a decrease in BIC (miR155) 
expression in COPD that was significantly associated with carbon monoxide gas-
transfer; indicating a possible involvement in restriction in gas exchange 
suggesting interstitial inflammation (unpublished data). The third factor was that 
we had the miR155-/- mice available and we tested three models of lung disease; 
LPS-induced acute lung injury, antigen plus adjuvant- induced allergic airway 
inflammation, and bleomycin-induced lung fibrosis. Our pilot results showed that 
there was no clear phenotype in asthma or LPS-induced acute lung injury models 
but that the bleomycin lung fibrosis model was greatly exacerbated. 
MiRNAs can act as regulators of mRNA translation. They exhibit this ability by 
coordinated regulation of multiple RNA targets often within the same molecular 
effector pathways. Using miR-155-/- mice we determine a marked exacerbation in 
the development of pulmonary fibrosis, and these results provide new evidence of 
a possible involvement of a miR155 regulated pathway in the development of 
fibrosis. If we can identify these pathways we may reveal a new therapeutic 
approach for treating pulmonary fibrosis. 
Administration of bleomycin to miR-155-/- compared with WT mice showed 
significant exacerbation in the pulmonary fibrosis. This was reflected by significant 
inflammatory changes including reduction in body weight, and major 
pathomorphological changes in the lung. Pottier and colleagues, reported that 
administration of bleomycin to either sensitive C57BL/6 resulted in significant up-
regulation in the lung miR-155 expression on comparison with bleomycin- resistant 
BALB/c mice or PBS treated mice [226]. Also miR-155-/- mice had an age-related 
phenotype revealed as increased lung airway remodelling similar to lung fibrosis 
[104]. Our results showed that administration of bleomycin to miR-155-/- mice had 
a significant detrimental effect on the body weight of these mice. This can be 
interpreted as being caused by cachexia related to an excessive systemic 
inflammatory process in these mice.  
Further investigation of the lung of these mice demonstrated a severe 
histopathological changes occurring in the miR-155-/- mice given bleomycin (Figure 
3.51). Scoring of the lung sections revealed highly significant inflammatory and 
fibrotic change in the miR-155-/- mice given bleomycin compared with wild type 
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mice given bleomycin or either mice types given PBS (Figure 3.52 and 3.53). Our 
results confirmed and extended the results of Rodriguez and colleagues, who 
showed that mice deficient for bic/miR-155 were characterised by increased lung 
airway pathomorphological changes; with abnormal peribronchial collagen 
deposition, accompanied by augmentation of the subbronchiolar myofibroblasts. 
They suggested that the miR-155 deletion could result in a phenotype that is 
susceptible to fibrosis [104]. Our results were in contrast to those observation of 
Kurowska-Stolarska and colleagues, who showed that miR-155-/- mice did not 
respond to administration of the antigen type II chicken collagen in a CIA model 
and there was no effect on articular inflammation and degradation of cartilage and 
bone which had seen in WT mice [99]. There was no excessive repair/fibrosis 
response in this model in miR-155-/- mice because of the differences between 
animal models while CIA  is resembling an autoimmune disease the bleomycin-
induced lung fibrosis is resembling a wound healing disease.  
miRNA-155 has an important role in regulation of the immune system, such as 
production of T cell–dependent antibody production by plasma cells, T helper cell 
differentiation and cytokine production [97]. Our results demonstrated an additional 
function role for miR155 in tissue inflammation and remodelling. We demonstrated 
a highly significant increase in the inflammatory cell numbers in the 
bronchoalveolar lavage of miR-155-/- mice given bleomycin. These results were in 
agreement with Rodriguez and colleges, who revealed significant increase in the 
number of BAL leukocytes that accompanied the airway remodelling changes in 
aged bic-deficient mice [104]. The increased number of BAL macrophages and 
lymphocytes in the present study indicated an active inflammatory process; these 
cells can potentially participate in the initiation and maintenance of the 
inflammation through different pathways such as cytokine and chemokine 
production.  The evidence for this was the significantly higher concentration of 
TGF1 and FGF basic in the serum and BAL of miR-155-/- mice given bleomycin 
compared with WT mice or mice given control PBS instead of bleomycin. 
The increased serum and BAL TGF was associated with a highly significant up-
regulation of TGF1 gene expression in the lungs of the same miR-155-/- mice 
given bleomycin compared with the other experimental group groups (Figure 3.57). 
The role of TGFin the process of fibrosis hasd been reported in different tissues 
such as lung, skin and joints. TGFβ1 receptor activation resulted in a strong 
downstream signalling pathway which maintains the fibro-proliferative process 
during the course of the disease [227]. The high TGF expression and 
concentration in miR-155-/- mice given bleomycin in our study may be because the 
independent TGF production mechanism does not require direct regulation by 
miR-155, in more details; absence of miR-155 does not stop processes regulated 
by TGF. This is in disagreement with Kong and colleague who found that TGF 
can induce miR-155 expression and mediated through Smad4. Also knockdown of 
miR-155 in epithelial cells resulted in a suppression in the TGF-induced cell 
transition, migration and invasion [110]. Knockdown of miR-155 in their cells did 
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not stop cell migration and invasion induced by TGF, this showed one of mediate 
mechanism of TGFβ signalling through miR-155.  
Our results demonstrated an enhanced fibrotic response in miR-155-/- mice given 
bleomycin compared with WT mice as determined by the increased total lung 
collagen content (Figure 3.59) and increased deposition of collagen seen in the 
lung tissue histology (Figure 3.51). Fibroblast and myofibroblast are abundant in 
the fibrotic area and act as a major source of collagen production. Our results 
appear to be in agreement with the work of Sato and colleagues who studied the 
role of miR-155 in cell differentiation [228]. Their analysis of microarray result 
showed that the fibroblast-like cells treated with IL-4 induced cells with a more 
fibrogenic phenotype because of the reduction in the miR-155 expression.  
A potential mechanism of miR-155  involvement in inflammation and apoptosis 
was suggested in one study that demonstrated an up-regulation of miR-155 
expression by pro-inflammatory stimuli such as Toll-like receptor agonists in 
macrophages [101]. Koch and colleagues propose that miR-155 has antiapoptotic 
activity which increases macrophage resistance to apoptosis induced by DNA 
damage during bacterial infection [229], and the same mechanism may apply to 
bleomycin injury which is thought to be partly related to its ability to induce DNA 
damage. 
Further analysis of my results determined a significantly increased expression of 
M2 macrophage phenotype markers YM1, IL-13R, and Arg 2 and reduction of M1 
macrophage phenotype markers NOS 2 in lung tissues. Macrophages have an 
important involvement in the initiation and maintenance of inflammation and 
fibrosis. Human alveolar macrophages from idiopathic pulmonary fibrosis patients 
can be characterised by their ability to express different mediators involved in the 
fibrotic process such as IL-10, IL-13, and PDGF [157]. The up-regulation of Arg 2 
expression observed in the lungs of miR-155-/- mice given bleomycin were in 
agreement with Arranz  and colleagues using Akt-/- macrophages [230]. Akt is a 
family of three serine / threonine protein kinases that participate in cell survival, 
proliferation and differentiation. Arranz demonstrated that down-regulation of miR-
155 in Akt2-/- macrophages lead to up-regulation of C/EBPβ, which is a target for 
mir-155 resulting in M2 macrophage polarization and the production of Arg1; which 
was restored by transfection of miR-155 into Akt2-/-macrophages. 
Conclusion                                                                                                                          
MiR-155 had been shown to have a potent involvement in the development of 
fibrosis in an experimental murine model. This suggests that miR-155 or the gene-
products that miR-155 may regulate could be involved directly in pulmonary 
fibrosis and they may be potential target candidates for therapeutic strategies. 
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3.5 General discussion and conclusion 
Recapitulation: The principal aim of this study was to investigate the potential 
regulatory role of the nuclear transcription factor LXR in pulmonary fibrosis. My 
initial approach was to search the literature for evidence of the possible 
involvement of LXR and found that it could function in murine models as either a 
positive immune-regulator such as in atherosclerosis or as a negative immune-
regulator such as in collagen- induced arthritis. There was one unsubstantiated 
manuscript that suggested genes associated with the LXR pathway were 
significantly and specifically altered in IPF patients [207]. Therefore the role of LXR 
in remodelling is unresolved, but has research potential in IPF because the 
treatment options for this disease are limited. My working hypothesis for the study, 
therefore, was that LXR agonists have a beneficial effect on pulmonary fibrosis 
because of the established reputation of LXR as a functional anti-inflammatory 
regulator in atherosclerosis.  
I designed experiments to demonstrate the effect of activation of LXR on the 
inflammatory and fibrotic process using a murine model of bleomycin-induced 
pulmonary fibrosis in order to identify potential mechanisms. I observed a pro-
inflammatory and pro-fibrotic effect of LXR agonism; confirmed by significant 
exacerbation of the inflammatory and fibrotic processes in the lungs of mice 
treated with bleomycin that were given LXR agonist. This was reflected by an 
increased loss of body weight, increased proportions of BAL inflammatory cells 
and the identification of alternatively- activated macrophages, along with increased 
concentrations of pro-inflammatory and pro-fibrotic mediators that together 
suggested some potential pathways that might offer suggestion for therapeutic 
intervention. In summary, this study suggested a novel pro-inflammatory and pro-
fibrotic role of LXRs activation that may affect the pathogenicity and progression of 
pulmonary fibrosis. 
LXR is primarily considered as a regulator of lipid metabolism and therefore has 
only been studied in models of inflammatory diseases and has been studied in 
fewer chronic fibrotic conditions. My results show that LXR activationBy GW3965 
exacerbate the inflammatory and fibrotic process of bleomycin-induced lung 
fibrosis  This activity appears to be in contrast to reports which suggest an anti-
inflammatory effect of LXR activation in atherosclerosis [58, 59, 69]. However, it is 
possible that the anti-inflammatory and repair processes are part of the same 
process of remodelling, and my results are consistent with a recent study which 
used a murine model of collagen-induced arthritis and demonstrated that 
activation of LXR with T1317 and GW3965 agonists resulted in exacerbation of the 
inflammatory response, with excessive cartilage destruction and remodelling [74].  
Many studies have used the murine model of bleomycin-induced pulmonary 
fibrosis to study the inflammatory and fibrotic processes [182, 192, 200, 201]. In 
my study additional LXR agonism exacerbated the inflammation and fibrosis as 
shown by an additional loss of body weight, and higher concentrations of lung and 
serum pro-inflammatory and pro-fibrotic mediators. 
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Another important question was the requirement of bleomycin to see the effect of 
LXR agonist in WT mice treated with LXR agonist and why the effect did not 
appear in the control mice given PBS and treated with LXR agonist. A pro-
inflammatory environment is the key characteristic of the pathogenesis of the 
different reactions to bleomycin. Human and animal studies had shown 
predominant pro-inflammatory cytokines in response to bleomycin administration 
into the lung [231, 232]. Challenging human and murine cells with bleomycin lead 
to the activation of  transcription factors nuclear factor-kappa B (NF- B), 
activating transcription factor-2, and activator protein-1 [233, 234], and secretion of 
pro-inflammatory cytokines such as TNF-α, IL1-β, MCP-1, and TGF-b [231, 235, 
236]. Studies on THP-1 cells or macrophage- derived foam cells treated with TGF-
1 revealed an up-regulation in LXR alpha mRNA expression and increased LXR 
protein levels. These effects were confirmed by treating the cells with siRNA for 
LXR which lead to down-regulation of LXRa protein expression by 84% [237]. A 
recent study showed cross-talk between TGF and LXR signalling pathways and 
stimulation of cells with TGF and LXR agonists had a synergistic effect increasing  
the expression of the LXR target gene ABCG1 [238]. Here, it is possible that that 
the pro-inflammatory environment generated by administration of bleomycin was  
manifest by high TGF level, which then lead to up-regulation of the expression of 
LXR mRNA and protein. Higher level of LXR in WT mice given bleomycin and the 
presence of the highly potent LXR agonist will potentiate the LXR pathway 
resulting in exacerbation of the pulmonary fibrosis. This pro-inflammatory 
environment is not found in WT mice given PBS. 
 
The role of LXR in inflammation can be demonstrated by its ability to regulate  the 
expression of genes for certain pro-inflammatory mediators such as TNF, IL-1, 
IL-6, cyclooxygenase (COX-2) and inducible nitric oxide synthase [68, 69]. 
Although not prominent, idiopathic pulmonary fibrosis (IPF) is characterised by an 
inflammatory response dominated by a lung infiltrate of macrophages with a 
phenotypic shift towards an  alternatively activated (M2) macrophage phenotype 
that is associated with tissue remodelling and wound healing [156]. Consistent 
with this, my results showed that LXR agonism can modulate the macrophage 
phenotype by up-regulation the mRNA of genes associated with alternatively-
activated macrophages (chitinase-like lectin YM-1, arginase type 2, and the IL-13 
receptor) accompanied by down-regulation of inducible nitric oxide synthase 2 
which is a biomarker of the classically-activated macrophages M1 phenotype in 
the lung tissue of bleomycin-treated mice. These data provide potential evidence 
for a direct effect of LXR agonism on macrophages exacerbating the bleomycin-
induced pulmonary fibrosis.  
Macrophages are considered to be the animportant source of the fibrogenic 
cytokines TGFandIL-13. It had been shown that IL-13 was able to selectively 
stimulate TGF1 production in transgenic mice [214]. Activation of LXR in a 
macrophage cell line and in primary murine macrophages lead to up-regulation of  
anti-inflammatory gene expression including arginase 2, which was accompanied  
by down-regulation  of the pro-inflammatory genes such as inducible nitric oxide 
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synthase (iNOS) and the suggested mechanism was by antagonism of NF-kappa 
B activity [197]. Together these observations plus the work presented in this thesis 
support that LXR agonism can drive the alveolar or lung macrophage phenotype 
towards an M2-type involved in remodelling.  
In addition to the increased numbers of pro-fibrotic effect of M2 macrophages, the 
disease process was associated with an increased infiltrate of lymphocytes and 
neutrophils in the BAL and pathomorphological changes in the lung tissue sections. 
The over-riding increase in the number of macrophages could mask the 
recognition and contribution of these cells; therefore, further studies are required 
to illustrate how the LXR agonism may impact on each of these inflammatory cell 
types to identify their involvement in the development and maintenance of 
pulmonary fibrosis in murine models and in IPF patients. 
The role of LXR in pulmonary fibrosis first attracted my attention because in 
preliminary studies we demonstrated that genes indicating activation of LXR were 
strongly expressed in blood monocytes of arthritis patients. We subsequently 
demonstrated in a murine model of collagen-induced arthritis that activation of 
LXR with T1317 and GW3965 agonists resulted in exacerbation of the 
inflammatory response, with excessive cartilage destruction and joint remodelling 
[74]. In addition,  approximately 50% of rheumatoid arthritis patients will develop 
respiratory disease during their lifetime [239]. It is possible therefore that there is a 
common abnormality of inappropriate tissue repair. This suggests the involvement 
of fibroblasts. A number of studies have demonstrated that rheumatoid arthritis 
synovial fibroblasts (RASFs) show alterations in morphology and behaviour, 
including molecular changes in signalling cascades, apoptosis response and in the 
expression of adhesion molecules as well as matrix-degrading enzymes. They 
produce a wide range of cytokines, chemokines and matrix-degrading enzymes 
that mediate the interaction with neighbouring inflammatory and endothelial cells 
and are responsible for the progressive destruction of articular cartilage and bone. 
In this scenario, the production of cytokines and chemokines within the rheumatoid 
synovium would help to recruit T cells, macrophages and neutrophils, which, in 
turn, attract more inflammatory cells and, ultimately, enhance the activated state of 
the RASFs and of osteoclasts [240]. 
LXR are important in modulating fibroblast function. Fibrocytes are precursor 
fibroblasts that are characterised by their ability to produce proteins and 
glycoproteins such as collagen types I and III, vimentin and MMPs which 
participate in tissue remodelling and they also produce a wide range of cytokines. 
There are increased numbers of circulating fibrocytes in the peripheral blood of 
bleomycin-treated mice [146], and fibrocytes isolated from the wounds of animal 
models of wound-repair expressed mRNA for cytokines including IL-1β, IL-10, 
TNF-α, MCP, MIP-1α, MIP-1β, MIP-2, PDGF-A, TGF-β1, and Macrophage colony 
stimulating factor (M-CSF) [147]. It was important therefore to explore whether 
there were functional LXR in fibroblasts and whether activating these receptors 
initiated a fibrotic response for example increased production of collagen. These 
experiments are conveniently  done using primary human and mouse fibroblast 
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lines in vitro or in vivo using genetically modified mice gene-deleted for LXRand 
 (LXR-/--/-) and LXR sufficient wild-type littermates. These can be used to 
investigate the effects on the expression of collagen type I and collagen type III 
gene in response to LXR agonists. It has been reported that collagen production 
after bleomycin administration is partially due to activation of interstitial fibroblasts 
with predominant up-regulation of collagen type III gene expression [215]. I 
demonstrated that the collagen gene expression was directly associated with LXR 
activation by using primary fibroblast from the lungs of LXR-/--/- and LXR wild-
type mice. I was able to confirm that LXR agonism directly stimulated collagen 
gene expression by using a control step by the addition of cycloheximide, which is 
an inhibitor of translation, which blocked this effect. 
I have shown that the up-regulation of collagen gene expression was mediated by 
the LXR agonist directly targeting the fibroblast LXRs. Using highly specific 
synthetic LXR agonist have been proven a potent systemic activation for LXR 
stimulation in comparison with the physiological ligands which show a divers in 
their ability depending on the location and their type [31]. Presence of more than 
one physiological ligand in the body and presence of different concentration 
across body tissues may affect the degree of activation of LXRs. Therefore, in our 
study we used a high potent synthetic LXR agonist (GW3965) which shown high-
affinity binding and activation. Further studies required to determine the different 
types of physiological endogenous ligand which may be involve in the pro-
inflammatory and pro-fibrotic process. This may include identification and 
classification of different type of cholesterols and oxysterols which may have the 
ability to activation of LXRs, also identification the concentration in different tissues 
such as in blood, serum or organs such as lung of the IPF patients. This will 
facilitate the understanding of the all possible endogenous factors that may involve 
in the exacerbation in the inflammation and fibrosis.  
Having demonstrated that GW3965 had a direct on human and mouse primary 
fibroblast, my next aim was to determine if the Col IA and Col IIIA genes have 
response elements for LXR in their promoter regions. This was carried out by 
performing a luciferase reporter assay which demonstrated that activation of LXR 
directly promotes collagen types 1 and 3 in mouse fibroblast cell line T1317. A 
study had been conducted on mesangial cells treated with the LXR agonist  
showed that activation of  LXRα with TO901317 synthetic agonist resulted in an a 
significantly increases production of collagen IV. To confirm this effect cells were 
transfected with siRNAs of LXRα and cultured with TO901317, a reduction in the 
level of LXRα protein to 70% and mRNA of LXRα to 76% had been demonstrated. 
The expressions of collagen IV were decreased in protein level to 28% and mRNA 
level to 80% [241]. My collagen promoter data came in parallel to the above 
mentioned study and we determined that both Col IA and Col IIIA genes have 
response elements for LXR in their promoter regions. 
 
My in vivo results have demonstrated an increased production of pro-inflammatory 
and pro-fibrotic cytokines such as TGF, TNF, IL-13 and FGF basic in response 
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to bleomycin along with LXR-agonists. This can also increase collagen production. 
It had been reported that TGFβ is able to bind the human collagen type 1A2 
promoter and activate Smad signalling in human skin fibroblasts [242]. It is now 
accepted that pathology associated with metabolic disease and chronic 
inflammatory diseases may cooperate to promote a state of generally enhanced 
inflammation. As well as understanding a role of LXRs in inflammation this study    
was also initiated in an attempt to understand how altered lipid metabolism may 
drive pulmonary fibrosis pathology. I hypothesise that cholesterol degradation 
within the periphery to form oxysterols could drive the development of pulmonary 
fibrosis pathology by activation of LXRs. Indeed, my results which suggest a pro-
inflammatory and pro-fibrotic effect of LXR activation support this hypothesis. 
However, although my studies, as with other reports in the literature using 
GW3965 or T1317, are informative of LXR activation they may not faithfully 
represent the action of specific endogenous oxysterol species upon the activation 
of LXRs. Synthetic LXR agonists induce activation of LXRs systemically whereas 
endogenous agonists are restricted to particular anatomical locations and indeed 
different oxysterols are recognised to differentially activate or inhibit LXRs [31]. 
Another important part of my work was to understand the specific involvement of 
each of the LXRα and LXRβ isotypes in pulmonary fibrosis. Their different function 
was investigated in lipid metabolic disease models such as atherosclerosis but not 
yet in fibrotic diseases. A murine model of atherosclerosis using ApoE-/- mice 
demonstrated that the absence of LXRα was strongly associated with severe 
atherosclerosis; characterised by the accumulation of cholesterol in peripheral 
tissues and in the aortic root; and this effect could not be compensated by an 
intact LXRβ [220]. However, the highly potent LXR agonist GW3965 was able to 
activate LXRβ resulting in attenuation of the atherosclerosis, suggesting that the 
different strengths of the ligand binding might modulate function. In my bleomycin 
induced lung fibrosis model, neither LXR nor LXR could compensate for the 
absence of each other, even using the highly specific LXR agonist GW3965. The 
reasons for this are unclear but may be because LXRα or LXRβ work in a 
cooperative pathway.. Understanding the individual roles of LXRα and LXRβ is 
important to understanding how lipid metabolism may impact upon inflammation 
and fibrosis and for the design of future therapeutics; For example it is recognised 
that agonists designed specifically towards the activation of LXRβ are more 
favourable than dual LXRα/LXRβ agonists for the treatment of atherosclerosis 
[220, 243]. Furthermore, deletion of LXRα or LXRβ is protective against the pro-
inflammatory and pro-fibrotic effects mediated by administration of GW3965 in a 
murine bleomycin-induced pulmonary fibrosis and suggests that cooperation 
between the LXR isoforms is necessary to drive the inflammation and fibrosis. The 
separate role of LXRα and LXRβ in inflammation and fibrosis still unknown. 
Interestingly these observations have considerable implications for the 
development of LXR agonists as future therapy in which LXR agonists are already 
been in use in pre-clinical trials for the treatment of atherosclerosis [244, 245].To 
validate our findings, further studies are required to test for the individual effects of 
each receptor in other fibrotic models.   
 
A related research topic was to explore the possible involvement of microRNA-155 
as a regulator for mRNA translation in lung fibrosis. The miR-155 gene-deleted 
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mouse was one of the first models of induced microRNA deficiency. The mice 
developed immune deficiency primarily of B-cell and innate immunity, however, 
with aging the mice developed mild lung fibrosis. It had been shown in our lab that 
miR-155 is upregulated in rheumatoid arthritis synovial macrophages associated 
with the development of autoimmunity and joint inflammation [99]. It is possible 
that preclinical arthritis may be associated with lung changes such as bronchial 
wall thickening. This was an important consideration for the clinical relevance of 
my findings because clinical targeting of the LXRs may be of benefit but may also 
be a risk because the receptors are ubiquitous and because these receptors are 
likely involved in more than one physiological function, therefore, targeting of the 
outcome of the LXRs agonism at post-transcriptional level may be an ideal option 
and this may be perform through miR-155. 
To better understand the contribution of the miR-155 in the regulation pathway of 
pulmonary fibrosis, a bleomycin pulmonary fibrosis model was established using 
miR-155-/- and miR-155 wild type mice. This demonstrated that the absence of 
miR-155 lead to exacerbation in the pulmonary fibrosis associated with bleomycin 
administration. The mechanism of this is unknown. Therefore, we studied the lung 
cytology and histology. This bleomycin model demonstrated a shift toward 
alternative activation of lung lavage macrophages. There is supporting literature 
showing that transfection of lung fibroblasts with a synthetic miR-155 resulted in 
modulating of translation of genes involved with cell movement, cell death and 
cell-to-cell signalling. The authors concluded that transfection of fibroblasts with 
miR-155 could promote apoptosis and reduce cell migration [226]. This might 
explain why fibrosis is more evident in miR-155-/- mice; the greater migratory ability 
with decreased apoptosis, along with excessive production of pro-inflammatory 
and pro-fibrotic cytokines especially TGF can drive the fibroblast to produce 
excessive collagen in the lung of these mice when given bleomycin. These results 
are in agreement with work on mice deficient for bic/miR-155, that showed lung 
airway pathomorphological changes; an increased peribronchial collagen 
deposition and large number of sub-bronchiolar myofibroblasts [104]. Further work 
needs to be done to determine whether the completely absence or low level of the 
miR-155 in fibroblast may lead to the similar results. 
TGF plays an important role in wound healing. It directly targets fibroblasts and 
stimulates collagen production. Previous work demonstrated a positive inter-
relationship between miR-155 and TGF in that TGF was able to induce miR-155 
expression through Smad4, and knockdown of miR-155 in epithelial cells resulted 
in the suppression of TGF-induced cell migration invasion [110]. It is likely that 
the high production of TGF in miR-155-/- mice is because of the independent 
TGF production mechanism which does not require direct regulation by miR-155. 
Further experiments are required to identify the tentative relationship between 
miR-155 and TGF, this may include in vitro work at a transcriptional level in the 
presence or absence of each component. 
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The work on this thesis prompted some pilot experiments to investigate whether 
there was a direct relationship between LXR and miR-155. Using luciferase 
assays we demonstrated that LXR alpha mRNA is a direct target of miR-155. 
Moreover, a highly significant up-regulation of the expression of LXR alpha was 
demonstrated in the lungs of miR-155-/- mice that were further increased in mice 
given bleomycin. In parallel experiments we demonstrated that administration of 
LXR agonist to WT mice lead to an increase in the LXR expression. Thus there is 
an important LXR-miR-155 axis that appears to modulate fibrosis. This is a novel 
concept that will direct new thinking into disease pathogenesis of IPF and perhaps 
improved therapeutic options for this devastating disease. 
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Conclusion  
 
My results demonstrate that both LXR and miR-155 have an important impact on 
murine bleomycin-induced pulmonary fibrosis. MiR-155 may have an important 
role in lung homeostasis, possibly by fine tuning levels of LXR resulting in a 
prevention of excessive remodelling. This may be envisaged as the possibility that 
miR-155 may act as a master switch determining the degree and duration of 
inflammation and the initiation of remodelling.  
 
My results showed that administration of exogenous synthetic LXR agonist 
GW3965 induced activation of LXRs systemically. Whereas in the body there are 
different endogenous agonists, it is possible that these endogenous physiological 
LXR ligands which are restricted to particular anatomical locations with different 
ability to recognise and activate or inhibit LXRs, therefore, further studies are 
required to determine how specific oxysterols exert their pro-inflammatory 
effects. Determining which species of oxysterols are present in the serum and 
BAL of IPF patients and if concentrations of these are altered relative to healthy 
controls is also important for understanding whether LXRs have a pathological 
role in IPF. 
 
Further work is required to determine the nature and diversity in the pro or anti-
inflammatory and pro or anti-fibrotic responses of the LXR in different disease 
models since the LXR activation shows divers effects across a wide range of 
disease models. Studies are needed to investigate the control of the inflammatory 
and fibrotic responses at the level of LXR activation because targeting the LXR in 
vivo is of potential risk because of the involvement of these receptors in many 
physiological processes.  
 
Finally, improved understanding of LXR in this context, perhaps with improved 
understanding of the role of miR155 may therefore be of considerable clinical 
importance. 
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IX Publications                                                                                                 
 
1- The liver X receptor pathway is highly upregulated in rheumatoid arthritis 
synovial macrophages and potentiates TLR-driven cytokine release. 
 
 
